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Chapter 1: Malaria vaccine candidates; Introduction 1
1 Potential candidates for a multi-antigen
malaria vaccine
1.1 Introduction
1.1.1 Malaria
1.1.1.1 Disease burden
Malaria is a debilitating disease occurring most frequently in tropical and sub-
tropical areas. The disease is not only a physical burden on those experiencing its
symptoms, but is also an economical and developmental burden on endemic areas.
Recent studies estimate that there are around 3.2 billion people currently at risk from
malaria, with transmission reported to occur in 107 countries and territories[1]. There are
believed to be between 350 and 500 million clinical cases of the disease annually. The
greatest proportion of these cases occurs in Africa, where there are still over 1 million
deaths per year due to malaria. Young children and pregnant women are often the worst
affected by malaria, indeed, most of the deaths from malaria in Africa are of children
under 5 years of age. If untreated in children, the disease can develop very rapidly (often
within 24 hours) from the initial symptoms of fever, vomiting and flu-like symptoms, to
convulsions, coma and death. Chronic anaemia caused by malaria may have adverse
effects on the growth and intellectual development of children. Pregnant women in areas
of unstable malaria transmission are two- to three times more likely to experience severe
disease in the case of malaria infection than non-pregnant adults in the same area. This
can lead to death either directly from severe malaria or indirectly from malaria-related
severe anaemia. Infection of the mother can also lead to adverse effects including
spontaneous abortion, neonatal death and low birth weight. In areas of stable malaria
transmission, mothers have usually developed enough immunity to avoid clinical
symptoms, and the main impact of malaria infection is associated with anaemia in the
mother and the presence of parasites in the placenta, which impairs foetal nutrition and is
one of the main causes of low birth weights and infant deaths.
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It is difficult to estimate the economic burden of malaria, which is recognised as
both a disease of poverty and a cause of poverty. The direct costs of malaria are spread
between individuals and public bodies. Personal expenditures include the purchase of
anti-malarial drugs, insecticide-treated nets, doctors’ fees and transport to health centres.
Public spending can be on maintaining healthcare facilities and infrastructure, on large-
scale vector control programs, on education and on research. Malaria is estimated to
account for up to 40% of public health spending in some countries. The indirect costs of
malaria include the loss of productivity due to illness or death. The disease also has an
adverse effect on children’s development and therefore possibly their future earning
potential. Children’s development is affected both by absence from school due to illness,
and also by permanent neurological and other damage associated with the disease. Other
indirect effects of malaria include the under-development of tourism in malaria-endemic
areas, and the reluctance of farmers to grow labour-intensive cash crops, due to the effect
of malaria on labour during the harvest season.
1.1.1.2 Transmission and distribution
Malaria is caused in humans by the four Plasmodium species P. falciparum, P.
vivax, P. ovale and P. malariae. Other Plasmodium species of interest are those that can
be grown in laboratory mice and rats (such as P. yoelii, P. vinckei, P. berghei and P.
chabaudi, all originally found in thicket rats in Africa), and those that infect rhesus
monkeys, namely P. knowlesi (P. falciparum-like) and P. cynomolgi (P. vivax-like). P.
falciparum causes the most cases of malaria in humans, followed by P. vivax. The most
serious cases, and hence also the most deaths due to malaria, are caused by P. falciparum.
The parasite is transmitted to humans by female anopheles mosquitoes. There are
currently at least 40 anopheline species known to transmit human malaria, and the species
vary in their transmission potential. The maps in Figure 1 illustrate the most recent
estimates of the incidence of clinical malaria episodes caused by any species, and those
caused by P. falciparum.
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Figure 1: (A) Incidence of clinical malaria episodes per person per year (all species). (B) Incidence of P.
falciparum malaria per person per year. (World Malaria Report 2005) [1]
1.1.1.3 Life cycle
The parasite has a complex life cycle which requires both the human and the
mosquito host for its successful completion. The life cycle is illustrated in Figure 2.
When an infected mosquito feeds on human blood, the parasite enters the body in the
form of sporozoites (A) which travel very quickly to the liver. The sporozoites are then
believed to migrate through several hepatocytes [2] before invading a hepatocyte by the
formation of a parasitophorous vacuole (B). The migration through the cytosol of liver
cells is necessary to activate the sporozoites for invasion [3]. Within the parasitophorous
vacuole, the sporozoites are able to differentiate and undergo asexual multiplication to
produce thousands of merozoites - the next infective stage of the parasite life cycle. The
length of the stage depends on the species but takes, for example, approximately 14 days
in the case of P. falciparum. The merozoites then burst out of the hepatocyte (C) and
begin to invade erythrocytes. Inside red blood cells, the merozoites differentiate into
trophozoites, which use the erythrocyte’s haemoglobin to replicate their nucleus, and
form 12-16 new merozoites. During this stage, the parasite also directs the formation of
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‘knobs’ on the surface of the red blood cell that makes the infected cell ‘sticky’ and helps
to fix it to a blood vessel wall, so that it cannot be easily transported to the spleen and
destroyed. The build-up of these ‘sticky’ erythrocytes in a blood vessel can block
circulation and can lead to coma or death in cerebral malaria. When a certain
concentration of merozoites has been formed, the erythrocyte is ruptured, releasing
merozoites which are able to reinvade new erythrocytes and recommence the cycle of
multiplication. This cycle takes approximately two days in infections of P. falciparum,
P. vivax and P. ovale, and three days for P. malariae. This is the stage of the disease at
which the symptoms of malaria – cycles of fever and chills begin to occur.
Approximately ten days after the first invasion of erythrocytes, some of the merozoites
are able to mature into male and female gametocytes (E). If taken up by a feeding
mosquito, the male microgametes fertilize the female macrogamete to produce a zygote
(F). After further maturation (G) (the whole process taking 10-15 days), sporozoites are
once again available in the mosquito’s salivary glands for invasion of a human host (H).
Figure 2: Malaria Life Cycle [4].
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1.1.1.4 Current Control Policies
As with most diseases, malaria control policies must focus both on prevention and
treatment. In the case of malaria, transmission can be prevented by preventing infected
mosquitoes from biting, or the parasite could be prevented from causing the disease once
it reached the human. Treatment targets the parasite which is already present in the body.
A very important aspect of current prevention policies is the use of insecticide-treated
mosquito nets. This is a simple and effective general control method, as long as the nets
are retreated with insecticide as frequently as necessary. Traditional nets need retreating
roughly every year, whereas nets developed more recently can remain effective for up to
5 years. The insecticide treatment is necessary because mosquitoes are able to bite
through untreated nets in order to feed on human blood. Untreated nets can also divert
extra biting to people in the same room who are not protected with nets [5], whereas
treated nets would be expected to improve protection for all inhabitants.
Mosquitoes can also be controlled by indoor insecticide spraying, which is
particularly important for reducing rates of transmission in times of epidemic.
Unfortunately, development of insecticides for such purposes has struggled to keep up
with the emergence of insecticide-resistant insects.
Travellers to malaria-endemic areas are obviously also advised to avoid mosquito
bites, but should also take antimalarial drugs (chemoprophylaxis) to prevent any possible
infection from developing into disease. The drug to be taken depends on the region to be
visited, due to the varying occurrence of drug resistance.
Malaria has been treated in the past using traditional drugs which fall into two
broad classes according to their targets in the parasite. Antifolates, along with
naphthoquinones, interrupt nucleic acid metabolism within the parasite [6, 7]. Quinolines
interfere with the detoxification of haem within the parasite. The antifolates inhibit
enzymes of the folate pathway, thus decreasing pyrimidine synthesis and therefore
reducing DNA, serine and methionine formation. Quinolines are believed to prevent the
polymerisation of haem which is used by the parasite as a detoxification mechanism.
Therefore the parasite is believed be poisoned by the haem produced as a side product of
its feeding on haemoglobin.
Unfortunately, there are now many strains of P. falciparum that have developed
Chapter 1: Malaria vaccine candidates; Introduction 6
resistance to the traditional drugs such as the quinolines chloroquine and mefloquine, and
the antifolate combination sulfadoxine-pyrimethamine [7]. The map in Figure 3 shows
areas where P. falciparum resistance to drugs has been found. Current World Health
Organization policy recommends the use of artemisinin-based combination therapies
(ACTs) as the most highly efficacious treatment method currently available [8].
Figure 3: Worldwide occurrence of P. falciparum resistance to traditional antimalarials. (World Malaria
Report 2005)[1]
Artemisinin is an interesting compound with an unusual endoperoxide bridge
(Figure 4) [9]. It is extracted from the plant Artemisia annua, which is mainly cultivated
in China and Vietnam, and has been used for many centuries in traditional Chinese
medicine as a treatment for the symptoms of malaria. Artemisinin and its derivatives are
believed to act by inhibiting the action of the ATPase PfATP6 [10], and the endoperoxide
bridge has been shown to be essential both for the inhibitory and for the antimalarial
action [10]. Although artemisinin is able to rapidly kill all asexual stages of P. falciparum
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when acting alone [11], its use in combination with conventional drugs is recommended
for several reasons. For example, it has been shown in studies in South-East Asia that
combinations of artemisinin compounds with some synthetic drugs can produce high cure
rates after only 3 days of treatment, compared to around 7 days of treatment when
artemisinins are used alone [8]. There is also evidence that the development of resistance
to the partner drug can be slowed down to a great extent by using it in combination with
artemisinin [12]. In general, derivatives of artemisinin are used in therapy, due to their
superior pharmacological properties. For the preparation of these deriviatives, artimisinin
is extracted from Artimisia annua, and reactions are carried out on the extract, as the de
novo synthesis of the compounds has proved extremely difficult. However, drug
discovery projects are underway to discover synthetic peroxide antimalarial drugs, and a
promising candidate has recently been identified [13].
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Figure 4: Artemisinins. A: artemisinin, B: dihydroartemisinin, C: artemether, D: arteether, E:
artesunic acid (artesunate)
Although artemisinin-based combination therapies are still effective at the
moment, and only isolated cases of resistance to artemisinin derivatives, in vitro, have
been reported [14], we must expect that strains of the parasite will develop resistance to
these compounds at some stage in the future. Also, anopheline species must be expected
to continue to develop resistance to currently-used insecticides. Therefore there must be
continued and relentless research into new possible preventive measures and treatments,
and the development of a malaria vaccine must form an important part of this research.
1.1.1.5 Vaccine development
Despite the global impact of malaria, and the clear advantages of vaccines as a
method of control of infectious diseases, no malaria vaccine is as yet approved or
Chapter 1: Malaria vaccine candidates; Introduction 8
available for use. This fact does not represent a lack of interest in or of research effort
towards a vaccine, but is rather due to a complex combination of several other factors. A
major obstacle is the complexity of the parasite’s life cycle. The parasite presents
different antigens to the immune system at different stages of its life cycle, and thousands
of antigens are presented throughout the course of a Plasmodium infection. It is difficult
to pinpoint which antigens could be key to an effective vaccine, and it is to be expected
that a fully effective vaccine would target more than one stage of the life cycle, so that
any parasite ‘escaping’ the immune response at one stage could be ‘caught’ at a later
stage. Infections of several strains of the same species, or indeed of more than one
species, can occur simultaneously, so an effective vaccine would also need to be as
general as possible, rather than strain-specific.
In 1967, it was reported that mice immunized with radiation-attenuated P. berghei
sporozoites were protected against subsequent challenge with fully infectious sporozoites
[15]. Studies were then carried out in humans during the 1970s, and the same effect was
found [16-19]. It was possible to protect volunteers from P. falciparum challenge by
immunizing them with the bites of irradiated mosquitoes carrying P. falciparum
sporozoites in their salivary glands. These investigations demonstrated that a malaria
vaccine offering protective immunity was feasible. It has also been shown that non-
immune individuals who receive immunoglobulins from volunteers with naturally
acquired immunity are subsequently protected against infection. Additionally, as
previously mentioned, people living in malaria endemic areas gradually obtain immunity
to severe disease and even to mild disease, over several years when regularly exposed to
infection [20] – also a good indication of the possibility of a working vaccine.
The role of a vaccine is to prepare the immune system to work quickly and
effectively in the case of a true infection, by presenting antigens to it in a ‘harmless’ form
so that the antigens can be promptly dealt with in subsequent ‘real’ attacks. Vaccines that
are currently approved and used occur in a number of forms. Some consist of live,
attenuated or intact, killed viruses or bacteria (for example the polio, typhoid and
chickenpox viruses [21]), others involve purified antigens.
Based on the knowledge that attenuated sporozoites can induce clinical immunity,
it would seem reasonable to develop a method for the use of sporozoites in a vaccine.
However, there would be many practical problems to overcome in this approach. The
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sporozoites must be delivered live either via mosquito bites (studies suggested that the
best protection was obtained when volunteers were immunized with more that 1000 bites
[22]), or intravenously. The delivery of vaccine by mosquito bite would not be
practicable, and all vaccines that are currently used as public health measures are
administered by intradermal, subcutaneous or intramuscular methods. There would also
be difficulties in producing a vaccine in mosquitoes that would meet safety requirements.
An obvious place to look when seeking an effective vaccine is at the naturally-
acquired immunity of people living in endemic areas. It is believed that acquired
immunity to malaria is probably due to low to moderate responses to many antigens [23].
However, the development of a vaccine containing a cocktail of many antigens, aiming to
mimic natural immunity, could be a very complex and costly venture. Research activity
has therefore focussed on the development of a vaccine presenting a few antigens, which
would therefore need to induce stronger and longer-lasting immune responses than are
observed in naturally-acquired immunity. Some of the antigens that have been
investigated as possible components of a subunit vaccine will now be discussed.
1.1.1.6 Subunit vaccines
As discussed earlier, an effective subunit vaccine would probably target more
than one stage of the Plasmodium life cycle. However, the individual antigens to be used
can be classed according to the stage of the life cycle that they would target.
Firstly, a vaccine candidate could target pre-erythrocytic stages. The immune
response elicited by immunization with irradiated sporozoites involves both neutralizing
antibodies that recognize the surface of sporozoites, and cell-mediated mechanisms that
inhibit liver-stage (exoerythrocytic stage) development[24]. Antibody-mediated protection
could be elicited by targeting sporozoite surface molecules. The most intensively studied
sporozoite surface antigens are the circumsporozoite (CS) protein, and the
thrombospondin-related anonymous protein (TRAP). The CS protein is a very abundant
sporozoite surface antigen, and neutralizing antibodies against it are found for all malaria
species [25]. CS plays an important role in the development of sporozoites in the mosquito
[26] and in the early stages of hepatocyte invasion. CS proteins from different
Plasmodium species have common structural features, which include a signal peptide, a
central repeat domain and a C-terminal hydrophobic sequence [27]. The central region of
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CS consists of tandem repeat regions, the sequence of which is species-specific (Figure
5). This tandem repeat region contains the immunodominant B-cell epitopes. In P.
falciparum, the repeat motif comprises 37 tandem repeats of the tetrapeptide Asn-Ala-
Asn-Pro (NANP), interspersed with four copies of Asn-Val-Asp-Pro (NVDP). The B
epitope (NANP)3 is found in all isolates of P. falciparum from all over the world [28], and
monoclonal antibodies to the repeat regions inhibit sporozoite cell invasion.
Figure 5: Schematic representation of the sequence of circumsporozoite protein. The flanking regions R1
and R2 are highly conserved among different species.
A CS-based vaccine, RTS,S/AS02A, is currently the most advanced malaria
vaccine candidate in clinical development, and has been shown to reduce risk of clinical
malaria and to reduce episodes of severe malaria in African children [29]. Although this
vaccine has as yet only been shown to confer partial protection, the results confirm that a
malaria vaccine can become a credible control tool. It has been shown that TRAP is
present on the plasma membrane of the parasite, and is required for cell invasion [30].
Unfortunately, it seems that most TRAP molecules are released when the parasite makes
contact with hepatocytes, and a tight junction is established between the extracellular
domain of TRAP and the cellular receptors. At this stage, therefore, antibodies to TRAP
are ineffective in sporozoite neutralization [31].
Liver stage antigens are attractive targets because the liver stage of the parasite
remains in the liver for at least one week, without symptoms of clinical malaria
occurring. However, there could be some difficulty in delivery of a vaccine targeting
liver stage antigens. It has been shown that intra-splenic injection of infected liver cells
into mice can elicit sterile immunity without the presence of antibodies [32], and that
administration of a virus expressing a cytotoxic T cell epitope of P. yoelii CS can induce
protective immunity in mice [33]. Studies have shown that immunization of non-human
primates with liver stage antigen 3 (LSA-3), which is a well-conserved blood stage as
well as a liver stage antigen, could induce protection [34]. It is hoped that heterologous
prime-boost methods could help to induce a good T-cell response to liver-stage antigens.
This technique involves the delivery of the same antigen in two different vectors, for
example, first ‘priming’ with a DNA vaccine, then ‘boosting’ with the same antigen in a
Repeat regionSignal hydrophobicR1 R2
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viral vector [35].
The next stage to be considered would be the blood stage. Vaccines aimed at the
blood stage of the malaria life cycle, that is, at the merozoite, would not prevent
infection, but if they could interfere with the entry of the merozoite into the red blood
cells, they would prevent the clinical symptoms of the disease from occurring. Important
targets are proteins believed to be involved in the recognition and initial contact between
merozoites and red blood cells, as well as proteins that play important roles in the fusion
of the merozoite and red blood cell membranes. Many merozoite surface antigens have
been identified and studied, some of the most important being apical membrane protein 1
(AMA 1), merozoite surface protein 1 (MSP 1), merozoite surface protein 2 (MSP 2),
merozoite surface protein 3 (MSP 3), glutamate rich protein (GLURP) and serine repeat
antigen (SERA).
Finally, the sexual stages of the parasite’s life cycle could be targeted. Vaccines
aimed at the sexual stages of the malaria life cycle would not protect the individual who
was immunized, but would help to reduce transmission of the disease. The aim would be
to produce antibodies against the gametocytes, which would then be taken up by the
mosquito in a blood meal, along with the gametocytes, and would block the fertilization
step. This would prevent further development of the parasite – it would not be able to
produce mature sporozoites, and therefore transmission would be blocked. A vaccine
aimed at sexual stages of the parasite’s life cycle, in combination with targets at other
stages of the life cycle, could be an important tool in the battle against the spread of
malaria. Another target under consideration is the mosquito itself (so-called anti-
mosquito vaccines). Trials carried out with Plasmodium vivax Pvs25 [36] and
Plasmodium falciparum Pfs25 [37] have shown promising results, and another antigen,
P28, has been shown to be essential for the infection of mosquitoes, and is also
considered a very important candidate.
1.1.2 Vaccine formulation
1.1.2.1 Adjuvants
As early as 1926, Glenny and co-workers discovered that diphtheria toxoid
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precipitated with alum represented a better vaccine than the toxoid alone [38]. In general,
most antigens, for example proteins or peptides, have only limited immunogenicity when
they are used as pure substances, and much research has been carried out into methods
for inducing a better immune response, since the first use of adjuvants in the form of
aluminium salts. One of the most famous adjuvants, complete Freund’s adjuvant (CFA)
was developed in 1937, and is an oil-in-water emulsion containing killed mycobacteria.
Vaccine components derived from pathogenic bacteria, such as derivatives of lipid A, or
lipopeptides, induce an innate immune response which is crucial for the subsequent
activation of the adaptive immune response. The set of structures that can induce such a
response is termed pathogen-associated molecular pattern (PAMP), and includes
microbial cell wall components, microbial structural proteins and microbial nucleic acids
[39]. Many PAMPs have been investigated as possible adjuvants, and at least one vaccine
using a PAMP, mono-phosphoryl lipid A (MPL), has been approved for use [40]. The
signal instructing the adaptive immune system to take an attack seriously can either be a
danger signal provided by the pathogen, such as the PAMPs described above or a
microbial toxin, or it can be in the form of a substance released by the host itself.
Therefore, there has been recent interest in the possibility of employing host-derived
substances as adjuvants, in particular the so-called heat shock proteins (HSPs) that seem
to possess very good immunological properties. The role of HSPs is to bind to
hydrophobic stretches of denatured proteins, in a variety of stress situations, in order to
prevent their aggregation. As well as this chaperone function, HSPs initiate either the
refolding of their substrate, or the proteolytic degradation if the unfolding was
irreversible. Due to their chaperone function, heat shock proteins can act as peptide
carriers, and HSP-peptide complexes have been shown to have a very strong
immunogenic potential [38]. Studies have shown that HSP-based immunization therapy
using a personalized tumour vaccine is well tolerated and can produce favourable results,
but the techniques have not yet been fully evaluated [41].
It has been shown that some of the reactivity induced by immunization with DNA
plasmid vaccines is not due to the antigen sequence, thus, DNA plasmid vaccines can be
said to be acting as an intrinsic adjuvant as well as encoding the antigen DNA [39].
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1.1.2.2 Particulate vaccine delivery systems
The Freund’s adjuvants mentioned earlier can be considered as particulate
adjuvants, since they contain ‘particles’ of oil in water. There has been much research in
recent years into microparticles as vaccine delivery systems. It has been shown that an
adjuvant effect occurs when antigens are linked to synthetic particles. The use of
polylactide-coglycolides (currently used as controlled-release drug-delivery systems) to
encapsulate antigens [42], and also the adsorption of antigens on similar particles has been
the subject of recent research. Another interesting approach is the use of recombinant
proteins that self-assemble into particulates.
An obvious method for delivering pure antigens to the immune system, whilst
retaining immunogenicity, is to include the antigen in a particle that looks like a
pathogen. Liposomes and virus-like particles are important examples of this type of
delivery system, which also includes cochleates and immune-stimulating complexes
(Figure 6).
A B C D
Figure 6: Schematic representations of (A) a lipsome; (B) a virosome; (C) a cochleate; (D) an immune-
stimulating complex.
Classical liposomes do not elicit a very strong immune response, but their
effectiveness as a delivery system can be enhanced by the inclusion in the lipid bilayer of
amphiphilic adjuvants, such as the monophosphoryl lipid A mentioned earlier.
Cochleates differ from most other liposome-related delivery systems in that they are not
spherical. They consist of bilayer sheets containing phosphatidyl ethanolamine,
phosphatidyl serine and cholesterol. They also contain calcium ions intercalated with the
bilayers. Immune-stimulating complexes are made up of saponin, cholesterol and
phospholipid, and the amphipathic antigen is usually included during the preparation, and
the products have a cage-like structure.
Chapter 1: Malaria vaccine candidates; Introduction 14
1.1.2.3 Immunopotentiating reconstituted influenza virosomes (IRIVs)
Research in the Robinson group has focused on the use of immunopotentiating
reconstituted influenza virosomes (IRIVs) for vaccine delivery. IRIVs are small
unilamellar vesicles with a mean diameter of 150 nm (Figure 7).
Figure 7: Schematic representation of an immunostimulating reconstituted influenza virosome.
The virosomes represent reconstituted empty influenza virus envelopes, devoid of
the genetic material of the source virus, so they are unable to replicate but are fusion-
active due to the presence of the influenza glycoproteins. More specifically, the IRIV
vesicle is constituted of phosphatidylcholine and phosphatidylethanolamine, with
functional viral envelope glycoproteins: hemagglutinin (HA) and neuraminidase (NA)
intercalated in the phospholipid bilayer. The influenza viral envelope proteins are
important both for the stability of the virosome and for its immunological properties [43].
Influenza viruses enter cells via receptor-mediated endocytosis, and virosomes have been
shown to act in the same way [44]. The influenza HA is believed to play an important role
in binding to receptors on antigen-presenting cells, to initiate a successful immune
response, and also to mediate the fusion of virosomal and endosomal membranes, to
initiate the infection of cells.
The composition of virosomes allows different models of antigen incorporation,
depending on properties of the antigen and the required type of immune response.
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Antibodies may be adsorbed on the surface, encapsulated in the virosomal cavity, or
integrated into the lipid membrane (Figure 8).
A B
Figure 8: Schematic representation of virosome with antigens integrated into the lipid membrane (A), or
encapsulated in the virosomal cavity (B). (see www.pevion.com)
Studies have shown that physical association between the virosomal carrier and
the antigen leads to optimal adjuvant effect of the virosome [45]. Depending on the
location of the antigens, virosomes can activate either a B-cell or a T-cell response.
Antigens linked to the virosomal surface are degraded within the endosome and peptide
fragments are presented to the immune system by MHC class II receptors, activating
CD4+ helper T cells, which in turn activate a B cell response. Antigens encapsulated
within a virosome are delivered to the cytosol during fusion and are presented by MHC
class I receptors, activating CD8+ killer T cells. In a mouse model, the use of synthetic
conformational malaria B-cell epitopes to induce highly specific antibodies has been
demonstrated [46, 47]. In our studies, peptide mimetics of malaria antigens are bound to a
phospholipid moiety so that the phospholipid tail can form part of the phospholipid
bilayer of the virosome, and the peptide mimetic is displayed to the immune system on
the surface of the virosome. This system has already been used for phase 1 clinical trials
of circumsporozoite and AMA-1 mimetics designed and developed in our group as part
of the malaria vaccine project. There are also already licensed vaccines against influenza
(Inflexal V, Berna Biotech) and hepatitis A (Epaxal, Berna Biotech) that make use of the
virosome technology.
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1.1.3 Epidermal Growth Factor-like Domains
1.1.3.1 Definition
The epidermal growth factor-like module was first sequenced in 1972 [48] within
epidermal growth factor itself and it has since become apparent that the module occurs in
a wide range of proteins. The domain usually comprises 40-50 residues including 5 to 6
cysteine residues forming two or three disulfide bonds. A domain can be classified as an
EGF-like domain if it is consistent with either the general definition (A) or with the
rather more stringent consensus pattern proposed by Campbell and Bork [49] (B) which
are both outlined in Figure 9:
(A) Cysteine and glycine residues in a pattern consistent with the consensus pattern:
CxnCxnCxnCxGx2C
Where: x = any amino acid
n = any number
(B) More stringent consensus pattern proposed by Campbell and Bork:
Cx2-7Cx 1-4(G/A)xCx1-13ttaxCxCxxGax1-6GxxC
Where: t = non-hydrophobic amino acid
a = aromatic amino acid
Figure 9: Consensus patterns defining EGF-like domains [49].
The disulfide bonding connectivities have been confirmed for murine EGF [50],
and for many other EGF-like domains, as forming a canonical 1-3, 2-4, 5-6 pattern as
illustrated in Figure 10.
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CxnCxnCxnCxnCxnC
Figure 10: Disulfide bonding pattern of human and murine EGF, and many EGF-like domains.
1.1.3.2 Features
The EGF-like module is found in many proteins in nature, including those
involved in cell adhesion, blood coagulation and neural development [49]. Many of them
have a membrane-bound precursor, including EGF itself, the heparin-binding EGF-like
domain, and Plasmodium falciparum merozoite surface protein 1. EGF–like modules are
believed to generally be involved in the mediation of protein-protein interactions, and
their structures usually show similar features, including stretches of -sheet [49, 51].
1.1.3.3 Folding pathway
The folding pathway of human EGF [52-54] has been the subject of intensive
investigation. Experiments carried out to trap the intermediates formed during the
folding of human EGF show that the first two disulfide bonds (the Cys2-Cys4 and Cys5-
Cys6 bonds) are formed rapidly, and a stable two-disulfide kinetic trap is obtained. The
third disulfide bond (the Cys1-Cys3 bond) is then formed slowly, and can only be formed
via substantial unfolding of the two-disulfide protein, despite its already representing a
native-like structure. The protein passes through three-disulfide scrambled isomers
before the native folded structure is finally attained. Although it is not certain that other
EGF-like domains follow an analogous folding pathway, the folding of human EGF has
been compared to the folding of other, non-EGF-like, multiply disulfide bonded proteins
[55]. The accumulation of predominant intermediates was only seen in the case of EGF,
but it was observed that the folding pathways of three other three disulfide-containing
proteins also involved scrambled three-disulfide isomers. For three proteins (hirudin,
potato carboxypeptidase inhibitor, and tick anticoagulant peptide), but not for EGF, the
accumulation of scrambled isomers could be enhanced by including oxidized glutathione
or cystine in the folding buffer. A further protein, bovine pancreatic trypsin inhibitor,
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whose folding pathway has also been the subject of much investigation, was shown to
fold correctly without passing through three-disulfide scrambled intermediates. An
interesting point was that, although tick anticoagulant peptide and bovine pancreatic
trypsin inhibitor belong to the same family of inhibitors and share structural homology in
their disulfide bonding pattern and three-dimensional structure, they follow diverse
folding pathways and their disulfide bonds seem to be stabilized in different ways. It
would seem, therefore, that at least until many more studies have been performed, it will
remain difficult to predict from the native structure of a multiply-disulfide bonded
protein, what its folding pathway may be, and indeed which may be the best conditions
for obtaining the correctly folded product. Optimal oxidative folding conditions for
various proteins are thus usually arrived at by trial and error, based on a few general
rules.
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1.2 Design, synthesis and characterisation of a
merozoite surface protein-1 mimetic
1.2.1 Merozoite surface proteins
To date, ten Plasmodium falciparum merozoite surface proteins (MSPs) have
been identified, and they can be divided into two groups: proteins that are linked to the
merozoite membrane via a glycosylphosphatidylinositol (GPI) anchor (MSP-1, 2, 4, 5, 8
and 10) and those that are soluble and, in some cases, non-covalently associated with the
merozoite surface (MSP-3, MSP-6, MSP-7 and MSP-9) [56]. It is interesting to note that
all of the GPI-anchored MSPs, except MSP-2, contain either one or two EGF-like
domains at the C-terminal end. It therefore seems possible that these MSPs could be
involved in important protein-protein interactions, as has been demonstrated for other
EGF-like domains. However, the exact function of the EGF-like domains on the
merozoite surface remains unknown. The location of these proteins on the surface of
merozoites means that they are exposed to the immune system during the blood stages of
malaria, and have therefore been extensively studied as possible targets for the
development of a blood-stage malaria vaccine.
1.2.2 Merozoite surface protein 1
The first Plasmodium MSP to be discovered was MSP-1, which is therefore also
the most intensively studied and the best characterised of the merozoite surface proteins.
Plasmodium falciparum MSP-1 is expressed as a ~200 kDa protein with a GPI anchor,
and is processed in two proteolytic steps before invasion of the human erythrocyte. In the
first step, the protein is cleaved into four fragments of 83 kDa (N-terminal fragment), 30
and 38 kDa (central fragments) and 42 kDa (C-terminal fragment) (Figure 11). The C-
terminal fragment, MSP-142, remains linked to the merozoite surface via the GPI anchor,
and the other fragments remain associated with the merozoite surface as a non-covalent
complex [57, 58]. In the second proteolytic step, which seems to occur just before or at the
point of erythrocyte invasion a further 33 kDa fragment is shed from the GPI-anchored
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protein, to leave a 19 kDa fragment attached to the membrane [59, 60].
Figure 11: Schematic representation of the fragments formed during proteolytic processing of MSP-1.
The 19 kDa fragment, MSP-119 is the only part of the protein that is carried into
the invaded erythrocyte, and the final processing step is believed to be essential for the
invasion of erythrocytes [61]. MSP-119 is a well-structured protein consisting of two EGF-
like domains [62]. The solution structure of P. falciparum MSP119 has been calculated
from NMR studies (Figure 12), and the crystal structure of P. cynomolgi MSP-119 has
also been determined [51, 63].
Figure 12: Solution NMR structure of MSP-119.
MSP-1 is believed to be one of the most abundant merozoite surface proteins and
is evenly distributed on the surface of the merozoite [64, 65], which suggests that it may
play an important role in the initial interaction of the merozoite with the red blood cell.
MSP-183 MSP-130 MSP-138 MSP-142
MSP-133 MSP-119
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The protein appears to be essential for the invasion of the erythrocyte and for the survival
of the parasite, as it has not been possible to knock out the gene [56]. Further evidence for
its importance in invasion is that antibodies directed against MSP-1 have been shown to
prevent erythrocyte invasion in vitro. It has also been demonstrated that immunisation
with recombinant MSP-119 or MSP-142 provides protection against subsequent parasite
challenge in mice and monkeys [66-70]. The presence of antibodies to MSP-119 in exposed
adults is associated with clinical immunity [71], and some human antibodies to MSP-119
possess parasite growth-inhibitory activity [72]. The binding of protective antibodies to
MSP-1 inhibits the second proteolytic processing step, and it has been suggested that the
blocking of this step is the basis of their protective function [73].
Several monoclonal antibodies (mAbs) specific to MSP-119 have been identified
[64] and these can be sorted into three classes. Some mAbs, as described, inhibit MSP-1
processing and erythrocyte invasion. These are called inhibitory antibodies. Other
antibodies interfere with the binding of inhibitory antibodies by competing with the
inhibitory antibodies for binding on the merozoite surface. These allow the secondary
processing step and erythrocyte invasion to take place [74] and are called blocking
antibodies. The third class consists of the neutral antibodies that bind to MSP-1 but
neither inhibit invasion nor block the inhibitory action of inhibitory antibodies.
Some MSP-119 monoclonal antibodies have been studied in detail by several
groups, using various methods including site-directed mutagenesis, TROSY NMR and
PEPSCAN [75, 76]. These investigations show that some of the inhibitory antibodies
studied bind only to the first (N-terminal) EGF-like domain of MSP-119, whereas others
require both domains in order to bind, and are probably binding to a non-continuous
conformational epitope involving both domains. It has also been shown that known
blocking antibodies bind to the same regions as the inhibitory antibodies [77, 78].
However, in the mutagenesis studies, it was demonstrated that all of the antibodies
studied (a selection of inhibitory, blocking, and neutral) showed a different response to
the various mutations [76]. That is, no two antibodies showed the same pattern of binding
to the range of mutant proteins tested. This suggests that even antibodies binding to the
same region recognise slightly different epitopes. It is interesting to note that it was
possible, based on information from the first round of mutations, to design a mutant
protein to which only the inhibitory antibodies studied, and none of the blocking
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antibodies, could bind [76]. This gives rise to the hope that it would eventually be possible
to design a mimetic that would induce only (or at least predominantly) inhibitory
antibodies.
1.2.3 Mimetic Design
As well as the established importance of this antigen in erythrocyte invasion,
Plasmodium falciparum MSP-119 was chosen as a good potential vaccine candidate
because of its low polymorphism (only 5 dimorphic sites, as illustrated in Figure 13), and
because antibodies to this region are found in most malaria-exposed individuals. Both of
these points suggest that it could be an important component in a broad-range malaria
vaccine.
N
1631 NISQHQCVKK QCPQNSGCFR HLDEREECKC LLNYKQEGDK CVENPNPTCN
T S R F
1681 ENNGGCDADA KCTEEDSGSN GKKITCECTK PDSYPLFDGI FCS
Figure 13: The sequence of the C-terminal region of MSP-1 for the Wellcome strain of P. falciparum is
shown. Residues in grey are dimorphic sites, and the possible amino acids found in different strains are
given above.
In initial work in the Robinson group, several co-workers were involved in the
design and synthesis of mimetics of the three hairpin loops highlighted in the NMR
structure of MSP-119 in Figure 14 [79, 80]. The sequence of these loops was transplanted
onto a DPro LPro, template, in order to induce a hairpin-like structure, and the mimetics
were produced bound to a phospholipid linker, to make them suitable for inclusion in
virosomes for immunization studies. Unfortunately, these early mimetics failed to induce
antibodies which could recognise the parasite, and so did not represent good vaccine
candidates.
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Figure 14: NMR structure of P. falciparum MSP-119 highlighting the two EGF-like domains and the
loops on which the first MSP-1 mimetics were based.
Studies have shown that the disulfide bonds in MSP-119 are crucial to its
immunological properties [78], therefore, the next logical step was to produce mimetics
containing disulfide bonds. Efforts were concentrated on the first EGF-like domain,
since several antibodies had been shown to bind exclusively to this domain. Also, only
one of the five dimorphic sites appears in this domain. A first series of mimetics was
designed and synthesised containing either no, one or two disulfide bonds, based on the
first 30 residues of the sequence. Unfortunately, as before, these mimetics failed to
induce antibodies that could recognise the parasite. Therefore, in a final effort to develop
a good vaccine candidate based on MSP-119, it was decided to synthesise the whole of
EGF-like domain 1 as a phospholipid-bound peptidomimetic.
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT-NH2
Figure 15: Amino acid sequence of peptide 1, a proposed MSP-119 domain 1 mimetic.
It was decided to initially synthesise the peptide sequence of EGF-like domain 1
Loop 1
Loop 2
Loop 3
EGF-like domain 1
EGF-like domain 2
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of MSP-1 (Figure 15) without any phospholipid anchor, in order to establish optimal
oxidative folding conditions for the peptide. A method has already been presented in the
literature [81] for the synthesis of MSP-119 domain 1. This method involved an orthogonal
protecting group strategy, where two cysteine residues were protected with Acm groups,
and the other four with Trt groups. Under acidic cleavage conditions, the Trt side chain
protection was removed and the peptide could be oxidized to give a two-disulfide
intermediate. In a second step, the Acm groups were removed and the third disulfide
bond was formed in the presence of iodine. The strategy is briefly outlined in Scheme 1.
SSSSSS
TrtTrtAcmTrtAcmTrt
TFA/thioanisole/thiophenol/
EDT/water
SHSHSSHSSH
AcmAcm
SSSS
AcmAcm
DMSO, urea, buffer
S I2
SSSS
S S
S
Scheme 1: Illustration of the two-step oxidation method developed by Spetzler et al. for the synthesis of
the first EGF-like domain of MSP-119 [81]
Encouraged, however, by the many descriptions of successful folding of multiply
disulfide-bonded proteins and peptides in the literature [82-89] we decided to attempt a one-
step oxidative folding of the synthetic peptide, in an effort to reduce time and yield losses
due to intermediate purification steps – an important consideration should the mimetic
eventually be developed as a commercial product. Therefore, the same protecting group
was used for all cysteine residues in our synthesis.
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1.2.4 Results
1.2.4.1 Peptide synthesis
The assembly of the 48-mer peptide, containing 6 Trt-protected cysteine residues,
was carried out on the solid phase using an ABI-433A peptide synthesiser and the Fmoc
strategy, illustrated in Scheme 2. The sequence was assembled on Rink Amide MBHA
resin, which releases a C-terminal amidated product on acid-mediated peptide cleavage.
The amino acids used were Fmoc-Asn(Trt)-OH, Fmoc-Ile-OH, Fmoc-Ser(tBu)-OH,
Fmoc-Gln(Trt)-OH, Fmoc-His(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Val-OH, Fmoc-
Lys(Boc)-OH, Fmoc-Pro-OH, Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Arg(Pbf)-OH,
Fmoc-Leu-OH, Fmoc-Asp(tBu)-OH, Fmoc-Tyr(tBu)-OH, Fmoc-Glu(tBu)-OH and Fmoc-
Thr(tBu)-OH. The synthesis was carried out on a 0.25 mmol scale, and a capping step
was introduced from the 20th coupling cycle onwards in order to block unreacted amine
groups. This step is important in the synthesis of long peptides, as it reduces the number
of side-products of similar molecular weights to the desired product and leads therefore,
in most cases, to a significantly simplified purification process.
HN
Fmoc
H2N
Fmoc-Thr(tBu)-OH
HBTU/HOBt/DIEA
NMPT
tBu
Fmoc
20% piperidine
DMF
fully protected peptide
fully deprotected peptide
TFA/TIS/H2O/EDT
94:1:2.5:2.5
SH SH SH SH SH SH
Scheme 2: Fmoc strategy for solid-phase peptide synthesis
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After assembly, the full peptide sequence was cleaved from the resin and the side
chains were fully deprotected in one step, using 2.5% EDT, 2.5% water and 1% TIS in
trifluoroacetic acid. Analytical RP-HPLC showed that one main product was obtained
from the synthesis. This product was purified by preparative RP-HPLC and analysed by
RP-HPLC and ESI-MS, and found to have the expected molecular weight for the desired
product. Calculated MW: 5592.3 g/mol, measured m/z (ESI-Tof-MS): 5591.72 (±
0.01%). The analytical chromatograms of the crude and the purified products are shown
in Figure 16.
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Figure 16: Chromatograms of crude linear peptide 1 (A) and purified peptide 1 (B). For HPLC conditions
see appendix 4.
1.2.4.2 Oxidative folding
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT-NH2
Figure 17: Amino acid sequence and disulfide bonding pattern of desired oxidation product, peptide 2.
From a survey of recent literature methods [82-95] it was noted that successful
oxidative folding of multiply disulfide bonded proteins is often carried out in a slightly
basic buffer, at fairly low protein concentration, in the presence of a denaturant such as
urea or DMF, and with reduced and oxidised glutathione, or with cysteine and cystine as
a redox pair to help with the disulfide shuffling which seems to occur along many
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refolding pathways. Therefore, in an initial trial, small portions of peptide were dissolved
in 0.1 M Tris buffer at 0.1 mM peptide concentration and pH 8.4. 2mM reduced
glutathione and 1mM oxidised glutathione were included in the buffer, and amounts of
urea and DMF were varied in a systematic way as shown in Table 1. The peptide
oxidation solutions were stirred for 24 hours in closed vessels but without the exclusion
of oxygen. The solutions were then analysed by analytical RP-HPLC and the
chromatograms compared to that of the starting material.
trial Urea
concentration
(M)
DMF
%
Peptide
concentration
mg/ml
Oxidised
glutathione
concentration
mM
Reduced
glutathione
concentration
mM
pH
1 0 0 0.5 1 2 8.4
2 1 0 0.5 1 2 8.4
3 2 0 0.5 1 2 8.4
4 3 0 0.5 1 2 8.4
5 0 5 0.5 1 2 8.4
6 1 5 0.5 1 2 8.4
7 2 5 0.5 1 2 8.4
8 3 5 0.5 1 2 8.4
9 0 15 0.5 1 2 8.4
10 1 15 0.5 1 2 8.4
11 2 15 0.5 1 2 8.4
12 3 15 0.5 1 2 8.4
13 0 25 0.5 1 2 8.4
14 1 25 0.5 1 2 8.4
15 2 25 0.5 1 2 8.4
16 3 25 0.5 1 2 8.4
Table 1: Conditions used for 16 trial oxidations of peptide 1.
The chromatograms of the products obtained from a selection of these trials are
illustrated in Figure 18.
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Figure 18: Comparison of the RP-HPLC chromatograms of reaction mixtures from the oxidation trials 5-8
described in Table 1. The chromatogram of the starting material is shown by the solid line and
the chromatograms of the oxidised products by the dotted line. For HPLC conditions see
appendix 4.
These trials seemed to lead to the formation of a product mixture containing one
major peak and several side-products. It was difficult to notice any trend in the results
obtained under systematically altered conditions, although the use of very high
concentrations of urea seemed to lead to a higher proportion of side products where 0%
or 5% DMF was used. It also seemed that higher concentrations of DMF led to fewer
side products, although little difference was seen between the products obtained when
15% or 25% DMF was used. At this point, the products were not further characterised
because it was decided to try a wider variety of different reaction conditions, with the aim
of obtaining a better yield of the major product. In the next trials, several different
oxidation conditions were used, based on methods found in the literature.
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Figure 19: RP-HPLC chromatograms from the oxidation trials described in Table 2. The chromatogram
of the starting material is shown by the solid line, oxidation products are shown by dotted lines. For HPLC
conditions see appendix 4.
Table 2 shows the conditions that were used for the second round of oxidation
trials. The peptide solutions were again stirred at room temperature for 24 hours before
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analysis by analytical RP-HPLC to compare the products obtained with each other and
with the starting material. The chromatograms of the oxidation products from these trials
are shown in Figure 19.
The chromatograms show, for each trial except the air oxidation (trial 23), a major
peak with shorter retention time than the starting material, along with several side peaks,
the retention times and relative intensities of which vary with the different oxidation
conditions. The major peak from each trial has the same retention time. It seems that in
order to form this major peak, the presence of a redox couple such as cysteine/cystine or
reduced and oxidised glutathione is necessary. This is not surprising as it is known that
the folding pathways of several multi-disulfide bonded proteins go through fully oxidised
disulfide scrambled intermediates before the correct fold is attained. In the air oxidation
trial, in the absence of a redox couple, the peptide may well become ‘trapped’ in these
intermediate folds, preventing the completion of the folding pathway.
The yields of the major product from several of the trials in the second round
seemed to be quite similar. The conditions of trial 21 were chosen for further
development because these oxidation conditions led to a major product with very few
side products, and the separation of the side products from the main peak also seemed
slightly better than under the other assay conditions. It was now decided to investigate
the effect of increased peptide concentration on the outcome of the oxidation reaction.
Trials were carried out using the same conditions as in trial 21, but with peptide
concentrations of 0.5 mg/ml, 1 mg/ml, 2 mg/ml and 5 mg/ml. Increasing the peptide
concentration did not seem to have any detrimental effect on the yield of the major
product, as illustrated in Figure 20, which shows the chromatogram of the product of
oxidation at a peptide concentration of 5 mg/ml.
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Figure 20: Chromatogram of the product of oxidation of peptide 1 at a peptide concentration of 5 mg/ml.
For HPLC conditions see appendix 4.
This higher concentration was therefore used in a larger-scale oxidation reaction
which provided sufficient oxidised product for purification by semi-preparative RP-
HPLC to yield a product of high purity that could be analysed by ESI-MS and NMR.
Calculated MW: 5586.31 g/mol, measured m/z (ESI-Tof-MS): 5586.3 ±0.1%. An
expansion of the amide proton region of the 1H NMR spectra of linear peptide 1 and
folded peptide 2 is shown in Figure 21. The wide spread of signals in the spectrum of
the oxidised product are a good indication that a well-structured product has been formed.
In order to confirm that three disulfide bonds had been formed, the Ellman test was
carried out on samples of both the linear and the oxidised peptide. The test showed that
no free thiol groups were present in the oxidised product.
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Figure 21: Expanded amide proton region of the NMR spectra of linear (1) (above) and the oxidatively
folded (2) (below) MSP-1 mimetics.
1.2.4.3 Disulfide connectivity determination
In order to unambiguously determine the disulfide bond connectivities of the six
Cys residues in the synthetic peptide, a combination of proteolytic digestion and mass
spectrometry methods was used. The principle of this technique is to obtain, by partial
proteolysis, peptidic fragments containing a single disulfide bond, which can be identified
by their molecular weight. Therefore, both the enzyme and the proteolysis conditions
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should be selected such that at least one potential cleavage site exists between each pair
of neighbouring cysteine residues. It was not possible to identify any single specific
enzyme that could fulfill these conditions. In particular, a cleavage in the region
12CPQNSG18C could only be expected to occur in the presence of a fairly unspecific
enzyme such as thermolysin, whereas a cleavage in the region 28CK30C could best be
achieved using trypsin.
Therefore, it was decided to carry out in parallel large scale trypsin and
thermolysin digestions of the synthetic folded peptide, under pH conditions that would
minimize the possibility of disulfide scrambling. The cleavage fragments were separated
and isolated by RP-HPLC and the corresponding chromatograms are shown in Figures
22 and 23. All main fractions were analyzed by ESI-MS and the measured masses were
compared to the theoretical masses of fragments which could be expected from the
digestion of each isomer. Key fragments containing a single disulfide bridge were
submitted to N-Edman sequencing to confirm the mass results. The fractions obtained
and the fragments identified are presented in Tables 3 and 4. Table 5 relates to the
reduction of a selection of fragments with DTT in order to confirm the structure implied
by the measured masses. The combination of the data obtained serves to confirm the
expected connectivity 1-3, 2-4 and 5-6.
In the case of the trypsin digests, four main products were identified for each of
the four main fractions 13, 19, 20 and 21. The two fragments identified in peaks 13 and
19 (MW = 2827.2 and MW= 4972.6) corresponded to peptides linked by two and three
disulfide bridges, respectively. In fragment 13, consisting of peptides 1NISQHQ7CV9K,
10KQ12CPQNSG18CF20R and 26EREE28C29K, linked by two disulfide bridges involving
7C (Cys-1), 12C (Cys-2), 18C (Cys-3) and 28C (Cys-4), the exact connectivity of the four
Cys residues could not be unequivocally attributed and could be either 1-2/3-4 or 1-3/2-4.
Masses determined for fractions 19 and 20 were consistent with 2 fragments, one
containing two discontinuous peptides 30CLLNY35K and 41CVENPNP48T linked via the
disulfide bond between 30C (Cys-5) and 41C (Cys-6), and the other corresponding to the
single stretch 30CLLNYKQEGDK41CVENPNP48T, containing the same disulfide bond.
The results of the trypsin digestion thus confirmed the connection of the cysteine
residues 5 and 6, as already identified in the NMR structure. The exact pairing between
Cys-1, Cys-2, Cys-3 and Cys-4, however, remained ambiguous at this stage.
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Many fragments were generated by the thermolytic digestion, of which fifteen
could be identified (Table 4). The fragments identified in the main fractions 3, 11 and 12
appeared to be of special interest for the attribution of the exact connectivities of the four
remaining cysteine residues 7C (Cys-1 ), 12C (Cys-2 ), 18C (Cys-3 ) and 28C (Cys-4 ).
Indeed, peak 3 contained two fragments (MW=1092.2 and MW=1005.1) whose masses
are consistent with the peptide 1NISQHQ7C linked via one disulfide bond to either the
tripeptide 16SG18C or the dipeptide 17G18C, thus confirming unequivocally the connection
between 7C (Cys-1) and 18C (Cys-3). Furthermore, three structurally related fragments
identified in fractions 11 and 12 were found to be constituted of three peptides linked by
two disulfide bridges involving the four cysteine residues 12C (Cys-2), and 28C (Cys-4),
30C (Cys-5) and 41C (Cys-6). Since the connection between 30C (Cys-5) and 41C (Cys-6)
had already been proved by the trypsin digestion experiment, the connection between the
two remaining cysteine residues 12C (Cys-2), and 28C (Cys-4) was implied.
In summary, the combination of the results of the trypsin digestion and of the
thermolysin digestion confirmed unambiguously, for this peptide, the disulfide bonding
pattern 1-3, 2-4 and 5-6 found in many EGF domains.
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Tryptic fragments.
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Figure 22: RP-HPLC of the trypsin digest of peptide 2. For HPLC conditions see appendix 4.
HPLC
Peak
Fragment Mass calc. m/z calc. m/z exp. Disulfides
Present
13
NISQHQCVK KQCPQNSGCFR EECK
2827.2 707.8(+4)
566.4(+5)
707.7(+4)
566.4(+5)
Cys1-Cys3
Cys2-Cys4
19
NISQHQCVK KQCPQNSGCFR EECKCLLNYKQEGDKCVENPNPT
4972.6 1244.2(+4)
995.5(+5)
829.8(+6)
711.4(+7)
1244.4(+4),
995.6(+5),
830.4(+6),
711.5(+7)
Cys1-Cys3
Cys2-Cys4
Cys5-Cys6
20
CLLNYK CVENPNPT
1623.9 813.0(+2) 813.1 (+2) Cys5-Cys6
21
CLLNYKQEGDKCVENPNPT
2163.4 1082.7(+2)
722.1(+3)
1082.9(+2),
722.3(+3)
Cys5-Cys6
Table 3: Fragments identified by LC-MS from the trypsin digest of peptide 2.
13
19
20
21
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Thermolytic fragments
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Figure 23: RP-HPLC of thermolysin digest of peptide 2. For HPLC conditions see appendix 4.
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HPLC
Peak
Fragment Mass
calc.
M/z calc. M/z exp. Disulfides
Present
1 YKQE
C YKQEGDKC
566.6
1089.2
567.6(+1)
1090.2(+1)
545.6(+3)
567.3(+1)
1089.7(+1),
545.3(+2)
-
Cys5-Cys6
2 NISQH 597.6 598.6(+1) 598.4(+1) -
3
CPQ ECKC DKC
1188.4 1189.4(+1)
595.2(+2)
1189.7(+1),
595.7(+2)
Cys2-Cys4
Cys5-Cys6
6
NISQHQC GC
NISQHQC SGC
VENPNPT
FRH
1005.1
1092.2
769.8
458.5
1006.1(+1)
1093.2(+1)
770.8(+1)
459.5(+1)
1005.4(+1)
1093.1(+1)
770.5(+1)
459.2(+1)
Cys1-Cys3
Cys1-Cys3
-
-
9
QCPQN HLDEREECKC DKC
2210.5 1106.3(+2)
737.8(+3)
553.6(+4)
1107.7(+2)
738.6(+3)
554.4(+4)
Cys2-Cys4
Cys5-Cys6
11
VKKQCPQN LDEREECKC YKQEGDKC
3034.4 1012.5(+3)
759.6(+4)
607.9(+5)
1012.4(+3),
759.4(+4),
607.9(+5)
Cys2-Cys4
Cys5-Cys6
12
VKKQCPQ LDEREECKC YKQEGDKC
2920.3 974.4(+3)
731.1(+4)
585.1(+5)
974.3(+3),
730.9(+4),
585.0(+5)
Cys2-Cys4
Cys5-Cys6
14
NISQHQC VKKQCPQNSGC DEREECKC YKQEGDKC
3995.5 1332.8(+3)
999.9(+4)
1332.6(+3)
1000.2(+4)
Cys1-Cys3
Cys2-Cys4
Cys5-Cys6
15
NISQHQC VKKQCPQNSGC LDEREECKC YKQEGDKC
4108.6 1028.2(+4)
822.7(+5)
685.8(+6)
587.9(+7)
1028.8(+4)
823.5(+5)
686.3(+6)
588.6(+7)
Cys1-Cys3
Cys2-Cys4
Cys5-Cys6
16 LLN 358.4 359.4(+1) 359.8(+1) -
19
NISQHQC VKKQCPQNSGC LDEREECKC YKQEGDKCVENPNPT
4860.4 1621.1(+3)
1216.1(+4)
973.1(+5)
1621.2(+3)
1216.1(+4)
973.3(+5)
Cys1-Cys3
Cys2-Cys4
Cys5-Cys6
Table 4: Fragments identified by LC-MS from the thermolysin digest of peptide 2.
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Important tryptic fragments of the thermolytic fragment 11:
Fragment 11:
VKKQCPQN(S)* LDEREECKC YKQEGDKC
* The fraction collected was found to contain both fragments with and without this serine
residue.
HPLC
Peak
Fragment Mass calc. M/z calc. M/z exp. Disulfides
present
1
KQCPQNS EECK
1309.5 655.8(+2) 656.0(+2) Cys2-Cys4
2
YKQEGDK 866.9 867.9(+1)
434.5(+2)
867.8(+1)
434.2(+2)
-
3
C YKQEGDKC
1089.2 1090.2(+1)
545.6(+2)
1089.6(+1)
545.5(+2)
Cys5-Cys6
Table 5: Fragments identified by LC-MS from the trypsin digest of the thermolytic fragment 11.
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Reduction samples:
Fragment Mass calc. Reduced
mass calc.
Reduced
mass exp.
(MALDI)
1
NISQHQCVK KQCPQNSGCFR EECK
or
NISQHQCVKK QCPQNSGCFR EECK
2827.2
1056.2
1267.5
507.6
1184.4
1139.3
507.6
1056.5
1267.5
n.f.
n.f.
n.f.
n.f.
2
NISQHQCVK KQCPQNSGCFR EECKCLLNYKQEGDKCVENPNPT
or
NISQHQCVKK QCPQNSGCFR EECKCLLNYKQEGDKCVENPNPT
4972.6
1056.2
1267.5
2655.0
1184.4
1139.3
2655.0
1056.6
1267.6
2653.1
(Cys5-Cys6
not reduced)
n.f.
1139.5
n.f.
3
CLLNYK CVENPNPT
1623.9 752.9
873.0
n.f.
873.5
4 VENPNPT 769.8 769.8 770.1
5
VKKQCPQ LDEREECKC YKQEGDKC
2920.3 830.0
1124.3
970.1
830.5
1124.5
970.5
Table 6: Masses found after the reduction of a selection of the fragments identified in the trypsin and
thermolysin digestion experiments.
1.2.4.4 NMR structure
From further synthesis, purification and oxidation reactions, carried out as
described above, it was possible to obtain enough pure folded peptide for 2D NMR
measurements. A series of 1H NMR spectra were first measured at temperatures ranging
from 278K to 303K, in order to determine the optimal temperature for 2D measurements.
298K was chosen as the best temperature and measurements were carried out at 600MHz
in H2O/D2O 9:1 at pH 5. NOESY spectra revealed a large number of well-resolved
medium- and long-range NOEs. The peaks could be assigned based on DQF-COSY and
TOCSY measurements, and distance restraints obtained from NOESY spectra with
mixing times of 50, 150 and 300 ms could be employed by Dr Kerstin Moehle to
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calculate a solution structure using CYANA [96]. The final ensemble of 20 structures
reveal a structure highly similar to that of the corresponding domain in the two-domain
protein MSP-119, as illustrated in Figure 24. The structures have been deposited in the
Protein Data Bank under the accession number 2FLG.
Figure 24: (A) Overlay of 20 best structures of peptide 2
A B
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Figure 24 (B): Comparison of solution structure of peptide 2 (blue) with that of domain 1 in the structure
of the whole MSP-119 protein (green) (published in the protein data bank under the accession number
1CEJ).
The N-terminal residues up to Cys7 appear to be disordered, whereas the region
between Cys7 and Pro13 is associated with both strong sequential HN-HN Val8-Lys9, Lys9-
Lys10) and H-HN (Lys10-Gln11, Gln11-Cys12, Cys12-Pro13) NOEs. A large ~2ppm
downshifted HN resonance of Val8, which seems to be caused by close contact to the side
chain of Glu26 was also observed in the structure of MSP-119 protein [51]. A type I -turn
conformation is seen between Pro13 and Ser16. A type 3:5 -turn is found between
residues Cys18 and Cys28, as defined by strong sequential d,N NOEs and typical cross-
strand H-H(Cys18-Cys28, Arg20-Glu26), HN-H (Phe19-Cys28, His21-Glu26) and HN-HN
(Phe19-Glu27, His21-Arg25) NOEs. A further type I -turn conformation occurs between
Leu31 and Tyr34. In the final hairpin loop between Tyr34 and Glu43, a distorted type II -
turn conformation is found with Gly38 and Asp 39 at positions i+1 and i+2.
B
C
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Table 7 outlines the ideal  and  torsion angles for some common types of -
turns [97], and Figure 25 illustrates how -hairpins are classified.
N
N
N
NO
O
O
O
H
H
H
H
i
i+1 i+2
i+3
1
1 2
2
Figure 25: Definition of and  angles in a -turn.
Type 1 1 2 2
I -60 -30 -90 0
II -60 120 80 0
III -60 -30 -60 -30
I’ 60 30 90 0
II’ 60 -120 -80 0
III’ 60 30 60 30
Table 7: Ideal torsion angles for some common -turns.
The NMR results show that the single domain mimetic adopts a native-like
structure, although an interesting feature of MSP-119 is the interface between the two
EGF-like domains, which involves several interacting non-polar amino acids (Phe19,
Leu31, Leu32, Leu86, Phe87, Ile90 and Phe91) [51]. Nevertheless, the Phe19, Leu31 and Leu32
side chains in peptide 2 adopt positions similar to those seen in the dual domain protein,
with the exception that the Phe19 side chain is rotated by 120o, and surface representations
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suggested that this exposed face of the EGF-like domain was not exceptionally
hydrophobic.
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Figure 26: Classification of -hairpins [98, 99]
1.2.4.5 Synthesis of lipopeptide mimetic for immunization studies
The usual strategy for the synthesis of phospholipid-coupled peptide mimetics in
the Robinson group involves the coupling of a modified phosphatidyl ethanolamine group
to the N-terminus of the peptide sequence whilst still attached to the solid support. The
linear phospholipidyl-peptide is then cleaved from the resin and further purification and
modification steps are carried out on the whole mimetic. This approach is outlined
schematically in Scheme 3.
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Scheme 3: Standard procedure for synthesis of PE-coupled peptide mimetics
The coupling of the phosphatidyl-ethanolamine moiety to the sequence of peptide
1 could be carried out satisfactorily and the product could be purified by RP-HPLC using
a C4 column to yield a clean product which showed the expected mass of the desired
product by LC-MS. The analytical HPLC chromatogram of this product is shown in
Figure 27.
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Figure 27: Chromatogram of purified lipopeptide 3. For HPLC conditions see appendix 4.
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Figure 28: Structure of lipopeptide 3
After purification, the oxidative folding of this linear mimetic was attempted. The
mimetic could be dissolved in the same oxidation solution as used for peptide 1, albeit at
a lower concentration. However, after several hours stirring, a precipitate was formed
that could not be solubilised although a number of solvents were tested. Trials were also
carried out with the addition of DMSO to the oxidation solution, but no satisfactory
results could be obtained. Therefore, it was decided to adopt a different strategy for the
synthesis of the lipopeptide mimetic.
It has recently been demonstrated that under suitable pH conditions, it is possible
to distinguish between the reactivity of amine groups and the NH2 of a hydrazine group
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within the same molecule [100]. This means that it should be possible to couple an
activated phospholipid chemoselectively to a hydrazine group in a fully deprotected
peptide containing lysine side chains. In order to produce a suitably modified peptide for
this coupling method, fully Boc-protected hydrazinoglycine was synthesised as described
in Scheme 4 [101].
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Scheme 4: Synthetic route to Boc-protected hydrazinoglycine.
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTN
H o
H2N
Peptide 8
NH2
Figure 29: Structure of peptide 8
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NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTN
H o
H2N
Peptide 9
NH2
Figure 30: Structure of oxidised peptide 9
This derivative could then be introduced into the peptide synthesis in the same
way as a side-chain protected amino acid, at the N-terminal end of the peptide sequence.
Cleavage from the resin and side-chain deprotection were then carried out in a single step
as described previously. Calculated mass: 5665.41 mol/g, measured: 1416.7 (M+4H)4+,
1133.8 (M+5H)5+, 945.1 (M+6H)6+, 810.2 (M+7H)7+ (± 0.01%). The modified linear
peptide 8 could then be oxidatively folded under the conditions described above, to yield
folded peptide 9. An example of the chromatogram of the modified peptide before and
after oxidative folding is shown in Figure 31.
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Figure 31: Oxidation of peptide 8 to give peptide 9. Chromatogram of peptide 8 is shown by the solid
line. Chromatogram of peptide 9 is shown by the dotted line. For HPLC conditions see appendix 4.
In later assays, it was discovered that it was possible to perform the oxidative
folding reaction on the crude peptide taken directly from solid-phase assembly, thus
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eliminating the intermediate purification steps and leading to higher overall yields of the
final product. Chromatograms of the linear and oxidatively folded crude product are
shown in Figure 32.
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Figure 32: Oxidation of crude peptide 8. The chromatogram of crude peptide 8 is shown by the solid line,
the chromatogram of crude oxidised peptide 9 by the dotted line. For HPLC conditions see appendix 4.
The chromatogram of purified oxidised peptide 9 is shown in Figure 33.
Calculated MW: 5659.36 g/mol, measured (ESI-Tof-MS): 5658.4 (± 0.1%).
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Figure 33: Chromatogram of purified peptide 9. For HPLC conditions see appendix 4.
After purification of this peptide, phospholipidyl peptide 13 could be obtained via
the reaction of peptide 9 with activated modified phosphatidyl ethanolamine. The
phospholipid was activated in the form of an N-hydroxysuccinimide ester, which was
freshly synthesised as described in Scheme 5 [102] and used for the coupling reaction
without further purification.
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Scheme 5: Synthetic route to activated phosphatidylethanolamine 12.
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Figure 34: Structure of lipopeptide 13
For the coupling reaction, peptide 9 was dissolved in water at high concentration
(6.5mg/ml) and the pH of the solution was adjusted to between pH 5.1 and 5.3 using
10mM NaOH. 1.5 to 2 eq. of the activated phospholipid 12 were dissolved in an equal
Chapter 1: Malaria vaccine candidates; MSP-1 52
volume of tert-butanol and the two solutions were stirred together. The progress of the
reaction was monitored by LC-MS and the product was purified by RP-HPLC directly as
soon as it was observed that no further lipopeptide product was being formed. An HPLC
chromatogram of the reaction mixture is shown in Figure 35. The peak at short retention
time is the unreacted peptide and the peak at a longer retention time is the newly formed
lipopeptide 13.
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Figure 35: Chromatogram of the solution from the coupling of peptide 9 with activated
phosphatidylethanolamine 12. For HPLC conditions see appendix 4.
The lipopeptide 13 could be purified and ESI-TOF-MS could be measured.
Calculated MW: 6432.4 g/mol, measured m/z (ESI-Tof-MS): 6432.5. The mass of the
product corresponded to the expected mass for the desired product. This product could
therefore be used for inclusion in virosomes for subsequent immunization studies.
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1.2.4.6 Immunological activity of MSP-119 domain 1 mimetic
For immunological studies, lipopeptide 13 was incorporated into virosomes by Dr R
Zurbriggen and co-workers at Pevion Biotech, using methods established earlier for short
linear peptides and peptidomimetics [47, 103, 104]. BALB/c mice were pre-immunized with
whole virus influenza antigen, and were then immunized three weeks later with peptide
13-loaded IRIVs, with subsequent immunizations at intervals of three weeks. Peptide 13-
loaded virosomes generated strong antibody responses in mice. In collaboration with
Prof. G. Pluschke (Swiss Tropical Institute) it was shown that all mice immunized
produced IgG that reacted with lipopeptide 13 in ELISA and that were cross-reactive with
P. falciparum blood stage parasites in IFA. IFA staining patterns characteristic of the
major parasite surface protein were obtained. In competition IFA, the binding of sera to
the parasite surface could only be fully blocked by folded peptide mimetic 43, and not by
unfolded reduced peptide 42 or unfolded reduced and alkylated peptide 44 (see page 62)
(Figure 36). Parasites were incubated with sera raised against lipopeptide 13 and with
linear or with folded peptide mimetic. Folded peptide blocked the binding of sera to
parasites (Figure 36(A)), suggesting that all antibodies recognised some part of the folded
peptide, whereas linear peptide mimetics seemed to block little or no binding to the
parasite surface (Figure 36(C) and (D)), suggesting that at least some antibodies were
present that did not recognise linear peptide. Moreover, the control where no peptide was
added to the solution (Figure 36 (B)) shows that antibodies raised against the mimetic
were able to recognise and bind to parasites. These results suggest that antibodies raised
against the mimetic recognise conformational epitopes, and therefore that correct
oxidative folding could be vital to the development of an MSP-1-based malaria vaccine
candidate.
Figure 36: Inhibition IFA results. Parasites were incubated for 30 mins with a mixture of mouse serum
(1:1000 diluted) and 50g/ml peptide. A: folded oxidised peptide 43, B: control without peptide, C:
reduced alkylated peptide 44, D:unfolded reduced peptide 42.
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For a detailed analysis of the humoral immune response, mimetic 13-specific
mouse B-cell hybridomas were generated in the group of Prof. G. Pluschke. From these
hybridomas it was possible to produce 50 monoclonal antibodies. Characterisation of the
mAbs is in progress.
1.2.4.7 Synthesis of alanine-scanning mimetics for epitope mapping studies
In order to investigate the epitopes recognised by the monoclonal antibodies
induced by immunization with peptide mimetic 13-loaded virosomes, it was decided to
synthesize a library of alanine-scanning mimetics.
peptide Sequence
14 NISQHQCAKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
15 NISQHQCVAKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
16 NISQHQCVKAQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
17 NISQHQCVKKACPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
18 NISQHQCVKKQCAQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
19 NISQHQCVKKQCPANSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
20 NISQHQCVKKQCPQASGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
21 NISQHQCVKKQCPQNAGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
22 NISQHQCVKKQCPQNSGCARHLDEREECKCLLNYKQEGDKCVENPNPT
23 NISQHQCVKKQCPQNSGCFAHLDEREECKCLLNYKQEGDKCVENPNPT
24 NISQHQCVKKQCPQNSGCFRALDEREECKCLLNYKQEGDKCVENPNPT
25 NISQHQCVKKQCPQNSGCFRHADEREECKCLLNYKQEGDKCVENPNPT
26 NISQHQCVKKQCPQNSGCFRHLAEREECKCLLNYKQEGDKCVENPNPT
27 NISQHQCVKKQCPQNSGCFRHLDAREECKCLLNYKQEGDKCVENPNPT
28 NISQHQCVKKQCPQNSGCFRHLDEAEECKCLLNYKQEGDKCVENPNPT
29 NISQHQCVKKQCPQNSGCFRHLDERAECKCLLNYKQEGDKCVENPNPT
30 NISQHQCVKKQCPQNSGCFRHLDEREACKCLLNYKQEGDKCVENPNPT
31 NISQHQCVKKQCPQNSGCFRHLDEREECACLLNYKQEGDKCVENPNPT
32 NISQHQCVKKQCPQNSGCFRHLDEREECKCALNYKQEGDKCVENPNPT
33 NISQHQCVKKQCPQNSGCFRHLDEREECKCLANYKQEGDKCVENPNPT
34 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLAYKQEGDKCVENPNPT
35 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNAKQEGDKCVENPNPT
36 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYAQEGDKCVENPNPT
37 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKAEGDKCVENPNPT
38 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQAGDKCVENPNPT
39 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGAKCVENPNPT
40 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDACVENPNPT
Table 8: Sequences of alanine-scanning peptide mimetics
These mimetics could then be used in binding assays with the antibodies, to
discover which mutations caused differences in binding behaviour. Initially, it was
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planned to synthesise a library where each residue, apart from cysteines and glycines and
omitting the N-terminal and C-terminal extremities, would be systematically mutated to
an alanine residue. The peptide sequences described in Table 8 were to be assembled by
parallel synthesis methods using a peptide synthesis robot.
The mimetics were to be synthesised in two batches, and the synthesis of the first
batch of peptides – peptides 14 to 26 was started on a Multisyntech Syro II parallel
peptide synthesiser. The synthesis was carried out on chlorotrityl chloride resin
preloaded with Fmoc-Thr(tBu)-OH, on a 0.03mmol scale. Since the robot used had no
automatic synthesis monitoring system, the syntheses were monitored by the regular
sampling of resin from several reaction vessels. After 10, 20 and 29 amino acid coupling
cycles, resin samples were taken and the peptide was cleaved from the resin and side-
chain deprotected for RP-HPLC and LC-MS analysis. The synthesis was then allowed to
continue until all coupling cycles were complete, and the final products were cleaved
from the solid support and side-chain deprotected using TFA containing H2O, EDT and
TIS as scavengers. Examples of chromatograms of the products obtained after 10, 20, 29
and 47 coupling cycles are shown in Figure 37.
0
100
200
300
400
500
600
5 10 15 20 25 30
ml
m
A
U
0
20
40
60
80
100
`
Figure 37: (A) Chromatogram of a peptide cleaved from the solid support after 10 coupling cycles.
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Figure 37 (continued): (B) Chromatogram of peptide cleaved after 20 cycles of coupling. (C)
Chromatogram of peptide cleaved after 29 cycles of coupling. (D) Chromatogram of peptide cleaved after
48 cycles of coupling. For HPLC conditions see appendix 4.
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Unfortunately, all of the products obtained from the robot after 47 coupling cycles
gave disappointing chromatograms similar to the example in Figure 37. The crude
peptide products were subjected to oxidising conditions, in the hope that the many peaks
may be due to the presence of several partially oxidised structures, which would resolve
themselves into one fully oxidised product under the correct conditions. Unfortunately,
no improvement was observed in the chromatograms of the products after oxidation,
although it seemed that oxidation occurred, since all peaks shifted slightly to lower
retention times, as illustrated by the chromatograms in Figure 38.
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Figure 38: Chromatograms of a peptide product from the robot synthesis before (A) and after (B)
treatment in oxidative conditions. For HPLC conditions see appendix 4.
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It was concluded that the assembly of such a long peptide sequence was beyond
the scope of a parallel synthesis robot where no monitoring of the success of coupling
steps and no feedback loops were available. Therefore, it was decided to revert to usual
batchwise peptide synthesis methods, and to begin with a smaller library of mimetics.
A new, smaller library was therefore designed, where only positively charged and
aromatic residues were to be mutated to alanine. This would provide a group of eleven
peptide mimetics, with the advantage that the mutations would be fairly well spread
throughout the peptide sequence. Table 9 gives the sequences of the mimetics in the
small library.
peptide sequence
40 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDACVENPNPT
36 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYAQEGDKCVENPNPT
35 NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNAKQEGDKCVENPNPT
31 NISQHQCVKKQCPQNSGCFRHLDEREECACLLNYKQEGDKCVENPNPT
28 NISQHQCVKKQCPQNSGCFRHLDEAEECKCLLNYKQEGDKCVENPNPT
24 NISQHQCVKKQCPQNSGCFRALDEREECKCLLNYKQEGDKCVENPNPT
23 NISQHQCVKKQCPQNSGCFAHLDEREECKCLLNYKQEGDKCVENPNPT
22 NISQHQCVKKQCPQNSGCARHLDEREECKCLLNYKQEGDKCVENPNPT
16 NISQHQCVKAQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
15 NISQHQCVAKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
41 NISQAQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
Table 9: Sequences of peptides to be synthesised in the small library
These peptides were prepared via a divergent synthesis method, beginning with
the synthesis of a large batch (1 mmol) of resin loaded with the sequence CVENPNPT,
common to all of the peptide mimetics. The resin was then split into three batches
corresponding to approximately 0.25 mmol, 0.375 mmol and 0.375 mmol. The first of
the 0.375 mmol batches was further split into four equal parts which were used for the
synthesis of peptides 31, 35, 36 and 40. The second of the 0.375 mmol batches was used
for the synthesis of the sequence EECKCLLNYKQEGDKCVENPNPT. The resin from
this synthesis was then split into four equal parts and used for the preparation of peptides
22, 23, 24 and 28. The remaining 0.25 mmol batch of resin was used for the assembly of
the sequence QCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT. Peptides
15, 16 and 41 were then prepared from this resin. The synthetic strategy is summarised
in Scheme 6.
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CVENPNPTCVENPNPT
QCPQNSGCFRHLDEREECKCLLNYKQEGDKCCVENPNPT
EECKCLLNYKQEGDKCVENPNPT
1mmol
0.375mmol
0.375mmol
0.25mmol
40
36
35
31
28 24
23 22
15
16 41
Scheme 6: Divergent synthetic strategy for the synthesis of a small library of mimetics based on peptide 2.
The peptides could all be synthesised successfully by this method, each showing
one major peak when the crude cleaved and deprotected product was analysed by RP-
HPLC. The crude products were directly treated with oxidising conditions (5 mg/ml
peptide in 0.1 M Tris buffer at pH 8.4 containing 3 mM cysteine, 0.3 mM cystine and 5
mM EDTA). Examples of the chromatograms of two crude linear products and the
corresponding oxidised products are shown in Figure 39. As illustrated here, the
oxidative folding of most of the peptides led to one major product in RP-HPLC which
could easily be purified to provide a good yield of a single clean product. However, the
oxidation of crude peptides 22 and 23 did not lead to a clear single product, as illustrated
in Figure 40. The two peaks of equal intensity seen in the chromatogram of peptide 23
were collected and analysed separately. Peptide 22 was not further developed, since
peptides 23 and 24 could be expected to give a good indication of whether this region is
important for binding to the antibodies.
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Figure 39: Oxidative folding of peptide 15 (above) and peptide 24 (below). The chromatograms of the
unfolded peptides are shown by the solid lines, and the chromatograms of the oxidatively folded products
by the dotted lines. For HPLC conditions see appendix 4.
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Figure 40: (A) Analytical HPLC chromatogram of unfolded peptide 23 (A), Chromatogram of oxidatively
folded peptide 23 from HPLC purification (B) and analytical chromatograms of unfolded (solid line) and
oxidatively folded (dotted line) peptide 22 (C).
A
B
C
Chapter 1: Malaria vaccine candidates; MSP-1 62
All of the purified oxidised peptides were analysed by RP-HPLC, MALDI-MS,
amino acid analysis, 1H, TOCSY and NOESY NMR measurements, and circular
dichroism. Circular dichroism spectra of peptide 42, peptide 43 (C-terminal free acid
analogues of peptides 1 and 2) and peptide 44, a modified analogue of peptide 42, where
the cysteine thiol groups were alkylated using iodoacetamide, were also measured for
comparison (Figure 41). Expected and measured masses of the products are given in
Table 10.
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
H2N H2N H2N
O O
NH2 NH2
O
O O
NH2
O
Peptide 42
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
Peptide 44
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
Peptide 43
Figure 41: Structures of peptides 42, 43 and 44
The NMR and circular dichroism spectra were measured in order to evaluate the
3-dimensional structural similarity between the mutant peptides and the original peptide
structure 2. It was considered important to be sure that the 3D structure was maintained
in the new mimetics before they could be used for epitope-mapping studies with the
monoclonal antibodies. Otherwise, changes in binding affinity could be due to structural
factors rather than due to the amino acid mutations.
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Linear peptide Calculated
mass linear
peptide
Oxidised
peptide
Calculated
mass oxidised
peptide
Measured
mass oxidised
peptide
(MALDI-Tof)
15 5536.2 45 5530.2 5529.838
16 5536.2 46 5530.2 5531.001
22 5517.2 47 5511.2 n.d.
23 5508.2 48 5502.2 5502.351
24 5527.2 49 5521.2 5520.637
28 5508.2 50 5502.2 5502.052
31 5536.2 51 5530.2 5530.885
35 5501.2 52 5495.2 5496.490
36 5536.2 53 5530.2 5530.525
40 5536.2 54 5530.2 5530.607
41 5527.2 55 5521.2 5520.631
42 5593.3 43 5587.3 5585.9
Table 10: Masses of peptides based on peptide 2. Typical error in the measurements was ±0.1%
1.2.4.8 NMR and circular dichroism
The 1H NMR spectra of the alanine scanning mimetics showed similarity to each
other and to the spectrum of the native peptide sequence. To identify in which residues
the few differences that were observed were occurring, TOCSY and NOESY spectra
were measured, to facilitate comparison with the assigned spectra of the native peptide.
The circular dichroism spectra are displayed in Figure 42 below. As can be seen,
all of the spectra of oxidised products, except that of 52 show a weak positive band at
232-234 nm, which is also observed in the spectrum of mouse EGF [105] and of other
EGF-like domains [106]. All spectra are dominated by a negative band at 201-203 nm,
which is also seen in other EGF-like domains. The spectra can be sorted into two main
categories: in most spectra, as in the spectrum of the native folded sequence, the positive
band has an intensity of around +1000 degcm2dmol-1, and the negative band around -
18000 degcm2dmol-1. Two spectra, those of peptides 48 and 50 show a weaker negative
band, whilst the positive band maintains a similar intensity. The spectra of the unfolded
peptides show a marked difference to those of the folded peptides in the absence of any
positive band. The lack of positive band in the spectrum of peptide 52 suggests that it
may have a different 3-dimensional structure. The alkylated linear peptide shows a
weaker positive band than its analogue containing free thiol groups. The peptide with
free thiol groups is possibly more likely to adopt a conformation related to the native
structure. Although some differences are seen in the CD spectra of the mimetics, all
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except mimetic 52 show positive and negative bands at the same positions and were
therefore presumed to be structurally related to the native peptide and useful for epitope-
mapping studies.
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Figure 42: CD spectra of native peptide 43 and mutant peptides 54, 53, 51, 46 and 45. samples were
measured in a 0.1 mm quartz thermostatable cuvette at 25oC, using a JASCO J-715 spectropolarimeter. A
scan speed of 50 nm/min, a 1 second response time and a 1 nm spectral bandwidth were used. CD spectra
are presented after subtraction of a blank containing only buffer and the optical activity is reported in units
of mean residue ellipticity (deg cm2 dmol-1). Spectra are presented as an average of four scans and results
are given for the range 185-260 nm.
Chapter 1: Malaria vaccine candidates; MSP-1 65
peptide 55
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
peptide 49
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
peptide 50
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
peptide 48
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
peptide 52
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
peptide 44
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
peptide 42
-25000
-20000
-15000
-10000
-5000
0
5000
185 195 205 215 225 235 245 255
nm
q
(d
eg
cm
2 d
m
ol
-1
)
Figure 42 (continued): CD spectra of linear peptides 42 and 44, and mutant folded peptides 48, 49, 50, 52
and 55.
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1.2.5 Discussion
Plasmodium falciparum merozoite surface protein 1 (MSP-1) is a major
merozoite surface antigen [64, 65] and the MSP-119 fragment that remains anchored to the
merozoite surface during erythrocyte invasion, along with its precursor MSP-142, are
leading malaria vaccine candidates now in clinical development [107]. MSP-119 contains
epitopes recognized by inhibitory antibodies [72]. Epitope mapping studies have identified
epitopes in the first EGF-like domain as well as conformational epitopes involving both
EGF-like domains [75, 76]. Immunization studies have shown that MSP-119 induces, as
well as inhibitory antibodies, blocking antibodies that block the invasion-inhibitory
function of the inhibitory antibodies [74], and also neutral antibodies that bind to epitopes
on the protein but have neither an inhibitory, nor a blocking function. The correct folding
of both EGF-like domains seems to be essential for induction of parasite cross-reactive
immune responses.
The aim of this project was to produce a synthetic, conformationally accurate
mimetic of the first EGF domain of P. falciparum MSP-119, to be tested as a potential
constituent of a multi-antigen malaria vaccine candidate. In initial studies, a 48-amino
acid residue peptide mimetic corresponding to the first EGF-like domain of the P.
falciparum MSP-1 could be synthesised.
Oxidation studies based on published methods for the oxidative folding of
multiply-disulfide bonded proteins and peptides showed that all conditions involving a
redox couple such as reduced and oxidised glutathione, or cyteine/cystine, led to one
major fully oxidised product. Air oxidation led to a complex mixture of products. After
optimisation, favourable conditions could be found for the oxidation of the linear peptide
mimetic to one major fully oxidised product, which could be shown by NMR and
proteolysis studies to possess the 1-3, 2-4, 5-6 disulfide bonding pattern expected for an
EGF-like domain. The solution structure of the peptide could be solved from NMR
measurements and was shown to compare favourably with the published structure of
MSP-119, the membrane-anchored double EGF-like domain protein that remains on the
merozoite surface during erythrocyte invasion.
Parallel to the structural investigation of the peptide mimetic, a lipopeptide was
developed for inclusion in virosomes for immunization studies. Attempted oxidative
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folding of a linear lipopeptide mimetic was unsuccessful due to solubility problems, but
through modification of the peptide sequence with a highly nucleophilic hydrazine group,
the oxidised peptide could be coupled to an activated phospholipid to provide a
lipopeptide that could be included in virosomes and used in immunizations of mice to
elicit an immune response. The sera obtained from the mice were found to be cross-
reactive with both the mimetic, and with Plasmodium falciparum parasites. Binding of
merozoites to antibodies could be competed by oxidised peptide, but not by reduced,
linear peptide, demonstrating the importance of a conformationally correct mimetic. 50
monoclonal antibodies could be produced from the immunized mice. These results
suggest that the synthetic peptide represents a good mimetic of the first EGF-like domain
of MSP-119.
For epitope mapping studies on these antibodies, a series of mutant peptides,
where a single residue of the original sequence was replaced by alanine, was produced by
solid-phase peptide synthesis, followed by oxidation using previously established
methods. Most of these mimetics were shown by circular dichroism and NMR studies to
be structurally related to the original mimetic structure. In future work the binding of the
monoclonal antibodies to these mimetics, along with the original natural sequence
mimetic, and reduced, linear analogues should be investigated, in a first step towards the
characterisation of the epitopes. Based on these investigations, and studies into the
immunological properties of the individual antibodies, it may be possible to develop
further mutants for binding studies, and the results could be exploited for the design of
vaccine candidates capable of eliciting only protective, rather than protecting and
blocking antibody responses. The chemical synthesis of a highly disulfide-bonded and
structured peptide mimetic of an important malaria antigen could be an important step
towards a synthetically feasible, immunologically competent vaccine candidate.
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1.3 Design, synthesis and characterisation of a
merozoite surface protein 4 mimetic
1.3.1 EGF-like domains in Plasmodium falciparum
As mentioned above, ten merozoite surface proteins (MSPs) have so far been
identified in Plasmodium falciparum. Five of these proteins contain EGF-like domains, as
does the sexual stage antigen Pfs25 [108]. Encouraged by the success of the oxidative
folding method developed for the first EGF-like domain of MSP-1, and by the
immunological results of immunizations with the synthetic EGF-like mimetic, we
decided to investigate the synthesis, oxidative folding and immunological properties of
other P. falciparum EGF-like domains. The synthesis of the first EGF-like domain of
MSP-8 was attempted in the Robinson group, but investigation of this mimetic could
unfortunately not be continued due to synthetic problems during the solid phase peptide
assembly, that could not be overcome by the usual methods (unpublished results). MSP-
8 contains two epidermal-growth factor-like domains [109], and it has been shown that
parasites whose MSP-1 EGF-like domains are substituted with the equivalent regions of
MSP-8 are still able to invade erythrocytes and grow efficiently [110], which suggests that
the EGF-like domains of MSP-8 play a related role to those in MSP-1, or that they play a
redundant role. Indeed, it has been recently shown that MSP-8 is non-essential for P.
falciparum growth [111].
MSP-4 was identified in 1997 and shown to be a 40kDa protein containing a
single EGF-like domain at the C-terminus [112]. Studies have shown that recombinantly
produced MSP-4 is immunogenic in laboratory animals and that several regions of the
protein are also natural antigens in P. falciparum infection of humans [113]. These
investigations also showed that the EGF-like domain is very important for the
conformation of the whole protein, since the disruption of the EGF-like domain led to
greatly reduced antibody reactivity of some sera, even in regions of the protein outside
the EGF-like domain. Later studies by the same group showed that oral immunization of
mice with MSP-4 could induce antibodies reacting with all regions of the protein,
including antibodies to at least one conformational epitope in the region containing the
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EGF-like domain [114]. During this study, mice were also orally immunized with the
Plasmodium yoelii homologue of MSP-4, PyMSP4/5. It was shown that this
immunization induced partial protection against subsequent lethal challenge with P.
yoelii. It has also been demonstrated that immunization with a combination of PyMSP4/5
and PyMSP-119 induced improved protection against lethal challenge compared to
immunization with either of these proteins alone [115, 116]. In some cases, a combination of
antigens led to an increase in antibody response to MSP-119, but a combination of
antigens always caused improved protection, whether an increased anti-MSP-119 response
was observed or not. It has also been shown that immunization with MSP4/5 from one
species can induce protection against challenge by another species in mice [117]. Although
several polymorphic sites have been identified in Plasmodium falciparum MSP-4, they
do not seem to be frequent in the EGF-like region [118]. These results provide evidence
that an MSP-4 mimetic could form a useful component of a multi-antigen subunit malaria
vaccine.
1.3.2 Mimetic design
To date, no 3D structure of the MSP-4 protein is available. However, we decided
to synthesise a mimetic of the EGF-like domain of MSP-4 using the methods developed
for the synthesis of the MSP-119 mimetic, in order to study the structure of the mimetic
and to test it as a possible malaria vaccine component. The amino acid sequence selected
for these studies is illustrated in Figure 43.
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS-NH2
Figure 43: Sequence of peptide 56.
1.3.3 Results
1.3.3.1 Peptide synthesis
The first attempted synthesis was monitored, as mentioned in the previous
chapter, by the measurement of the UV absorbance at 301 nm of the Fmoc-deprotection
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solution. The amount of dibenzofulvene present in the solution flowing from the solid
phase reaction vessel gives a qualitative indication of how much Fmoc was present on the
resin before deprotection and thus of the efficiency of the preceding amino acid coupling
step. These UV absorbance values are stored in the machine as a ‘deprotection profile’.
Figure 44: Fmoc deprotection profile from initial attempted synthesis of peptide 56.
Unfortunately, as illustrated in Figure 44, there was a rapid drop in the
absorbance of the deprotection solution after the 6th coupling reaction in the initial
attempted synthesis of peptide 56, indicating a decrease in coupling efficiencies. The
coupling efficiencies continued to drop rapidly from this point onwards so that after 23
coupling reactions almost no coupling was occurring any more. This kind of profile is
not unusual for the first attempt at synthesis of a new long peptide sequence. Indeed, the
most frequently encountered synthetic problem in the solid phase assembly of peptides is
the occurrence of a rapid decrease in amino acid coupling yields, which leads to poor
yields of the desired peptide product and, where no capping of free amine sites is
employed in between the coupling reactions, a mixture of undesired products of similar
molecular weights and physical properties to the desired product, which lead to difficult
purification steps. These drops in coupling yields can occur anywhere in the peptide
sequence, and their occurrence is not predictable from knowledge of the sequence alone.
Obviously, the longer the peptide sequence, the higher the probability of such a problem
arising at some point during the peptide assembly, so that this phenomenon is quite
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familiar to those involved in the preparation of longer peptide mimetics. There are some
general features of peptide sequences which can indicate whether they are more or less
likely to present synthetic problems, since the problem is in general believed to be caused
by the formation of intra-chain or inter-chain hydrogen bonding between backbone
residues, or hydrophobic interactions, which can reduce the permeability of the peptidyl-
resin for reagents and solvents. The problem is more likely to occur, for example, where
there are several consecutive identical residues, or a series of consecutive uncharged
residues or consecutive charged residues. The chances of the problem occurring are
reduced in sequences containing proline residues, which are known for their structure-
disrupting properties. Many solutions have been proposed to overcome the problems of
‘difficult sequences’, including reduced resin loading [119], the use of polar matrices as the
solid support [120, 121], solubilizing protecting groups [122] and amide protecting groups
within the peptide chain [123]. In order to improve the yield of peptide 56, two of these
techniques were employed, namely diminished resin loading and the use of pseudoproline
residues to introduce solubilizing protecting groups. Pseudo-prolines [122] (Pro) are
serine-, threonine-, and cysteine-derived cyclic building blocks that act as reversible
protecting groups for Ser Thr and Cys and disrupt -sheet structures that can be a source
of interchain aggregation in peptide synthesis. A generalized structure is shown in
Figure 45.
H2N
R
N
O
X
HOOC
R'
R: any side chain
R': H or CH3
X: O or S
Figure 45: The general structure of a pseudo-proline building block.
These building blocks can therefore be incorporated into any sequences where
Ser, Thr and Cys residues occur. Thus, where difficulties are encountered in an initial
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trial synthesis of a certain sequence, a second trial can be carried out including a Pro,
preferably such that the Pro is introduced in the peptide assembly a few synthetic steps
before the drop in coupling was observed in the initial trial synthesis. In general, it is
desirable to introduce the Pro rather closer to the beginning of the peptide assembly
than to the end. Many of these Pro building blocks are now commercially available in
a form suitable for use in automated solid phase peptide synthesis. In the assembly of
peptide 56, a Pro could be introduced at position 48, that is, in the fourth amino acid
coupling cycle. The building block used was Fmoc-Leu-Ser(Me,Mepro)-OH, 57,
illustrated in Figure 46.
O N
H
O
N
O
O
HOOC
Fmoc-Leu-Ser(Me,Mepro), 57
Figure 46. Structure of pseudoproline 57.
The Rink amide MBHA resin, which is supplied in the Fmoc-protected form, is
usually supplied with a loading of around 0.6-0.7 mmol/g. In order to reduce the loading
of peptide on this resin, 1g of resin was filled into the reaction vessel of the peptide
synthesiser and Fmoc-deprotected. 0.27 mmol Fmoc-Ser(tBu)-OH were used for the
loading of the resin, with an extended coupling reaction time, with the aim of producing
resin loaded with approximately 0.25 mmol/g Ser(tBu). Capping was then carried out
using acetic anhydride in order to block the remaining free amine site on the resin, to
prevent the loading of other amino acid residues on these sites at later stages of the
peptide assembly. The peptide sequence was then assembled as usual, with the use of 4
equivalents (1 mmol) of each protected amino acid for the coupling steps. The
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combination of reduced loading and the inclusion of a pseudoproline building block,
along with some double coupling cycles (coupling is repeated with a fresh aliquot of the
amino acid/activation agent/base) led to a much more successful peptide assembly, which
could be carried all the way to the final 51 residue product. The Fmoc deprotection
profile from the improved synthetic method is illustrated in Figure 47.
Figure 47: Fmoc deprotection profile from synthesis of peptide 56 after improvements in synthetic
methods.
The peptide sequence could thus be completely assembled, and was subsequently
cleaved from the resin and side-chain deprotected in one step using TFA containing 1%
TIS, 2.5% EDT and 2.5% water as scavengers. This step also removed the protecting
group from the pseudoproline building block to release it as a Leu-Ser dipeptide unit.
The RP-HPLC profile of the crude deprotected peptide is shown in Figure 48. As
illustrated by the chromatogram, the assembly of this peptide sequence did not result in
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such a clean product as seen after the assembly of peptide 1. However, it was possible to
identify the peak corresponding to the desired peptide by mass spectrometry, and to
separate it by RP-HPLC to obtain a purified product, the chromatogram of which is
shown in Figure 49.
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Figure 48: Chromatogram of crude peptide 56. For HPLC conditions see Appendix 4.
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Figure 49: Chromatogram of purified linear peptide 56. For HPLC conditions see Appendix 4.
Calculated MW: 5735.42 g/mol, measured ESI-Tof-MS: 5735.1±0.01% (m/z).
1.3.3.2 Oxidative folding
This product was treated under the same oxidation conditions as peptide 1,
namely 5mg/ml peptide in 0.1 M Tris buffer at pH 8.4 containing 3 mM cysteine, 0.3 mM
cystine and 10 mM EDTA. After 48 h stirring at room temperature, the chromatogram
shown in Figure 50 was recorded. The product that forms the main peak in this
chromatogram could be separated, and the chromatogram of the purified product is
shown in Figure 51. Calculated MW: 5729.53g/mol, measured ESI-Tof MS:
5729.2±0.01% (m/z). The peptide was shown by the Ellman test to contain no free thiol
groups. The 1H NMR spectrum of this oxidised product showed a wide spread of peaks
in the amide proton region, as illustrated in Figure 52, suggesting that the product should
have a well-defined structure.
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Figure 50: Chromatogram of crude oxidised peptide 58. For HPLC conditions see Appendix 4.
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Figure 51: Chromatogram of purified peptide 58. For HPLC conditions see Appendix 4.
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Figure 52: NH region of NMR spectrum of peptide 58.
It is presumed that the product obtained was the desired peptide mimetic 58
illustrated in Figure 53, although due to the lack of a 3D structure, and since disulfide
mapping of this product has not been completed, the exact pattern of the disulfide
bonding has not yet been confirmed.
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS NH2
peptide 58
Figure 53: Presumed disulfide bonding in oxidised peptide 58.
1.3.3.3 Synthesis of modified MSP-4 mimetic for immunizations
Based on the success of the oxidative folding of peptide 56 to form peptide 58, it
was decided to directly use the hydrazinoglycine-based coupling method in order to
produce a phospholipid-bound peptide to be used for immunizations. The modified
peptide 59 could be assembled using the same methods as described for peptide 56, and
could be oxidatively folded in the same way, to produce the putative oxidised mimetic
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peptide 60. These products were analysed by ESI-MS and RP-HPLC. The
chromatograms of the purified linear peptide 59, as well as the crude oxidation product
and the purified peptide 60 are shown in Figure 55. Calculated MW of 59: 5807.65
g/mol, measured ESI-Tof-MS (m/z): 5806.9±0.01%. Calculated MW of 60: 5801.60
g/mol), measured ESI-Tof-MS (m/z): 5801.4±0.01%.
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS NH2
H
N
H2N
O
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS NH2
H
N
H2N
O
Peptide 59
Peptide 60
Figure 54: Structures of peptide mimetics 59 and 60.
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Figure 55: (A) Chromatogram of purified peptide mimetic 59. For HPLC conditions see Appendix 4.
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Figure 55 (B): Chromatogram of crude peptide 60. For HPLC conditions see Appendix 4.
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Figure 55 (C) Chromatogram of purified peptide 60. For HPLC conditions see Appendix 4.
1.3.3.4 Lipopeptide synthesis
Peptide 60 was used in coupling reactions with activated phosphatidyl
ethanolamine (12). The peptide was dissolved in water at a concentration of between 5
mg/ml and 7.5 mg/ml and the pH of the solution was adjusted to between 5.1 and 5.4.
This solution was then mixed with between 1 and 2 equivalents of the NHS-activated
ester of phosphatidyl ethanolamine (12), dissolved in tert-butanol. The mixture was
stirred at room temperature and the progress of the reaction was monitored by LC-MS.
After 1 h of reaction it was possible to observe a peak which displayed a mass spectrum
corresponding to the desired product: 1316 (M+5H)/5, 1097 (M+6H)/6. The RP-HPLC
chromatogram of the coupling reaction mixture is shown in Figure 56. After 4 h of
reaction, it was observed that no more of the product peak was being formed. The
product was therefore purified. Calculated MW for lipopeptide 61: 6574.45, measured
ESI-Tof-MS (m/z): 6575.1±0.01%.
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Figure 56: Crude reaction mixture after reaction of peptide 60 with activated phosphatidyl ethanolamine
(12). The final peak is the lipopeptide 61. For HPLC conditions see Appendix 4.
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Figure 57: Structure of the lipopeptide 61.
Unfortunately, the yields of product 61 were quite low (~10%), and variation of
the reaction conditions, for example, by increasing or decreasing concentrations, or
increasing the number of equivalents of the activated phospholipid, or the proportion of
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tert-butanol in the reaction mixture, had very little effect on the outcome. This problem
could be explained by the nature of the purified product, which had a waxy consistency
and was not easily water-soluble, and could possibly be adhering to reaction vessels as it
was formed, without being easily observed. Attempts to clean glass vessels with various
solvents in order to recover adsorbed product met with little success. However, it was
possible to obtain a sufficient quantity of the product for immunization studies.
Unfortunately, probably due to the physical properties of the product, it was not found to
induce any immune response after loading into virosomes under standard conditions. It is
as yet unclear whether the waxy product had truly been incorporated into the virosomes.
In any case, it seemed that this poorly soluble mimetic did not represent a good vaccine
candidate.
1.3.3.5 Synthesis of modified MSP-4 mimetic with improved solubility
In the Robinson group, some success has been seen in the improvement of
solubility of phospholipidyl-peptide mimetics by the inclusion of a series of lysine
residues at the N-terminus of the peptide sequence adjacent to the linker used for
phospholipid attachment. It was decided to test the effect of such a modification on the
properties of mimetic 61. Therefore the modified amino acid sequence of peptide 62,
illustrated below, was assembled on Rink amide resin.
KKKKLEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS
H
N
H2N
O 62
NH2
Figure 58: Structure of modified peptide mimetic 62.
The crude product, cleaved from the resin and side-chain deprotected could be
oxidatively folded without any previous purification, using the same conditions as
described for the oxidation of peptide 56, and leading to the product (63) illustrated by
the chromatogram in Figure 59 (A). The peak at lowest retention time was shown by
LC-MS to correspond to the expected molecular weight of the desired product, and was
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separated to obtain the purified product illustrated in the chromatogram in Figure 59 (B).
Calculated MW of mimetic 63: 6314.30, measured MALDI-MS (m/z): 6314.021.
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Figure 59 (A): Chromatogram of crude peptide mimetic 63. For HPLC conditions see Appendix 4.
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Figure 59 (B): Purified peptide mimetic 63. For HPLC conditions see Appendix 4.
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Figure 60: Presumed disulfide bonding in peptide mimetic 63.
This oxidised peptide could be used in coupling reactions with activated
phosphatidyl ethanolamine (12) as previously described. An example of a RP-HPLC
chromatogram of the reaction mixture is given in Figure 61. The marked peak was
shown by LC-MS analysis to correspond to the expected mass of the desired product.
Calculated MW of lipopeptide 64: 7087.33, measured m/z (ESI-MS): 1418.2 (M+5H/5),
1182.0 (M+6H/6), 1012.5 (M+7H)/7) (±0.01%). After HPLC purification, lipopeptide 64
was shown by MALDI-MS to have a molecular weight of 7088.022 (±0.1%).
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Figure 61: Crude mixture after reaction of peptide 63 with activated phospholipid (12). The marked peak
corresponds to the lipopeptide 64.
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This product showed better physical properties than peptide mimetic 61, being a
white fluffy powder which was easily soluble in acetonitrile-water mixtures.
Investigations into the immunological properties of this peptide when incorporated into
virosomes have yet to be carried out.
KKKKLEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS
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Figure 62: Structure of lipopeptide 64.
1.3.4 Discussion
MSP-4 is an immunogenic protein containing a single EGF-like domain at its C-
terminus, and regions of the protein are natural antigens in malaria infections. The
correct conformation of the EGF-like domain is important for the folded structure and the
immunogenicity of the whole protein [113]. The combination of MSP-4 and MSP-119 has
been shown to induce improved protection against P. falciparum and in some cases an
increased antibody response to MSP-119 [115, 116]. Therefore, this protein was chosen as an
interesting target for development as a potential component of a multi-antigen synthetic
malaria vaccine candidate.
Based on the successful methods developed for the synthesis of the MSP-1
peptides 2 and 13, a peptide mimetic based on the EGF-like domain of MSP-4 of P.
falciparum was synthesised. Initial peptide chain assembly difficulties could be
overcome by the introduction of a pseudoproline unit. Pseudoprolines are used to disrupt
-sheet formation, [122] which can be a source of interchain aggregation, leading to poor
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amino acid coupling yields in peptide assembly. The peptide chain could be oxidatively
folded under conditions described in the previous chapter. The oxidative conditions led
to the formation of one main product which was shown by Ellman test to contain no free
thiol groups. NMR studies showed a wide spread of peaks in the amide proton region,
suggestive of a well-structured product.
A modified analogue of the linear peptide chain containing an N-terminal
hydrazinoglycine could be oxidatively folded in the same way, and the side chain
deprotected folded product could be coupled in solution with an activated form of
phosphatidylethanolamine to provide a poorly soluble phospholipidyl peptide. This
product proved difficult to handle and gave negative results in immunological testing as a
vaccine candidate.
However, the modification of the peptide sequence to include 4 further N-terminal
lysine residues permitted the synthesis, in better yields, of an MSP-4 mimetic with more
favourable physical properties. Inclusion of this mimetic in virosomes and immunisation
of mice would make it possible to evaluate the suitability of this EGF-like domain
mimetic for inclusion in a multi-stage, multi-antigen malaria vaccine. In these studies, it
would also be very interesting to investigate the effect of combining MSP-119 mimetics
with the MSP-4 mimetic in the same immunization. An MSP-4 mimetic could prove a
useful adjuvant if it were to enhance the response to other antigens such as MSP-119.
Enzymatic digestion of the peptide mimetic should also be carried out in the future in
order to confirm the disulfide bonding connectivities. Proteolytic studies on the native
protein should also be undertaken, as there is currently no evidence available about the
disulfide bonding in this EGF-like domain.
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1.4 Glutamate-rich protein (GLURP)
1.4.1 Structure and location of GLURP
The 220 kDa glutamate rich protein (GLURP) was identified in 1991. It was
investigated as an antigen that is released on the rupture of P. falciparum schizonts, but
was subsequently found to be expressed at all stages of the parasite’s life cycle within the
human host, including on the surface of newly released merozoites [124]. Three regions of
interest are identified in the protein: the repeat regions R1 and R2, and the N-terminal
non-repeat region which is termed R0, illustrated in Figure 63.
24 489 702 816 1091 1271
Figure 63: Schematic representation of the structure of the glutamate rich protein.
The R0 region is found to be relatively well-conserved between several
laboratory lines and field isolates of P. falciparum, showing, for example, considerably
less polymorphism than the circumsporozoite protein [125]. In an extensive study
involving a phage-display library and a library of synthetic peptides in affinity studies
with IgG from immune adults, six major B-cell epitopes were identified in the R0 region,
of which four were frequently recognized by high-titre IgG antibodies from immune
adults, suggesting them as good potential targets for vaccine development [126]. No three-
dimensional structural information for GLURP is as yet available, but the epitopes P1, P3
and P4 (three of the four epitopes well-recognized by immune sera) share a common
sequence motif and could therefore be structurally related.
1.4.2 Evidence for GLURP as a vaccine candidate
Several studies have shown that high levels of anti-GLURP antibodies are
associated with low levels of parasitemia and with absence of disease in humans in
malaria-endemic regions [127-131]. Furthermore, purified human anti-GLURP antibodies
have been shown to induce antibody-dependent monocyte-mediated inhibition (ADCI) of
parasite growth in vitro [132]. This study showed that none of the human antibodies
R0 R1 R2
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investigated that reacted with GLURP were able to inhibit invasion of erythrocytes by
merozoites directly, but when they were allowed to co-operate with monocytes they
showed a dose-dependent, monocyte-dependent parasite growth inhibitory activity. It has
recently been shown that the combination of P. falciparum GLURP and MSP-3 in the
form of a recombinant protein can induce partial protection against subsequent challenge
with P. falciparum-infected red blood cells in Saimiri monkeys [133]. Antibodies against
MSP-3 are also believed to protect via ADCI. The limited polymorphism mentioned
above also suggests that GLURP mimetics could provide good candidates for a non-
species-specific vaccine, and could also indicate that GLURP is important for parasite
survival.
1.4.3 GLURP peptide mimetics
1.4.3.1 Mimetic design.
Based on the findings of Theisen et al. [126], it was decided to synthesise a small
library of 16 peptide mimetics incorporating the epitopes P1, P3 and P4, as well as the
peptide sequence P2, which overlaps with P1 and P3. The epitopes identified by Theisen
et al. are illustrated in Figure 64 and the peptide mimetics to be synthesised in this study
are presented in Figure 65.
(a)
160 170 180 190 200
LENSSQDNLD KDTISTEPFP NQKHKDLQQD LNDEPLEPFP TQIHKDYKEK
210 220 230
NLINEEDSEP FPRQKHKKVD NHNEEKNVFH
(b)
173 183 193 203
P1) ISTEPFPNQK HKDLQ
P2) QK HKDLQQDLND EPL
P3) EPLEPFPTQI HKDYK
216 226
P4) DSEPFPRQKH KKVD
Figure 64: (a) Fragment of the sequence of the R0 region of GLURP. The repeated motif is highlighted in
bold. (b) Sequences of the epitopes P1, P3 and P4 and of the peptide sequence P2 identified by Theisen et
al. [126].
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For peptides 73-78, X= -COCH3, For peptides 65-72, X=
Figure 65: Structures of peptide mimetics designed to mimic epitopes on GLURP. Peptides 65-72 were
designed for loading into virosomes and immunizations, peptides 73-78 for NMR studies.
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As can be clearly seen in Figure 65, peptides 65 and 73 were designed to mimic
epitope P1, peptides 66 and 74 to mimic peptide P2, peptides 67 and 75 to mimic epitope
P3, peptides 68-70 and 76-78 to mimic epitope P4, peptide 71 to cover the entire
sequence from P1 to P3 and peptide 72 to cover the sequence from P3 to P4. In each
peptide mimetic, glycine residues were introduced at the N-terminal end as a linker to
provide some space between the epitope sequence and the phospholipid moiety, in the
cases of the phospholipidyl-peptides 65-72. In mimetics 69, 70, 77 and 78, cysteine
residues were introduced. A disulfide bond was to be formed between the two cysteines
in mimetics 70 and 78, in order to study the effect of this constraint on NMR properties
and on immunological responses. In mimetics 69 and 77, the cysteine thiol groups were
alkylated for comparison with mimetics 70 and 78. In order to synthesise the N-terminal
acetylated products 73-78, peptidyl-resin was treated after final Fmoc-deprotection with
acetic anhydride. The success of the acetylation reaction was monitored using the Kaiser
test [134], which gave a positive result, indicating free amine, before the reaction, and a
negative result after the reaction. To synthesise the lipopeptide mimetics 65-72, Fmoc-
deprotected peptidyl resin was treated with succinyl-PE 11, HATU and HOAt in DMF
with DIEA. This reaction was carried out overnight and completion was monitored by
the Kaiser test.
1.4.3.2 Mimetics 65-68 and 73-76
For the synthesis of peptides 65 and 73, the peptide sequence
GGKDTISTEPFPNQKHKDLQQDLN was assembled on Rapp Polymere amide resin
with an initial loading of 0.74 mmol/g.
For the synthesis of peptides 66 and 74, the peptide sequence
GGNQKHKDLQQDLNDEPLEPFPTQ was assembled on Rink amide resin with an
initial loading of 0.64 mmol/g.
For the synthesis of peptides 67 and 75, the peptide sequence
GGNDEPLEPFPTQIHKDYKEKNLINEE was assembled on Rink amide resin with an
initial loading of 0.64 mmol/g.
For the synthesis of peptides 68 and 76, the peptide sequence
GGNEEDSEPFPRQKHKKVDNHNEEK was assembled on Rink amide resin with an
initial loading of 0.64 mmol/g.
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For all peptides, single (20 mins) coupling cycles were used for each amino acid,
with an acetic anhydride capping step before each Fmoc deprotection, in order to cap
unreacted sites and thus simplify purification steps.
The resin was then split into two portions, one being treated with succinyl-PE as
described above to provide mimetics 65-68, and the other with acetic anhydride to
provide mimetics 73-76. Both peptidyl resins were then treated with TFA containing
2.5% EDT, 2.5% water and 1% TIS, to provide the fully side-chain deprotected products
which could be purified by RP-HPLC. The purified products were analysed by RP-
HPLC and ESI-MS. The chromatograms of the products are shown in Figures 66-69.
The masses found were as follows:
65: Calculated MW: 3484.02 g/mol
Measured: 1742.5 (M+2H)/2, 1162.3 (M+3H)/3, 871.8 (M+4H)/4 (± 0.01%)
73: Calculated MW:2752.02 g/mol
Measured: 1376.8 (M+2H)/2, 918.0 (M+3H)/3, 688.7 (M+4H)/4 (± 0.01%)
66: Calculated MW: 3522.02 g/mol
Measured: 1761.7 (M+2H)/2, 1174.9 (M+3H)/3, 881.0 (M+4H)/4 (± 0.01%)
74: Calculated MW: 2790.02 g/mol
Measured: 1395.8 (M+2H)/2, 930.8 (M+3H)/3, 698.6 (M+4H)/4 (± 0.01%)
67: Calculated MW: 3928.50 g/mol
Measured: 1964.9 (M+2H)/2, 1310.5 (M+3H)/3, 982.8 (M+4H)/4 (± 0.01%)
75: Calculated MW: 3196.50 g/mol
Measured: 1066.2 (M+3H)/3, 800.0 (M+4H)/4 (± 0.01%)
68: Calculated MW: 3722.18 g/mol
Measured: 1241.7 (M+3H)/3, 931.4 (M+4H)/4, 745.2 (M+5H)/5 (± 0.01%)
76: Calculated MW: 2990.18 g/mol
Measured: 997.6 (M+3H)/3, 748.5 (M+4H)/4, 599.0 (M+5H)/5 (± 0.01%)
For HPLC conditions for all peptides see Appendix 4.
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Figure 66: (A) Chromatogram of pure lipopeptide 65.
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Figure 66: (B) Chromatogram of pure peptide 73.
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Figure 67: (A) Chromatogram of lipopeptide 66. (B) Chromatogram of peptide 74.
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Figure 68: (A) Chromatogram of lipopeptide 67. (B) Chromatogram of peptide 75.
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Figure 69: (A) Chromatogram of lipopeptide 68.
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Figure 69: (B) Chromatogram of peptide 76.
1.4.3.3 Mimetics 69 and 77
The peptide sequence GGCINEEDSEPFPRQKHKKVDNHNECG was assembled
on Rink amide resin with an initial loading of 0.66 mmol/g. Single (20mins) coupling
cycles were used for each amino acid, with an acetic anhydride capping step before each
Fmoc deprotection, in order to cap unreacted sites and thus simplify purification steps.
The peptidyl resin was then split into two batches. The first batch was treated with
succinyl-PE in order to produce mimetic 69. The coupling reaction was monitored using
the Kaiser test. The second batch was treated with acetic anhydride as described above in
A
B
Chapter 1: Malaria vaccine candidates; GLURP 96
order to produce mimetic 77. Both peptide mimetics were then cleaved from the solid
support and side-chain deprotected using TFA containing 2.5% EDT, 2.5% water and 1%
TIS.
The crude phosphatidyl-peptide was then purified by RP-HPLC to produce the
intermediate product 79 with free cysteine thiol groups. This product was analysed by
LC-MS: Calculated MW: 3840.38 g/mol, Measured: 1281.5 (M+3H)/3, 961.9
(M+4H)/4, 769.7 (M+5H)/5 (± 0.01%).
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Figure 70: Structure of the intermediate product 79.
This intermediate product was then treated with 20 eq of iodoacetamide in
phosphate buffer at pH 7.5 [135], to produce mimetic 69 with almost 100% conversion
after 1 hour of reaction. This reaction solution was frozen and lyophilised to stop the
reaction, and then the product was redissolved in water and purified by RP-HPLC to
obtain pure mimetic 69, which was analysed by analytical HPLC and ESI-MS. The
chromatogram of pure mimetic 69 is shown in Figure 71.
Calculated MW: 3954.48 g/mol, measured: 1319.5 (M+3H)/3, 791.9 (M+5H)/5 (±
0.01%).
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Figure 71: Chromatogram of lipopeptide 69. For HPLC conditions see Appendix 4.
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Figure 72: Structure of intermediate peptide 80.
The crude acetylated product 80 was alkylated using iodoacetamide in phosphate
buffer as described for the synthesis of mimetic 69, to produce crude mimetic 77, which
could be purified by HPLC to obtain pure mimetic 77, which was analysed by HPLC and
ESI-MS. The chromatogram of the pure product is shown in Figure 73.
Calculated MW: 3221.44 g/mol, measured: 1612.2 (M+2H)/2, 1075.1 (M+3H)/3,
806.7 (M+4H)/4, 645.6 (M+5H)/5 (± 0.01%).
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Figure 73: Chromatogram of peptide 77. For HPLC conditions see Appendix 4.
Mimetic 69 was used for virosome formulation and immunization trials. Mimetic
77 was used for 1H NMR measurements.
1.4.3.4 Mimetics 70 and 78
A new batch of the peptide sequence GGCINEEDSEPFPRQKHKKVDNHNECG
was prepared on the solid support as described above, and the intermediates 79 and 80
were obtained in the same fashion. It was decided to concentrate effort on the more
challenging oxidation of intermediate 79 to form mimetic 70, and to return to the
oxidation of mimetic 80 to give 78 for NMR studies after immunizations had been carried
out, to evaluate whether mimetic 70 was a good vaccine candidate. Therefore, some
small-scale oxidation reactions were carried out using the purified intermediate 79, and it
was found that stirring the mimetic for approximately 48 hours in a 1:1 mixture of
ammonium acetate buffer (pH 8)/trifluoroethanol, in an open vessel, allowed an almost
complete conversion of the starting material to a new product. This product could be
purified directly from the reaction mixture, and the purified mimetic obtained was shown
by Ellman test to contain no free thiol groups. The product was analysed by RP-HPLC
and by ESI-MS. Chromatograms of various stages of the oxidation reaction and of the
purified product are shown in Figure 74.
Calculated MW: 3838.29 g/mol, measured: 1920.2 (M+2H)/2, 1280.4 (M+3H)/3,
960.6 (M+4H)/4 (± 0.01%).
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Mimetic 70 was used for inclusion in virosomes and immunization studies.
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Figure 74: (A) Reaction mixture after 2 hours of oxidation. (B) Reaction mixture after 4 hours of
oxidation. (C) Reaction mixture after 9 hours of reaction. (D) Purified peptide 70. For HPLC conditions
see Appendix 4.
1.4.3.5 Mimetics 71 and 72
For the synthesis of peptide 71, the peptide sequence
GGDTISTEPFPNQKHKDLQQDLNDEPLEPFPTQIHKDYKEKN was assembled on Rink amide
resin with an initial loading of 0.64 mmol/g.
For the synthesis of peptide 72, the peptide sequence
GGNDEPLEPFPTQIHKDYKEKNLINEEDSEPFPRQKHKKVDN was assembled on Rink amide
resin with an initial loading of 0.64mmol/g.
Single (20 mins) coupling cycles were used for each amino acid, with an acetic
anhydride capping step before each Fmoc deprotection, in order to cap unreacted sites
and thus simplify purification steps.
The resins were then treated with succinyl-PE to provide mimetics 71 and 72.
The peptidyl resin was then treated with TFA containing 2.5% EDT, 2.5% water and 1%
A B
C
D
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TIS, to provide the fully side-chain deprotected products which could be purified by RP-
HPLC. The purified products were analysed by RP-HPLC and ESI-MS. The
chromatograms of the products are shown in Figures 75 and 76. The masses found were
as follows:
71: Calculated MW: 5666.41 g/mol, measured: 1417.2 (M+4H)/4, 1134.1
(M+5H)/5, 945.4 (M+6H)/6 (± 0.01%).
72: Calculated MW: 5735.52 g/mol, measured: 1434.3 (M+4H)/4, 1148.0
(M+5H)/5, 956.9 (M+6H)/6 (± 0.01%).
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Figure 75: Chromatogram of lipopeptide 71. For HPLC conditions see Appendix 4.
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Figure 76: Chromatogram of lipopeptide 72. For HPLC conditions see Appendix 4.
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1.4.3.6 Immunization results
All of the mimetics were able to elicit a strong anti-mimetic immune response, but
unfortunately, the binding of the antibodies in the sera to whole parasites in
immunoflourescence assays, even after four immunizations, was very weak. The
presence or absence of a disulfide bond seemed to have little influence on the
immunological properties of the mimetics.
1.4.3.7 NMR results
1H NMR spectra of the mimetics are presented in Appendix 2. Unfortunately, the
spectra do not seem to indicate well-structured products, showing only the typical narrow
range of amide NH signals seen in an unfolded protein, and not showing any NH-
CHcoupling constants indicating well-defined structure.
1.4.4 Discussion
The glutamate rich protein is expressed at all stages of the malaria parasite’s life
cycle, including on the surface of newly released merozoites [124]. The protein contains
two repeat regions, and an N-terminal non-repeat region that is relatively well-conserved
between several strains [125]. Studies revealed major B-cell epitopes in the non-repeat
region which were recognised by high-titre antibodies from immune adults [126],
suggesting that the non-repeat region of GLURP could provide good targets for a
potential malaria vaccine. It has also been shown that high levels of anti-GLURP
antibodies are associated with low levels of parasitemia in malaria endemic regions.
The aim of this project was to prepare peptide mimetics suitable for virosomal
formulation based on the epitopes identified by Theisen et al. Mimetics based on each of
four epitopes were designed, as were two longer peptide sequences, each spanning at
least two of the epitopes proposed by Theisen et al[126].
Linear and cyclised mimetics of epitopes from the R0 non-repeat region of the
glutamate-rich protein of P. falciparum could be prepared by solid-phase peptide
synthesis. N-terminal acylated peptides could be prepared for NMR studies, and
lipopeptides could be prepared via on-resin coupling of a modified phosphatidyl-
ethanolamine (PE), followed by cleavage and purification of the whole mimetic. A
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disulfide bridged mimetic could be prepared by introducing cysteine residues before and
after the sequence of interest. The linear lipopeptide precursor could be cyclised in a
clean air oxidation reaction. The PE-coupled peptides were included in virosomes
prepared by Pevion Biotech and were used to elicit an immune response in mice.
Unfortunately, the sera obtained were only poorly cross-reactive with P.
falciparum parasites in IFA. It must be concluded that the mimetics in their current form
are not good candidates as potential components of a multi-stage, multi-antigen malaria
vaccine. Although the work of Theisen et al. [126] showed that the peptide sequences P1 –
P4 were recognised by high-titre antibodies from immune adults, there was no indication
that these peptide sequences would be able to induce a meaningful immune response
when taken alone. The antibodies may be able to recognise unstructured peptide
sequences to a certain extent, even if the antigens required to induce the antibody
response are conformational. Unfortunately, the lack of current knowledge about the
three-dimensional structure of the native protein makes the design of conformational
mimetics difficult. If future NMR or crystal studies were to reveal structural information
about GLURP, new mimetics could be designed based on this knowledge, and constraints
could be introduced in order to lock peptide structures into a conformation mimicking the
protein as found in the parasite. Such mimetics may then be able to induce antibodies
that would recognise the parasite and therefore play a role in protective immunity.
1.5 Conclusions
Three different proteins, MSP-1, MSP-4 and GLURP were investigated for their
potential as components of a multi-antigen malaria vaccine candidate. The MSP-1 and
MSP-4 mimetics both contained six cysteine residues and for both, folding in the
presence of cysteine/cystine led to the formation of one main fully oxidised product.
NMR spectra of both mimetics suggested a well-structured product, and the
solution structure of the MSP-1 mimetic could be determined and was shown to be very
similar to the structure of the corresponding domain in the two-domain protein MSP-119.
Proteolysis studies showed that the MSP-1 mimetic conformed to the EGF-like disulfide
bonding pattern. The MSP-1-based lipopeptide developed for immunizations induced a
good immune response and the sera obtained were cross-reactive with blood-stage P.
falciparum parasites. This mimetic could therefore represent a good candidate for
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inclusion in a multi-antigen malaria vaccine. 50 monoclonal antibodies could be derived
from the mice immunized with this mimetic, and the binding of these with mutant
mimetics should be investigated in the future, in order to characterise the immune
response to the peptide mimetic. Based on these epitope-mapping studies, new mimetics
could be developed for immunizations, perhaps eventually leading to a mimetic that
could induce only inhibitory antibodies, with the exclusion of the blocking antibodies that
are induced by native MSP-119.
The mimetics based on MSP-4 and GLURP unfortunately induced sera that only
responded weakly to blood stage P. falciparum parasites in immunofluorescence assays.
However, it was interesting to note that the synthetic difficulties encountered in the first
attempt at synthesis of the MSP-4 mimetic could be overcome by the introduction of a
pseudoproline unit during chain assembly. The oxidative folding of the linear peptide
again led to one main fully oxidised product, suggesting that the method developed could
serve as a good general technique for the oxidative folding of synthetic EGF-like
domains. This could be of particular interest in the development of malaria vaccine
candidates, since several EGF-like domains are present in merozoite surface proteins.
The development of peptide vaccines directed against other EGF-like domains,
for example against human EGF or HER-2/neu, which are frequently overexpressed in
cancer, is also of great interest. There is already evidence that there is a direct
relationship between anti-EGF antibody titers and immune response duration with
survival time in cancer patients [136]. The development of a synthetic virosome-based
vaccine presenting these kinds of antigens could be envisaged, based on the methods
developed in this work.
Another interesting result to emerge from this work was that the physical
properties of one lipopeptide could be improved by the introduction of a series of
contiguous lysine residues at the N-terminus, a technique that could be attempted with
other difficult peptide products in the future.
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2 Peptoid-peptide hybrids as antimicrobial
agents
2.1 Antimicrobial peptides
2.1.1 Physical and structural properties
Naturally-occurring antimicrobial peptides (AMPs) have been identified in a wide
variety of plant, invertebrate and vertebrate species [137-141]. They form part of the innate
immune system, protecting against a broad range of microorganisms, including Gram-
positive and Gram-negative bacteria, fungi and parasites. Due to their function as a first
line of defence, AMPs tend to be found in those parts of organisms that most frequently
come into contact with pathogens, such as skin, eyes and epithelial surfaces. Although
they are found in a wide range of organisms, AMPs share several common
characteristics. Most of the sequences fall into the range of ~10 to ~50 amino acid
residues, although antimicrobial activity has even been reported for di- and tripeptides
[142]. The largest known AMPs are made up of over 60 residues. AMPs are often
charged. Cationic peptides, rich in arginine and lysine, as well as anionic peptides that
are complexed with zinc, are often more active than neutral peptides or those with a low
charge. AMPs can form a wide variety of secondary structures, and those with well-
defined secondary structures such as antiparallel -sheets or-helices are often more
active than those with less well-defined structures. Defined structure can be an aid to the
next common characteristic of AMPs, which is amphipathicity – that is, the aligning of
hydrophilic residues along one face of the molecule, and of hydrophobic residues on the
opposite face. The sequence of AMPs is encoded by the genetic material of the host
organism, and there can be some posttranslational modifications after transcription often
including cleavage from a precursor protein, C-terminal amidation, and disulfide
formation. The AMPs are therefore not to be confused with peptide antibiotics, which
are mostly synthesised by special metabolic pathways and are highly modified. Over 800
antimicrobial peptides have already been discovered [143] and these can be divided into
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subgroups based on their amino acid composition and structure [142]. Some subgroups are
briefly described here, and examples are presented in Table 11.
Subgroup Examples Source Sequence
Cecropin A insect KWKLFKKIEKVGQNIRDGIIKAGPAVAWGQATQIAKa
Magainin 2 amphibian GIGKFLHSAKKFGKAFVGEIMNS
LL-37 human LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES
-helical,
cationic
Dermaseptin amphibian ALWKTMLKKLGTMALHAGKAALGAAADTISQGTQ
Indolicidin cow ILPWKWPWWPWRRa
Prophenin pig AFPPPNFPGPRFPPPNVPGPRFPPPNFPGPRFPPPNFPGPR
FPPPNFPGPPFPPPIFPGPWFPPPPPFRPPPFGPPRFP
Histatin 5 human DSHAKRHHGYKRKFHEKHHRSHRGY
Amino
acid-
enriched
Apidaecin bee GNNRPVYIPQPRPPHPRI
Bactenecin
(1 Cys-Cys)
cow RLCRIVVIRVCR
Tachyplesin
(2 Cys-Cys)
crab RWCFRVCYRGICYRKCRa
Disulfide-
bonded
Protegrin 1
(2 Cys-Cys)
pig RGGRLCYCRRRFCVCVGRa
Table 11: Structures of a range of naturally-occurring antimicrobial peptides. a indicates that the peptide
is C-terminally amidated. [139]
2.1.2 Classification
A large subgroup consists of short (<40 residues) cationic peptides, that do not
contain cysteine residues. Many of these peptides are unstructured in aqueous solution,
but part of or even all of the molecule becomes structured as an -helix in the presence of
TFE, SDS micelles, phospholipid vesicles, liposomes or lipid A. It seems that increased
-helical content correlates with better antimicrobial activity [144]. A smaller subgroup
contains peptides that also lack cysteine residues, but are enriched in certain amino acids,
including proline-rich peptides, arginine-rich peptides and tryptophan-rich peptides.
These peptides tend to have linear structures, although some form extended coils. The
largest subgroup consists of anionic and cationic peptides that contain cysteine residues
forming one or more disulfide bonds. Many of these peptides are constrained by their
disulfide bonds into stable -sheets. A fourth, smaller subgroup contains anionic
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peptides that are active against Gram-positive and Gram-negative bacteria and require
zinc as a co-factor for activity.
2.1.3 Selectivity and modes of action
The increasing emergence of bacterial resistance to known antibiotics has
prompted intensive research into new sources of antimicrobial agents [145, 146]. One of the
areas of great interest is the study of the mechanisms of action and selectivity of the
antimicrobial peptides, and the development of antimicrobial peptides with clinical
applicability. Obviously, if drugs are to be developed based on AMPs, they need to have
a very good selectivity for microbial over eukaryotic cells. Although many AMPs, e.g.
melittin [147], show poor selectivity for bacteria, several naturally-occurring AMPs have
been shown to have no haemolytic activity [148, 149] at the concentration needed for
antimicrobial activity, including the magainins and cecropins. It seems that the most
important factor in selectivity is the difference in the composition of bacterial and
eukaryotic cell membranes [139]. The outer leaflet of eukaryotic membranes is composed
of zwitterionic phospholipids, whereas bacterial cell membranes contain a large
proportion of negatively-charged phospholipids.
The cationic nature of most AMPs facilitates their interaction with negatively
charged bacterial outer membranes. A second difference between the two types of
membrane is the absence of cholesterol in bacterial cell membranes. This renders the
membrane more flexible and also more susceptible to disruption and destabilization by
amphiphilic AMPs. Due to the long history of the exploitation of AMPs by the innate
immune system, bacterial species have had time to develop resistance mechanisms. One
of the most common is the modification of the bacterial cell membrane components [150],
but membrane proteases and efflux pumps are also employed by some species to
deactivate or expel the peptides [151, 152]. Based on the common characteristics of AMPs,
on the knowledge that in many cases, synthetic all-D-amino acid enantiomers of AMPs
have comparable antimicrobial activity to their L-amino acid natural counterparts [139],
and on the evidence that the presence of AMPs enhances ion permeability of lipid
bilayers, it was for many years believed that all AMPs act via a membrane
permeabilisation mechanism to cause leakage and eventual cell death. However, there is
increasing evidence that at least some AMPs act on intracellular targets, for example by
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inhibiting cell-wall synthesis [153], nucleic acid synthesis [154, 155] or protein synthesis [154,
156].
2.1.4 Design of AMP-based drug candidates
At present, understanding of the interactions between AMPs and their putative
intracellular targets is not at such an advanced stage that synthetic AMP-based drug
candidates can be designed to target specific bacterial mechanisms. An alternative
approach is to design and synthesise peptidomimetics with consideration of the general
characteristics of known AMPs, and then to conduct studies on their mechanisms of
action. In any case, whether to act by membrane permeabilisation, or to act on some
more specific target within the bacterial cell, AMPs and AMP-based peptidomimetics
must first interact with the bacterial membrane before disrupting it or gaining access to
their secondary targets via transport through the membrane. Many research groups are
currently investigating the possibility of designing molecules based on AMPs, as new
agents in the fight against resistant microorganisms, aiming to attain the goals of high
antimicrobial activity, high selectivity, and good pharmacological properties. In the
Robinson group, there has been much research into the design and synthesis of
peptidomimetics based on naturally-occurring AMPs, with particular emphasis on those
displaying -hairpin like structures, and subsequent studies of their structure,
antimicrobial activity, selectivity towards bacterial cells, and possible modes of action.
2.2 Peptoids
2.2.1 Peptidomimetics
Peptidomimetics are molecules designed to resemble bioactive peptides in
functionality and/or overall shape, but having structural features that diverge from those
of the peptide, for example in that they have different types of bonding, or
conformational constraints [157]. Many different types of change can be introduced into
synthetic mimetics of peptides. For example, to improve the stability of the mimetic
towards proteases or to constrain the amino acid side chains into an amphipathic
conformation. Many mimetics have been designed involving some kind of structural
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constraint such as backbone-backbone, sidechain-backbone, or sidechain-sidechain
cyclisations [158].
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Figure 77: Templates used in the synthesis of -sheet and -hairpin peptide mimetics.
These constraints should help to mimic the conformation of a disulfide-bonded
peptide, or should fix the mimetic into a conformation that is usually only attained by the
peptide on interaction with a membrane, or perhaps increase the stability of the mimetic
towards proteases. Some popular techniques for inducing a particular secondary structure
include the use of -amino acids to make -peptides [159-161], the introduction of C-
disubstituted-amino acids into peptide sequences [162] and the use of templates to induce
turn structures. Some examples of these templates are presented in Figure 77.
Depending on the substitution pattern of the -and -carbons, a 14-helix, 12-helix
or 10-helix conformation can be conferred on a -peptide. The introduction of
substituted amino acids such as -aminoisobutyric acid into a peptide sequence tends to
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induce the formation of an - or 310 helix. Several organic templates have been shown to
induce -turn structures in peptide mimetics [163, 164]. Within the Robinson group, the
DPro-LPro template has been extensively exploited for its -hairpin inducing properties
[165-169].
2.2.2 Structure and synthesis of peptoids
A valuable tool available to chemists in the pursuit of antimicrobial peptide
mimetics, is the diversity of structures available to them, not being restricted to the 20
naturally-occurring amino acids. One possibility is the introduction of synthetic non-
natural amino acids into peptide sequences, another being the synthesis of peptoids,
which are polymers of N-substituted glycines (i.e. the side-chain is ‘shifted’ from the -
carbon onto the amide nitrogen of the amino acid residues). The generalized structure of
a peptoid is presented in Figure 78. Peptoid analogues of natural amino acids Xaa are
usually named Nxaa [170], such that, for example a glycine substituted with -CH3 on the
N-atom is called Nala, and a glycine substituted with -CH2COOH on the N-atom is called
Nasp. Peptoid units containing side chains not occurring in natural amino acids are also
assigned symbols of the form Nxxx, such as Nade – N-adamantylethylglycine. The most
common, ‘submonomer’ method [171, 172] of solid-phase synthesis, illustrated in Scheme 7,
allows the introduction of as wide a range of side chains as there are amines available for
coupling, as it proceeds in two steps, the first being the introduction of an -haloacetyl
moiety and the second the substitution of the halide with a primary amine. Peptoids are
additionally believed to be more stable towards proteases than their peptide analogues
[173]. Although the solid phase submonomer method is synthetically the simplest route to
peptoid structures, other pathways have also been successfully employed, including solid-
phase synthesis based on peptoid monomers analogous to the protected amino acids used
in standard Fmoc solid-phase peptide synthesis [170] and solution-phase assembly using
similar Fmoc-protected monomers [174]. There have also been advances in coupling
techniques in recent years, for example the use of microwave-assisted solid-phase
chemistry to allow the inclusion of amine submonomer building blocks of low intrinsic
reactivity [175].
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Figure 78: The generalized structure of a peptoid.
Cl
X
HO
O
X
O
HN
O
R4
R4NH2
X
HO
O
N
O
R4
X
O
R3NH2
N
O
R4
HN
OR3
etc
Coupling
conditions
X: Br or Cl
O O
OO
Scheme 7: The submonomer method for solid-phase synthesis of peptoids.
Some important structural features of peptoids, as compared to their peptide
analogues, can be clearly observed in the sketch in Figure 78. Firstly, due to the
presence of the side chain, the amide nitrogen atoms no longer possess a hydrogen atom
which could be involved in intra- or interchain hydrogen bonding, thus precluding them
from the hydrogen-bond stabilized secondary structures of natural polypeptides.
Secondly, there is a loss of chirality at the -carbon atom. Nevertheless, it has been
shown that peptoid oligomers can form stable, chiral, polyproline-like helices in both
organic and aqueous solvents, if they contain a high proportion of -chiral, aromatic side
chains [176]. Based on this knowledge, amphiphilic helical peptoids were designed and
were found to assemble into oligomers in aqueous conditions, which could bind 1-
anilinonaphthalene-8-sulfonate, suggesting that they formed a hydrophobic pocket [177].
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Peptoids containing bulky chiral side-chains have also been shown to fold into an unusual
‘threaded loop’ structure, albeit only in the absence of hydrogen-bonding solvents [178].
Therefore, it seems that it should be possible in the future to design peptoid oligomers
with defined folded structures.
2.2.3 Peptoids and peptide-peptoid hybrids with biological activity
The modular nature of peptoids makes them highly amenable to combinatorial
synthetic methods. Ng et al. [179] designed a library of peptoid trimers based on structures
that had shown antimicrobial activity in a screen of a wide range of combinatorial
libraries. 65 pools, each containing 13 compounds were produced and screened for
antimicrobial activity in a growth inhibitory assay. Peptoids containing N-terminal
dehydroabietylamine (85) all showed growth inhibitory activity against S. aureus at 1M
concentration and two peptoid trimers also inhibited E. coli growth at the same
concentration. On further investigation, the most active compounds were shown to have
MICs in the micromolar range for a wide range of bacteria, including methicillin-
resistant, penicillin-resistant and vancomycin-resistant strains, and showed batericidal,
rather than bacteriostatic killing kinetics [180]. Unfortunately, the most active peptoids
also showed significant haemolytic activity on red blood cells at higher concentrations.
However, these studies, and subsequent combinatorial methods [181] have shown that it is
possible to synthesize peptoid oligomers with some antimicrobial activity and selectivity
for Gram-positive bacteria.
H2N
85
Figure 79: Structure of dehydroabietylamine.
Tripeptoids have also been discovered in a combinatorial library that can
neutralize the lipopolysaccharide from Gram-negative bacteria [182], as have tripeptoids
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that have some effect on multidrug resistant (MDR) tumour cells (cross-resistance of
tumour cell lines to several structurally unrelated chemotherapeutic agents after exposure
to a single cytotoxic drug). MDR is a major cause of treatment failure in cancer
chemotherapy and is often associated with the overexpression of a transmembrane
glycoprotein (P-gp) that acts as a drug efflux pump [183]. Target-oriented synthesis of
peptoid oligomers to mimic known biologically active peptides, with improved
properties, is also of interest, for example the magainin-2 analogues investigated by Patch
et al. [184], of which some showed reasonable antimicrobial activity and low haemolysis at
MIC levels.
Libraries of peptide-peptoid hybrids have also been synthesised, usually with the
aim of producing molecules with a particular type of biological activity. For example,
Kruijtzer et al. [185] synthesised all possible peptoid-peptide hybrids of an MC4 receptor
peptide agonist. Ryge and Hansen [186] synthesised lysine-peptoid hybrids based on
antimicrobially active peptoid trimers, and could produce molecules with reasonable
antimicrobial activity and reasonably low haemolytic activity. Song et al. [187]
incorporated peptoid residues into different positions of a model -helical amphiphilic
peptide sequence. These products showed similar or improved antimicrobial activity as
compared to the pure peptide sequence, and most also showed reduced haemolytic
activity. The most promising compound from this study seems to exert its antimicrobial
activity by binding to intracellular targets rather than by a membrane permeabilisation
mechanism.
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2.2.4 Peptide-peptoid hybrids as potential antimicrobial agents
In the Robinson group, there is much interest in the design of backbone-cyclised
peptides based on naturally-occurring antimicrobial peptides, as potential antimicrobial
agents. In a series of compounds based on the naturally-occurring pig peptide protegrin-
I, 86, backbone cyclisation was introduced with the aim of improving stability towards
proteases, and also to help to constrain the backbone conformation [165]. The natural
product has a -hairpin structure, which is stabilised by two disulfide bonds. A DPro-
LPro template was introduced into the synthetic mimetics with the aim of inducing a
similar -hairpin structure. One of the peptide mimetics that showed good antimicrobial
activity, along with low haemolytic activity and a -hairpin structure in contact with
micelles was peptide 87. It was decided to investigate the effect of introducing peptoid
units into the sequence of this product, which could allow the introduction of more varied
side-chain functionalities, and could help to improve proteolytic stability. Initially, the
peptoid unit Nlys was to be introduced, as this would involve minimal changes in key
side-chain functionalities. It was also decided to introduce the peptoid units in positions
not believed to play an important role in cross-strand hydrogen bonding. The structures
of the peptides on which the mimetics were based are presented in Figure 80. The
structures of the mimetics are presented in Figure 81. The expected inter-strand
hydrogen bonding pattern for a -hairpin is illustrated in Figure 82. Based on this
Figure, the changes in backbone structure caused by the introduction of peptoid units at
positions 4 and 6 should have no effect on the inter-strand hydrogen bonding.
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Figure 80: Structures of naturally-occurring antimicrobial peptide Protegrin-I, and synthetic
peptidomimetic 87.
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Figure 81: Structures of peptide-peptoid hybrids 88 and 89.
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2.2.5 Peptide-peptoid hybrids containing Nlys
2.2.5.1 Synthesis via on-resin cyclisation
Cl
H2N
NH2
NH
O
Br
O
NH
NH2 NH
O
O
Fmoc-Lys(Boc)-OH
HOBt, HBTU, DIEA
NH
N
O
O(Boc)Lys
Fmoc
20% piperidine in DMFNH
N
O
O(Boc)Lys
NH
N
O
O(Boc)Lys
(Boc)Lys
Leu
(Pbf)Arg
Leu
Pro
p
ro
Val
Arg(Pbf)
Tyr(tBu)
Lys(Boc)
Trp(Boc)
(Pbf)Arg
Fmoc
Pd(PPh3)4, NMM, AcOH
DCM, Ar
NH
N
OH
O(Boc)Lys
(Boc)Lys
Leu
(Pbf)Arg
Leu
Pro
p
ro
Val
Arg(Pbf)
Tyr(tBu)
Lys(Boc)
Trp(Boc)
(Pbf)Arg
Fmoc
1. 20% piperidine in DMF
2. HBTU/HOBt/DIEA
NH
N
(Boc)Lys
(Boc)Lys
Leu
(Pbf)Arg
Leu
Pro
p
ro
Val
Arg(Pbf)
Tyr(tBu)
Lys(Boc)
Trp(Boc)
Arg(Pbf)
OH2N
N
Lys
Lys
Leu
Arg
Leu
Pro
p
ro
Val
Arg
Tyr
Lys
Trp
Arg
O
TFA/H2O/TIS
Scheme 8: Proposed synthetic strategy for the solid phase synthesis and on-resin cyclisation of a peptide-
peptoid hybrid.
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The initial pathway designed for the synthesis of a peptoid-peptide hybrid
containing Nlys is outlined in Scheme 8. The intention was to couple 1,4-diaminobutane
to the solid support, followed by reaction with an allyl 1-bromoacetate, in a reversal of
the usual peptoid submonomer synthesis strategy. This would create an orthogonally
protected C-terminus, which could be deprotected whilst still attached to the solid
support, so that on-resin backbone cyclisation could be carried out on the fully side-chain
protected peptide. Acidic cleavage conditions would then release the N-butylamine side
chain from the resin and remove the side-chain protecting groups in one step. The
coupling of the diamine to the solid support could be monitored using the Kaiser test and
proceeded as expected. Allyl 1-bromoacetate 90 was prepared by azeotropic
condensation of bromoacetic acid and allyl alcohol [188].
Br
O
O90
Figure 83: Structure of allyl 1-bromoacetate.
The reaction with allyl 1-bromoacetate was also monitored using the Kaiser test.
A negative Kaiser test result suggested that this step had also been successful. However,
the attempt to couple a further amino acid residue was unsuccessful. Therefore, it was
decided to investigate the product of the first two coupling reactions by acidic cleavage
from the resin and LC-MS analysis of the products. It was found that the major product
was a tertiary amine, 91 as illustrated in Figure 84, and that the desired product 92, was a
minor constituent of the product mixture.
H2N
N
H2N
H
N
O
OO
O
O
O91 92
Figure 84: Products obtained from reaction of resin-bound 1,4-diaminobutane with allyl-protected
bromoacetic acid.
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Trial reactions were carried out where the number of equivalents of bromoacetate
were varied, but in all cases, both mono- and disubstituted product was obtained. It was
therefore decided to synthesise a peptoid monomer in order to introduce this peptoid unit.
The advantage of solution synthesis over solid-phase synthesis in this case lies in the
possibility to separate the desired product from any undesired side products, and the
possibility of using a large excess of diamine. Therefore, an Fmoc-protected peptoid
monomer 96 was prepared as outlined in Scheme 9.
Br
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O
H2N NH2
(Boc)2O, CH2Cl2
0oC
H2N NH
Boc
, Et3N, THF
H
N
NH
Boc
O
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CH2Cl2
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NH
Boc
O
O Fmoc
N
NH2O
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TFA/DCM 3:7
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93
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Scheme 9: Synthetic route leading to Fmoc-protected peptoid monomer 96.
This monomer unit could be successfully coupled to the solid support through the
free amine group as before. The Fmoc protecting group was removed using 20%
piperidine in DMF, and Fmoc-Lys(Boc)-OH could be coupled to this unit at the less
sterically hindered secondary amine position. The Fmoc protecting group of the first
lysine residue was removed (to give a positive Kaiser test result), and when the coupling
of the second lysine residue was attempted, a negative Kaiser test result was observed,
suggesting that the coupling had been carried out successfully. However, when the
Fmoc-deprotection of this lysine residue was attempted, no positive Kaiser test result
could be obtained. Longer reaction times and higher concentrations of piperidine were
attempted to no avail. In order to investigate the source of this problem, a portion of the
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peptide-resin was treated under mild acidic conditions to cleave the product from the
resin. The product obtained was then analysed by LC-ESI-MS, and found to contain
mainly a product of molecular mass (M+H)/1: 357.4. This mass corresponds to the N-
substituted diketopiperazine 97 (calculated mass 356.4 g/mol), which could be formed as
outlined in Scheme 10.
H2N
N
NH
O
O
HN
O
O
97
Figure 85: Structure of diketopiperazine 97.
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Scheme 10: Proposed pathway leading to the diketopiperazine 97.
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Our strategy to overcome this hurdle involved the separate preparation of the
lysine-lysine dipeptide unit 98 illustrated in Scheme 11, which could then be introduced
into the peptoid-peptide hybrid synthesis in the same way as a standard Fmoc-protected
amino acid derivative.
Cl
Fmoc-Lys(Boc)-OH
DIEA
OLysFmoc
Boc
OLysLys
BocBoc
Fmoc
1. 20% piperidine
2. Fmoc-Lys(Boc)-OH,
HBTU/HOBt/DIEA
1% TFA in DCM
OHLysLys
BocBoc
Fmoc
98
Scheme 11: Synthetic route to dipeptide unit 98.
With these modifications, the whole of the desired peptoid-peptide chain could be
assembled, to provide a product with an Fmoc-protected N-terminus, an allyl-protected
C-terminus, linked to the solid support via the peptoid side chain. The allyl protecting
group was removed in a palladium-catalysed reaction using N-methyl morpholine, then
the Fmoc group was removed using piperidine. Finally, on-resin backbone cyclisation
was carried out using HBTU and HOBt with DIEA as the base. The peptoid-peptide
hybrid could then be cleaved from the solid support and side chain deprotected in one
step using TFA containing 2.5% TIS and 2.5% water. The crude product was analysed
by RP-HPLC. The chromatogram is shown in Figure 86. The four major peaks were
collected and analysed by LC-MS. The largest peak was found to have the expected
mass for the desired product. This product could be purified by preparative RP-HPLC to
provide peptide-peptoid hybrid 88, which was analysed by analytical RP-HPLC and ESI-
MS. The chromatogram of the pure product is shown in Figure 87. Calculated MW:
1850.35 g/mol, measured m/z (ESI-MS): 926.5 (M+2H)/2.
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Figure 86: Chromatogram of crude peptoid-peptide hybrid 88. For HPLC conditions see Appendix 4.
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Figure 87. Chromatogram of purified peptoid-peptide hybrid 88. For HPLC conditions see Appendix 4.
2.2.5.2 Peptide-peptoid hybrids containing Nlys via solution cyclisation
The synthesis described above demonstrated that it is possible to synthesise
backbone-cyclised peptide-peptoid hybrids via an on-resin cyclisation strategy.
However, the yield of the final product was rather disappointing and the necessity of
using a dipeptide as one of the building blocks renders this method rather awkward for
the preparation of products containing a lysine residue adjacent to the Nlys residue.
Chapter 2: Antimicrobial peptoid-peptide hybrids; Nlys 121
Therefore, the synthesis was also carried out using the usual submonomer method to
prepare the peptoid unit, and a solution-phase cyclisation of the fully side-chain protected
peptide-peptoid chain was then undertaken, after cleavage from the highly acid-labile
resin. This strategy is outlined in Scheme 12.
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Scheme 12: Alternative synthetic route to peptoid-peptide hybrid 88.
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The attachment of bromoacetic acid to the resin was carried out as for an amino
acid derivative, using DIEA as the base. Boc protected diamine 93 was prepared as
described in Scheme 9 and added in a ten fold excess to the resin to produce resin-bound,
Boc-protected Nlys. Fmoc-Lys(Boc)-OH was then coupled and the level of loading was
estimated by measuring the UV absorption at 290nm of two weighed samples of resin in
20% piperidine solution. The Fmoc protecting group was removed from the lysine
residue using 20% piperidine, then resin was transferred to an automated peptide
synthesizer and the remainder of the peptide chain was assembled by automated SPPS,
with final Fmoc-deprotection to leave a free N-terminal amine group. The crude side-
chain protected peptide was then cleaved from the resin using TFE/DCM (2:8) [189]. The
crude product was analysed by RP-HPLC, the chromatogram is shown in Figure 88 and
the product was cyclised with HOAt and HATU. The reaction was monitored by RP-
HPLC. After overnight cyclisation a new product was observed, as illustrated in Figure
89. This was treated with TFA to remove side-chain protecting groups. The
chromatogram of the crude product showed one major peak, as illustrated in Figure 90.
This product was purified and analysed by ESI-MS. Calculated MW: 1850.35 g/mol,
measured m/z (ESI-MS): 926.5 (M+2H)/2.
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Figure 88: Chromatogram of crude linear protected peptide. For HPLC conditions see Appendix 4.
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Figure 89: Chromatogram of crude cyclised protected peptide. For HPLC conditions see Appendix 4.
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Figure 90: Chromatogram of crude cyclised peptide 88. For HPLC conditions see Appendix 4.
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Figure 91: Chromatogram of purified cyclic peptide 88. For HPLC conditions see Appendix 4.
2.2.5.3 Synthesis of mimetic containing two peptoid units
Based on the synthetic method outlined above, peptide-peptoid hybrid 89 was also
prepared, as described in Scheme 13. In this case, full coupling of the leucine residue to
the second peptoid unit could not be achieved using HBTU/HOBt, but the use of DIC and
HOAt was found to be successful.
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Scheme 13: Synthetic route to peptoid-peptide hybrid 89.
Coupling of amino acids to secondary amines was monitored using the chloranil
test (Table 12) [190]. Again, after the difficult coupling to the secondary amine, the
peptide-peptoid resin was transferred to an automated peptide synthesiser and the peptide
chain was assembled with final Fmoc deprotection to give a peptide-peptoid resin with
free N-terminal amine. The fully side-chain protected product could be cleaved from the
resin using 1% TFA in DCM [189] and backbone cyclisation was again carried out
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overnight with 1.5 eq HOAt, 1.5 eq HATU and 3.5 eq DIEA. Conversion of the linear to
the backbone-cyclised product was monitored by RP-HPLC. Chromatograms are shown
in Figure 92. The side chain protecting groups of the crude cyclic product were removed
using TFA containing 2.5% TIS and 2.5% water. The crude deprotected cyclic product
could be purified by preparative RP-HPLC to provide the desired product 89, which was
analysed by HPLC (Figure 93) and ESI-MS. Calculated MW: 1850.35 g/mol., measured
m/z: 926.0 (M+2H)/2
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Figure 92: (A) Chromatogram of crude linear side-chain protected peptide. (B) Chromatogram of crude
cyclised side-chain protected peptide. For HPLC conditions see Appendix 4.
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Figure 93: Chromatogram of purified peptoid-peptide hybrid 89. For HPLC conditions see Appendix 4.
2.2.5.4 Antimicrobial activities
The antimicrobial activities of the peptide-peptoid hybrid mimetics were
determined as minimum inhibitory concentrations using the NCCLS broth microdilution
method [191]. The haemolytic activity of the mimetics was also measured and the values
are compared here with those of the naturally-occurring antimicrobial peptide protegrin-
1, 86 and the backbone-cyclised peptide mimetic on which they are based, 87.
PeptideTest microorganism
86 87 88 89
E. coli ATCC25922 4 16 8 32
P. aeruginosa ATCC27853 4 8 4 8
S. aureus ATCC29213 4 32 24 32
S. aureus ATCC25923 4 64 64 64
% haemolysis at 100g/ml 37 1.4 0.5 1.4
Table 12: Antimicrobial activities of peptidomimetics 87, 88 and 89.
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2.2.5.5 NMR measurements
1H spectra, TOCSY (100ms), DQF-COSY and ROESY (40ms, 80ms, 120ms and
250ms mixing times) of peptide-peptoid hybrids 88 and 89 were measured at pH 5 and
300K. The 1H spectra showed well-defined amide proton signals, with relatively large
3JHN-H coupling constants. Such signals are often indicative of a well-defined 3D
structure. The chemical shifts of the amide protons and the coupling constants are
presented in Table 13. The 1H spectra are presented in Appendix 1. From the 2D
measurements, the spectra were assigned and the average solution structure of mimetic 88
was calculated by Dr Kerstin Moehle. An overlay of 15 calculated structures of the
backbone of peptide-peptoid hybrid 88 is shown in Figure 94. A typical structure of the
mimetic, illustrating side-chain orientations, is shown in Figure 95.
Figure 94: Overlay of 16 DYANA structures for mimetic 88. The dotted lines indicate key NOE distance
restraints.
Figure 95: A typical NMR structure of mimetic 88. The coloured ribbon traces the backbone.
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The calculations describe a well-defined hairpin conformation in aqueous
solution. This is in contrast to peptide mimetic 87, which seems to be unstructured in
aqueous solution but adopts a hairpin conformation upon contact with micelles [165]. This
reflects the enhanced conformational stability of the peptide-peptoid hybrid due to the
presence of the peptoid unit [192]. To complement the NMR data, H/D exchange rates and
temperature coefficients for the amide protons of mimetic 88 were investigated. These
data can provide a useful insight into the hydrogen bonding patterns in a compound. H/D
exchange rates are measured by dissolving peptide mimetics in D2O and repeatedly
measuring 1H spectra of the sample, recording the relative rates at which the amide
proton signals disappear from the spectrum. Temperature coefficients are calculated
from the measurement of 1H spectra over a range of temperatures. Amide proton
chemical shifts can be highly sensitive to temperature, and the shift of signals with
changing temperature can be tracked by comparison of spectra. Protons involved in
hydrogen bonding exchange more slowly with solvent deuterium and are less sensitive to
temperature changes. The H/D exchange rates and temperature coefficients are presented
along with the chemical shifts and coupling constants of the amide protons in Table 13.
Residue Chemical shift
(ppm)
3J (, NH)
[Hz]a
-/T [ppb/K]b H/D relative c
1Leu 7.86 8.2 0.7 >
2Arg 8.43 9.5 4.6 >>>
3Leu 8.50 9.5 0.8 >>
4Lys 8.32 8.9 5.7 >>>
5Lys 8.99 8.9 5.3 >>
7Arg 8.41 - 7.8 >>>
8Trp 8.08 8.7 2.6 >>>
9Lys 8.30 9.5 6.0 >>>
10Tyr 8.69 8.0 1.6 >>
11Arg 8.53 9.0 7.0 >>>
12Val 8.35 9.6 0.1 >>
a: Measured in 1H or COSY
b: Measurements made over the range 279-214K
c: Relative exchange rates: > slow, >> medium, >>> fast
Table 13: Chemical shifts, coupling constants, temperature coefficients and H/D exchange rates for
peptoid-peptide hybrid 88
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The small temperature coefficients for the amide protons of residues 1Leu, 3Leu,
10Tyr and 12Val along with the slower H/D exchange rates for these positions suggest the
presence of cross-strand H-bonding between 1Leu NH and 12Val CO, 12Val NH and 1Leu
CO, 3Leu NH and 10Tyr CO and 10Tyr NH and 3Leu CO.
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2.2.6 Peptide-peptoid hybrids containing triethylenetetramine
2.2.6.1 Introduction
As mentioned previously, one of the advantages of the introduction of peptoid
units into peptidomimetics is the wider range of side-chain functionalities available for
inclusion. That is, a peptide-peptoid sequence can be adapted for a variety of purposes by
varying the peptoid side chains present. One possible target is a molecule capable of
chelating a radiometal for therapeutic or diagnostic purposes. 99mTc is an ideal label for
diagnostic nuclear medicine, due to its optimal half-life of 6 hours, along with its low cost
and easy availability via commercial 99Mo/99mTc generators. Many 99mTc-labelled
receptor ligands have been prepared for receptor imaging [193] , targeting, for example,
thrombosis [194], infection and inflammation [195] or tumours [196-198]. A recent publication
reported the possible use of radiolabelled antifungal agents for the detection of fungal
infections [199]. These studies showed that 99mTc-labelled fluconazole could distinguish
C. albicans infections from bacterial infections and sterile inflammations, and that
labelled peptides derived from human ubiquicidin and lactoferrin could distinguish fungal
infections from sterile inflammation, although not from bacterial infection. The labelling
of biologically-active peptides could be useful in two ways. Radiolabelled analogues of
peptides with known targets and activities could be used to locate infections and other
targets in radiopharmaceutical research. It could, however, also help researchers in the
field of peptide-based therapeutics to better understand the possible biodistribution,
excretion and metabolism of their molecules, although it must be borne in mind that the
presence of the radiolabel could have some effect on these properties of the peptide.
2.2.6.2 Peptide synthesis
Our goal was to introduce a peptoid side-chain into a molecule similar to peptoid-
peptide hybrid 88, capable of chelating 99mTc. Amines have been reported to be good
chelators for stable 99mTc binding [200], so the peptide-peptoid hybrid designed for this
purpose was mimetic 99, shown schematically in Figure 96, and the building block
chosen was the triethylenediamine derivative 100, with the intention of chelating the
metal with three of the four amine groups. The synthetic route to the Boc protected
building block 104 is described in Scheme 14.
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Figure 96: Structure of peptide-peptoid hybrid 99.
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Figure 97: Structure of proposed peptoid monomer 100.
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The synthetic strategy for the preparation of the peptoid-peptide hybrid 99 is
outlined in Scheme 15.
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Scheme 14: Synthetic route to Boc protected building block 104.
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Scheme 15: Synthetic route to peptoid-peptide hybrid 99.
The peptoid unit was prepared as before via the submonomer strategy.
Subsequent coupling of Fmoc-Lys(Boc)-OH to the secondary amine was carried out
using DIC and HOAt as coupling agents and monitored using the chloranil test. The
peptide-peptoid resin was then transferred to an automated peptide synthesiser where the
remainder of the peptide chain was assembled. After final Fmoc-deprotection, the side-
chain protected peptide was cleaved from the solid support using 1% TFA in DCM, and
backbone cyclisation was carried out using HOAt and HATU as coupling agents with
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DIEA as the base. Finally, TFA containing TIS and water was used to remove the side-
chain protection groups. The fully deprotected crude cyclic product, was purified by RP-
HPLC. The chromatogram of the purified product is shown in Figure 98. Calculated
MW: 1908.43, Measured m/z (ESI-MS): 1908.0 (± 0.01%).
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Figure 98: Chromatogram of pure peptoid-peptide hybrid 99. For HPLC conditions see Appendix 4.
2.2.6.3 Rhenium labelling
This product could be successfully labelled with rhenium in the group of Prof. R. Alberto
to provide the labelled product 105. which Calculated MW: 2178.64, Measured m/z (ESI-
MS): 1090.1 (M+2H)/2, 727.1 (M+3H)/3. (± 0.01%).
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Figure 99: Structure of labelled peptoid-peptide hybrid 105.
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2.2.7 Discussion and conclusions
A backbone-cyclised peptide-peptoid hybrid 88 could be synthesised by a novel
solid-phase method involving attachment of the peptoid unit 96 via its side chain to the
resin, with orthogonal protection of the peptoid carboxylic acid. On-resin cyclisation
could be performed to provide the desired product in reasonable yield. The problem of
diketopiperazine formation (Scheme 10) during the synthesis could be overcome by the
use of a protected dipeptide unit (98) as a building block. The same backbone cyclised
peptide-peptoid hybrid, along with a second mimetic containing two peptoid units (89),
was also synthesised by solid-phase assembly using the submonomer strategy for the
formation of the peptoid units, followed by solution-phase cyclisation of the fully side-
chain protected product, and deprotection to provide the desired backbone cyclic product.
In biological assays, both of these mimetics showed antimicrobial activities (Table 12)
comparable to, or slightly improved with respect to those of the backbone cyclic peptide
87, on which they were based. Mimetic 88 showed a lower haemolytic activity than
cyclic peptide 87, which would be an important property for a potential candidate for
clinical use as an antibiotic. Cyclic peptide 87 shows a well-defined -hairpin structure
in the presence of micelles, but is unstructured in aqueous solution [165]. However, both
peptide-peptoid hybrids 88 and 89 show well-defined amide proton signals in NMR
spectra measured in aqueous solution, with relatively large coupling constants, often an
indication of a well-defined structure. Indeed, the solution structure of peptide-peptoid
hybrid 88 could be determined and it was found to form a -hairpin structure in aqueous
solution. H/D exchange rates and temperature coefficients for the amide protons of
mimetic 88 suggested that it contained at least some of the cross-strand hydrogen bonds
expected for a -hairpin structure. This work showed that in the development of peptide
mimetics as potential antimicrobial agents, the inclusion of a peptoid unit at the tip of a
loop could stabilise -hairpin conformations and could be compatible with the selective
targeting of bacterial cells over human erythrocytes. The inclusion of peptoid units could
also help to stabilise mimetics towards enzymatic degradation, which would be an
important consideration if a peptidomimetic were to be developed as a clinical antibiotic.
It was further possible to introduce a non-natural side-chain into a backbone-
cyclised peptide-peptoid hybrid based on the synthetic strategy developed for the
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synthesis of mimetics 88 and 89. The peptide-peptoid hybrid 99 could be used to form a
complex with Re(CO)3, presumably the triamine chain chleates the metal atom. Since
rhenium and technetium are believed to show similar chemical behaviour [201], these
studies could form the basis for the development of a radiolabelled antimicrobial
peptidomimetic for diagnostic use. A complex of this type could be used in diagnosis to
distinguish between bacterial infections and non-specific inflammation, and could also be
useful for research into antimicrobial peptides, to provide valuable information about
their uptake, metabolism and excretion in humans. In future work, larger quantities of
this kind of complex could also be prepared for crystallisation assays in order to
determine the crystal structure of the mimetic.
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3 Experimental part
3.1 General notes
3.1.1 Chemical synthesis
N,N’-diisopropylcarbodiimide (DIC), N,N’-dicyclohexylcarbodiimide (DCC),
bromoacetic acid, methyl trifluoroacetate and 1,4,-diaminobutane were purchased from
Fluka and used without further purification. Triethylene tetramine (technical grade,
~70%) was purchased from Fluka and fractionally distilled under reduced pressure. Di-
tert-butyl dicarbonate ((Boc)2O) was purchased from NovaBioChem or Acros organics.
Dichloromethane (DCM) was distilled from CaCl2 and redistilled from CaH2. Methanol
(HPLC grade) was purchased from Biosolve Ltd. Ethyl acetate was distilled from
potassium carbonate.
Flash chromatography was carried out on silica gel 60 (230-400 mesh, 0.04-0.063
mm) from Merck or Chemie Uetikon AG. Thin layer chromatography (TLC) was
performed using Polygram SIL G/UV254 from Machery-Nagel or Silica gel 60 F254 from
Merck.
1H NMR spectra were measured at 300 MHz on a Bruker ARX-300 or Bruker AV-
300 spectrometer.
3.1.2 Peptide synthesis
Peptides were synthesised on an Applied Biosystems ABI 433A automated peptide
synthesiser coupled to a Perkin-Elmer 785A UV/VIS detector or a Perkin-Elmer Series
200 UV/VIS detector using the FastMoc® method. NMP and piperidine were purchased
from Acros and used without further distillation. DMF was purchased from Acros and
redistilled from ninhydrin. DIEA was purchased from Acros and redistilled first from
ninhydrin then from KOH. HOBt and HBTU were purchased from Biosolve. Water was
purified using an Elgastat® UHP-UF instrument. Kaiser test kit was purchased from
Fluka. Amino acids were purchased from Novabiochem or Bachem and Rink amide resin
from Novabiochem or Rapp Polymere. 2-Chlorotrityl chloride resin (100-200 mesh) with
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1.2 mmol/g loading was purchased from Novabiochem. The amino acids used were:
Fmoc-Asn(Trt)-OH, Fmoc-Ile-OH, Fmoc-Ser(tBu)-OH, Fmoc-Gln(Trt)-OH, Fmoc-
His(Trt)-OH, Fmoc-Cys(Trt)-OH, Fmoc-Val-OH, Fmoc-Lys(Boc)-OH, Fmoc-Pro-OH,
Fmoc-Gly-OH, Fmoc-Phe-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, Fmoc-Asp(tBu)-OH,
Fmoc-Tyr(tBu)-OH, Fmoc-Glu(tBu)-OH and Fmoc-Thr(tBu)-OH. Capping solution for
the blocking of unreacted sites contained Ac2O (0.5 M), DIEA (0.125 M) and HOBt
(0.015 M) in NMP. The monitoring of the deprotection in the ABI 433A was performed
by the removal of a 6 l aliquot of the 20% piperidine/80% NMP deprotection solution
after 1.75 minutes. This sample was passed through the UV detector at 301 nm and a
peak was recorded. After washing with NMP the deprotection step was repeated and a
second peak recorded. If the height of the second peak was less than 4% of the first peak
the deprotection was continued for another 8 minutes and then the rest of the coupling
cycle was carried out. If this condition was not met, the deprotection step was carried out
a third time and monitored. The deprotections were continued until the condition was
met.
TFA was purchased from Acros, EDT and TIS from Fluka. Diethyl ether was
redistilled from CaCl2. DCM was redistilled first from CaCl2 and then from CaH2.
Chloroform was purchased from Scharlau and THF from Fluka.
For purification and analysis reversed-phase high performance liquid
chromatography was performed using an Äkta purifier (Amersham Pharmacia Biotech)
system. The columns used were Vydac C4 214TP104 (10 m, 125 Å, 4 x 100 mm, flow
rate 1 ml/min), Vydac C18 218TP104(10 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min),
Zorbax eclipse analytical C18, (4.6 x 250 mm, 5 m, flow rate 1 ml/min) and Vydac C18
218TP54 (5 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min) for analytical runs. For semi-
preparative runs, Vydac C18 218TP1010 (10 m, 125 Å, 10 x 100 mm, flow rate 5
ml/min), Vydac C4 214TP104 (10 m, 125 Å, 10 x 100 mm, flow rate 5 ml/min) and a
Zorbax eclipse XDB-C18 (9.4 x 250 mm, 5 m, 4 ml/min flow rate) were used. For
large-scale preparative runs, Vydac C18 218TP1022 (10 m, 125 Å, 22 x 100 mm, flow
rate 10 ml/min), Zorbax eclipse XDB-C18 (7 m, 21.2 x 250 mm) and Interchrom
UP10WC4/25M (21.2 x 250 mm) were used. The solvents used were acetonitrile from
Biosolve and double distilled water, each containing 0.1% TFA. UV detection was at 226
nm and 278 nm.
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LC-MS analyses were carried out on an RP-HPLC system connected to a
ThermoFinnigan Quadrupole-ESI mass spectrometer.
Mass analyses were carried out by the MS-service of the University of Zurich or
the Protein Analysis Unit of the Biochemistry Institute of the University of Zurich.
Electrospray measurements were performed either on a Waters Q-tof Ultima API
instrument, a Bruker ESQUIRE-LC quadrupole ion trap instrument or a Finnigan TSQ-
700 instrument. Typical measurement error is 0.01%. MALDI-TOF measurements were
performed either on a Bruker Biflex III with delayed extraction and reflection and Scout
26 ion source, or on a Bruker Autoflex I. Typical measurement error is 0.1%.
Amino acid analyses were carried out by the Protein Analysis Unit of the
Biochemistry Institute using a Hewlett-Packard AminoQuant II instrument with high
sensitivity fluorescence detection.
3.1.2.1 Kaiser test [134]
After normal washing of the resin, a few resin beads were place in a small test
tube and washed 3 times with diethyl ether. 2 drops of 5% ninhydrin in ethanol, 3 drops
of KCN in pyridine and 2 drops of 80% phenol in ethanol were added and the tube placed
in an oil bath at 120oC for 5 mins. Blue resin beads indicate the presence of free resin-
bound amine.
3.1.2.2 Chloranil test [202]
After normal washing of the resin, a few beads were placed in a small test tube
and washed 3 times with diethyl ether. 1 drop of 2% p-chloranil in DMF and 1 drop of
2% acetaldehyde in DMF were added and the beads allowed to stand at r.t. for 20 mins.
Blue resin beads indicate the presence of resin-bound amines.
3.1.3 NMR analysis of peptides
1D and 2D spectra were recorded at 600MHz on a Bruker DRX-600 or Bruker
AV-600 spectrometer, or at 700MHz on a Bruker AV-700 spectrometer, typically at
peptide concentrations of 10-20 mg/ml or with as much peptide as was available. The
solvent system used was H2O/D2O 9:1, at pH 5, with sodium 3-trimethylsilyl (2,2,3,3,-
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D4)propionate (TSP) as an internal reference. For structural calculations, spectra were
also recorded in 100% D2O. Water suppression was performed using presaturation.
3.2 MSP-1 peptides
3.2.1 Synthesis of peptide 1
Peptide 1:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT-NH2
The linear peptide was assembled on 390 mg of Rink Amide resin (loading 0.64
mmol/g) on a 0.25 mmol scale. The standard coupling time for amino acids was 20 mins.
For the following residues, an extended coupling time of 55 mins was used: Ile(2),
Ser(3), Val(8), Lys(9), Lys(10), His(21), Lys(29), Cys(30), Asn(33), Lys(35), Gln(36),
Lys(40), Cys(41), Asn(44), Pro(45), Asn(46), Pro(47). For some residues a long
extended coupling time of 85 mins was used: Asn(1), Gln(4), His(5), Gln(6), Cys(7),
Gln(11), Cys(12), Pro(13), Gln(14), Asn(15), Cys(18), Arg(20), Arg(25), Cys (28). Each
coupling cycle was followed by Ac2O capping to block unreacted sites. Following
completion of peptide chain assembly, the resin was dried under vacuum over KOH for 5
hours. The peptide was cleaved from the resin and side-chain deprotected by treatment
with 30 ml of a mixture of TFA/TIS/H2O/EDT 94:1:2.5:2.5 for 3 hours. The resin was
then filtered off and washed twice with 1ml TFA. The solution was concentrated under
reduced pressure until a precipitate began to form. The suspension was then transferred
into 2 centrifuge tubes and the product was fully precipitated by the addition of cold
diethyl ether. The tubes were centrifuged at 2500 rpm for 7 minutes, then the liquid was
decanted off. The peptide was washed twice with diethyl ether and centrifuged in the
same way, then allowed to air-dry for 1 hour, to give approx. 1g of crude product. This
product was purified by preparative RP-HPLC using a Vydac C18 218TP1022 column
and a gradient of 5 to 35% acetonitrile over 25 mins. Analytical HPLC: Vydac C18
218TP54, gradient 5 to 17% acetonitrile over 4 mins then 17 to 33% over 29 mins.
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Retention time: 19 mins. 72 mg of purified peptide were obtained (5% yield).
Calculated MW: 5592.3 g/mol, measured m/z (ESI-Tof-MS): 5591.72 (±0.01%).
3.2.2 Oxidation trials on peptide 1
For oxidation trials 1 to 16, 4 vials were each initially prepared, each containing 2
mg of peptide, 2.5 mg of reduced glutathione and 2.6 mg of oxidised glutathione. To the
first vial were added 4 ml of 0.1M Tris buffer (pH 8.4), to the second vial, 3.8 ml of the
same buffer and 200 l DMF, to the third, 3.4 ml of buffer and 600 l DMF and to the
fourth, 3 ml of buffer and 1 ml DMF. The solutions were all stirred well, then each was
split into 4 separate vials, so that there were now 16 vials each containing 1 ml of
solution. Varying amounts of urea were then added to the vials to give the final reaction
mixtures described in Table 1. The solutions were stirred overnight then analysed by
RP-HPLC and compared to a sample of the linear starting material (0.5 mg/ml in water).
200 l of each solution were injected on a Vydac C18 218TP54 column with a gradient
of 5 to 50% acetonitrile over 30 mins. In all cases the starting material was shown to be
no longer present in the solution.
For oxidation trials 17 to 24, 8 vials were prepared containing the volumes of
solvent and masses of peptide and reagents described in Table 15.
peptide NaHCO3 GnHCl Cysteine Cystine vol GSH GSSG urea DMF EDTA
(mg) mg M mg mg ml mg mg mg % mg
17 0.5 15 1 727 144 2 _ _ _ _ _
18 0.5 7 _ _ _ 1 922 197 120 15 _
19 0.5 _ _ _ _ 2 92 394 _ _ 0.74
20 0.5 _ _ _ _ 5 230 985 _ _ 1.9
21 0.5 _ _ 1817 360 5 _ _ _ _ 19
22 0.5 _ _ _ _ 2 615 1313 180 _ _
23 0.5 _ 1 _ _ 2 _ _ _ _ _
24 0.5 _ _ _ _ 5 2306 9849 _ _ 1.9
Table 15: Composition of oxidation trial samples.
These mixtures were also stirred overnight and then analysed by RP-HPLC in the
same way as described for the previous trials. The volume injected for analysis was
adjusted so that the same amount of product should be injected for each trial.
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The conditions 21 were chosen as optimal and a larger-scale trial under these
conditions was carried out: 5 mg of peptide 1 were dissolved in 50 ml of Tris buffer (0.1
M, pH 8.4), with 18 mg Cysteine, 3.6 mg Cystine and 186 mg EDTA. The mixture was
stirred overnight and then purified by RP-HPLC using an analytical Vydac C18 218TP54
column with a gradient of 5 to 40% acetonitrile over 25 mins. The sample was frozen
and lyophilised and finally submitted for ESI-Tof-MS. Calculated MW: 5586.31 g/mol,
measured m/z: 5586.3 (±0.01%).
In the final trial, different concentrations of peptide were tested. 10ml of the
oxidation solution were prepared (0.1 M Tris buffer, pH 8.4, 10 mM EDTA, 3 mM
Cysteine, 0.3 mM Cystine). 4 vials were prepared with (a) 0.5 mg peptide, 1ml solution
(0.5 mg/ml), (b) 0.5 mg peptide, 0.5 ml solution (1 mg/ml), (c) 1 mg peptide, 0.5 ml
solution (2 mg/ml), (d) 2.5 mg peptide, 0.5 ml solution (5 mg/ml). The solutions were
stirred overnight and then analysed by RP-HPLC. All chromatograms showed, as before,
one main peak with the same retention time as the products from the previous trials,
suggesting that the same product was formed and that higher peptide concentration had
no detrimental effect on the oxidation process.
3.2.3 Synthesis of folded peptide 2
Peptide 2:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT-NH2
16.5 mg of peptide 1 were dissolved in 3.5 ml of an oxidation buffer made up of
0.1 M Tris buffer (pH 8.4) containing 10 mM EDTA, 3 mM Cysteine and 0.3 mM
Cystine. The mixture was stirred for 48 hours and then the product was purified by semi-
preparative RP-HPLC using a Vydac C18 218TP1010 column and a gradient of 5 to 30%
acetonitrile over 25 mins. Analytical HPLC: Vydac C18 218TP54, 5 to 17% acetonitrile
over 4 mins, then 17 to 33% over 26 mins. Retention time: 11 mins. Injections of 200
l were made, the main peak collected each time and the collected product frozen and
lyophilised to give 4 mg of pure product (24% yield). A small portion of the product was
taken for ESI-MS analysis. The remainder was used in the NMR studies.
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3.2.4 NMR studies on peptide 2
1D and 2D 1H NMR spectra were recorded at 600 MHz at a peptide concentration
of 15 mg/ml in H2O/D2O 9:1 and in 100% D2O at pH 5 and 298 K. Water suppression
was performed by presaturation [203]. The sequential resonance assignments were based
on DQF-COSY [204] and TOCSY [205] measurements. Distance restraints were obtained
from NOESY [206] spectra with mixing times of 50, 150 and 300 ms. Spectra were
collected with 1024 x 256 complex data points zero-filled prior to Fourier transformation
to 2048 x 1024, and transformed with a cosine-bell weighting function. Data processing
was carried out with XWINNMR (Bruker) and XEASY [207].
The structure calculations were performed by restrained molecular dynamics in
torsion angle space by applying the simulated annealing protocol implemented in the
program CYANA [208]. Starting from 100 randomized conformations, a bundle of 20
conformations were selected with the lowest CYANA target energy function. The
structures were analysed by PROCHECK-NMR [209] and have been deposited in the
Protein Data Bank under the accession number 2FLG. The program MOLMOL [210] was
used for structure analysis and visulisation of the molecular models.
3.2.5 Enzymatic digestions
For trypsin digestions, peptide 2 (1 mg) was digested with TPCK-treated trypsin
(50 g) in phosphate buffer (2 ml, 50 mM, pH 6.8) for 24 h at 37oC. The digest was then
analysed by RP-HPLC (Vydac 218TP54 column, flow rate 1 ml/min) using a gradient of
5 to 23% acetonitrile over 34 mins. The digestion products were then separated by RP-
HPLC (same conditions) into the fractions identified in chapter 1.2. The fractions were
analysed by LC-MS.
For thermolysin digestions, peptide 2 was digested with thermolysin (100 g) in
N-ethyl morpholine/acetate buffer (2 ml, 25 mM, pH 6.4) for 2 h at 40oC. The digest was
analysed by RP-HPLC (Zorbax eclipse analytical C18, 4.6 x 250 mm, 5 m, flow rate 1
ml/min) using a gradient of 3 to 30% acetonitrile over 34 mins. The digestion products
were then separated by RP-HPLC under the same conditions into the fragments identified
in chapter 1.2.
Chapter 3: Experimental part 145
For the trypsin digestion of the thermolytic fragment 11, the fraction (estimated
70 g) was digested with TPCK-treated trypsin (3.5 g) in phosphate buffer (200 l, 50
mM, pH 6.8) for 24 h at 37oC. The digest was analysed by RP-HPLC (Zorbax eclipse
analytical C18, 4.6 x 250 mm, 5 m, flow rate 1 ml/min) using a gradient of 3 to 30%
acetonitrile over 34 mins. The digestion products were then separated by RP-HPLC
under the same conditions into the fragments identified in chapter 1.2.
Five fragments were selected for further investigation by reduction. Samples of
each digestion product were treated with DTT (5 eq per cysteine residue) in ammonium
carbonate buffer (0.1 M, pH 8.0) for 6 h at room temperature. To stop the reaction, 10%
(v/v) acetic acid was added to each sample to give a final pH of 2-3. The samples were
frozen, lyophilized and analysed by MALDI-MS.
3.2.6 Synthesis of ethyl [N’-(tert-butoxycarbonyl)hydrazino]-acetate 5
This product was prepared from 4 according to the method of Bonnet et al by F.
Boato [211].
3.2.7 Synthesis of ethyl [N’,N’,N-Tris(tert-butoxycarbonyl)hydrazino]
acetate 6
Ethyl [N’-(tert-butoxycarbonyl)hydrazino]-acetate 5 (10 g) was dissolved in
CH2Cl2 (10 ml) and Et3N (13.5 ml) at 0oC. Di-tert-butyl dicarbonate (21 g) and DMAP
(1.75 g) were dissolved in CH2Cl2 (17 ml) and this solution was also cooled to 0oC. The
solution of 5 was then added dropwise over 40 minutes. The mixture was stirred for 20
minutes at 0oC and then gradually allowed to reach room temperature over 2 h. The
solution was diluted with CH2Cl2 (30 ml) and then extracted with saturated KH2PO4
solution (3 x 70 ml). The aqueous phase was then extracted once with CH2Cl2 (100 ml).
The organic phases were combined, dried over Na2SO4, and concentrated under reduced
pressure to give 15.2 g of an orange oil. Approximately half of this oil was purified by
flash chromatography using silica gel (650 g) in a column of 6 cm diameter. The column
was eluted with CH2Cl2/EtOAc 97/3 and the fastest eluting product (Rf value 0.39) was
collected. The product was concentrated and dried under high vacuum to give 1.9 g of a
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yellow oil (22% yield). 1H NMR:(CDCl3, 300 MHz) 4.3-4.1 ppm, (m, 4H,
CH2COCH2CH3), 1.48-1.6 ppm (m, 27H), 1.3ppm (t, 3H).
3.2.8 Synthesis of [N’,N’,N-Tris(tert-butoxycarbonyl)hydrazino]-acetic
acid (7)
Ethyl [N’,N’,N-Tris(tert-butoxycarbonyl)hydrazino]- acetate 6 (1.9 g)
wasdissolved in ethanol (15 ml) and stirred in an ice bath. NaOH (10 ml, 1M solution)
was also cooled in an ice bath and then added dropwise over 1h to the solution of 6. The
mixture was stirred at 0oC for a further 30 mins. The solution was then neutralised to pH
4 using a 10% citric acid solution. At around pH 5 a precipitate began to form. The
solution was diluted with water (30 ml) and then diethyl ether (50 ml) was added. The
precipitate dissolved in diethyl ether and the aqueous phase was extracted twice more
with diethyl ether (50 ml), then twice with CH2Cl2 (50 ml). The organic phases were
combined and washed twice with brine, dried over Na2SO4 and concentrated under
vacuum to leave a pale yellow oil. The oil was then cooled and a small amount of cooled
diethyl ether/heptane 2/3 was added, upon which a white precipitate formed. The
precipitate was filtered off and washed several times with cooled diethyl ether/heptane
2/3, then dried under vacuum to leave 1.14 g of a white powdery solid (64 % yield). 1H
NMR:(CDCl3, 300 MHz): 4.15ppm (s, 1H), 4.05ppm (s, 1H), 1.48-1.6ppm (m, 27H).
ESI-MS: 413.2 (M+Na)+
3.2.9 Synthesis of peptide 8
Peptide 8:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTN
H o
H2N
NH2
The peptide sequence was prepared on the ABI 433A using the same method as
described in section 3.2.1. Before cleavage from the resin, the hydrazinoglycine was
coupled as follows.
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500 mg (approx 3/10) of the resin were swelled in 2 ml DMF. 7 (75 mg, 0.19
mmol, 2.5 eq), HOAt (45 mg 0.3 mmol, 4eq), HATU (114 mg, 0.3 mmol, 4 eq) and
DIEA (148 l, 0.9 mmol, 12 eq) were dissolved in a minimal amount of DMF (~4 ml)
and this solution was added to the resin. The resin suspension was agitated for 3.5 h, then
the resin was filtered off and washed (3 x DMF, 5 x CH2Cl2).
Finally, the peptide was cleaved from the resin and deprotected using
TFA/TIS/H2O/EDT 94:1:2.5:2.5 (30 ml) for 3 h. After this time the resin was filtered off
and the solution was concentrated under vacuum until a precipitate formed. The product
was transferred to 2 centrifuge tubes and fully precipitated by the addition of cooled
diethyl ether. The tubes were centrifuged at 2500 rpm for 7 mins at 10 oC, then the liquid
was decanted off. The peptide was washed with diethyl ether and centrifuged twice more
in the same way, and was then allowed to air-dry for 1 hour. LC-MS: 1416.7 (M+4H)/4,
1133.8 (M+5H)/5, 945.1 (M+6H)/6, 810.2 (M+7H)/7. 260 mg of peptide were obtained
(46% yield).
3.2.10 Oxidative folding of peptide 8 to give peptide 9
Peptide 9:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTN
H o
H2N
NH2
Dry crude peptide 8 (260mg) was dissolved in 100 ml of 0.1 M Tris buffer (pH
8.4) containing EDTA (372 mg, 1 mmol). cysteine (36 mg, 0.3 mmol) and cystine (7 mg,
0.03mmol) were added and the solution was stirred overnight. RP-HPLC analysis using a
Vydac C18 218TP104 column and a gradient of 5 to 35% acetonitrile over 30 mins
showed that the starting material was no longer present and that one main new peak had
been formed. The product was purified using semi-preparative HPLC using a Vydac C18
218TP1010 column and a gradient of 10 to 35% acetonitrile over 30 mins to collect the
main peak. Analytical HPLC: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50%
acetonitrile over 29 mins.
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Retention time: 12.5 mins. The fractions containing the main peak were collected
together, frozen and lyophilised to give 51 mg of white powder peptide 9 (19.6% yield).
Measured m/z (ESI-Tof-MS): 5658.4 (±0.01%).
3.2.11 Synthesis of PE-succ (11)
PE (10) (700 mg, 1mmol) was dissolved in CHCl3/MeOH (100 ml, 9:1). Succinic
anhydride (163 mg, 1.6mmol) was dissolved in DCM (100 ml) and added to the solution
of 10, along with Et3N (420 l, 3 mmol). The mixture was stirred overnight, then
citrate/phosphate buffer (200 ml, 0.02 M, pH 5.5) and CHCl3 (200 ml) were added, and
the mixture stirred for a further 1 h. The aqueous phase was then extracted four times
with CHCl3 (150 ml). The organic phases were collected and dried over Na2SO4, then the
solvents were removed under reduced pressure to give 770 mg of a white waxy product
(96% yield). 1H NMR: 0.8 ppm (t, 6H), 1.1-1.3 ppm (m, 48H), 1.6 ppm (m, 4H), 2.25
ppm (t, 4H), 2.5-2.65 ppm (m, 4H), 3.05 ppm (m, 4H), 3.35 ppm (m, 2H), 3.9 ppm (m,
2H), 4.2 ppm (m,4H), 4.4 ppm (m, 1H). M/z (ESI-MS): 790.7 (M-H)-.
3.2.12 Synthesis of PE-succ-NHS (12)
11 (50 mg, 63 mol) was dissolved in THF/CHCl3 (approx. 2 ml, 1:1). To this
solution were added DCC (11.4 mg, 55 mol) and N-hydroxysuccinimide (7.25 mg, 63
mol). The mixture was stirred and the reaction followed by TLC. After 6 h, the starting
material had disappeared and a new product formed. The precipitated urea was filtered
off. The solvents were removed by rotary evaporation and the product immediately
dissolved in tert-butanol (10 ml) and used in the coupling reaction.
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3.2.13 Synthesis of lipopeptide 13
Lipopeptide 13:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPTN
H o
H
N
O
N
H
O
OP
O
O-
O
O
O
C15H31
C15H31
O
O
N
H
2
Peptide 9 (3 mg) was dissolved in water (500 l) and the pH adjusted to 5.0-5.4
using 0.1 M NaOH. The solution of 12 in tert-butanol (150 l, 1.5 eq) was added to this
solution along with tert-butanol (350 l). The mixture was stirred at room temperature
and samples were removed at frequent intervals for LC-MS analysis. A peak appeared at
high retention time with the expected mass of the desired product (calculated MW:
6432.4 g/mol, observed m/z: 1287.5 (M+5H)/5, 1073.1 (M+6H)/6, 919.7 (M+7H)/7
(±0.01%). After 1-4 h, the peak of desired mass no longer increased in size and the
product was purified by RP-HPLC using an analytical Vydac C4 214TP104 column and a
gradient of 10 to 100% acetonitrile over 16.5 mins. Retention time: 15 mins. The
fractions containing the product peak were collected together, frozen and lyophilised.
Measured m/z (ESI-Tof-MS): 6432.5 (±0.01%).
3.2.14 Immunization studies
Preparation of peptide-loaded virosomes and immunizations were carried out at
Pevion Biotech. A solution of purified influenza A/Singapore virus hemagglutinin (4
mg) in phosphate-buffered saline (PBS) was centrifuged for 30 mins at 100000g and the
pellet was dissolved in PBS containing 100 mM octaethyleneglycolmonodecylether
(PBS-OEG). Lipopeptide 13 (4 mg), phosphatidylcholine (32 mg, Lipoid, Ludwigshafen,
Germany), and phosphatidylethanolamine (6 mg) were dissolved in PBS-OEG (2.66 ml).
The phospholipid and the hemagglutinin solutions were mixed and sonicated for 1 min.
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This solution was then centrifuged for 1 h at 100000g, and the supernatant was filtered
(0.22 m) under sterile conditions. Virosomes were then formed by detergent removal
with SM BioBeads (Bio-Rad, Glattbrugg, Switzerland).
For immunogenicity studies, five BALB/c mice were pre-immunized
intramuscularly with 2 mg of whole virus influenza antigen. Three weeks later they were
immunized with peptide-loaded IRIVs at intervals of three weeks.
Analyses were carried out at the Swiss Tropical Institute. For ELISA analyses,
Polysorp ™ plates (Nunc, Fisher Scientific) were coated overnight at 4oC with 100 l of
a 10g/ml solution of 13 in PBS (pH 7.2). Wells were then blocked with 5% milk
powder in PBS for 30 mins at r.t. followed by three washings with PBS containing 0.05%
Tween-20. Plates were then incubated with serial dilutions of anti-13 mouse sera in PBS
containing 0.05% Tween-20 and 0.5% milk powder for 2 h at r.t. After washing, plates
were incubated with alkaline phosphatase-conjugated goat anti-mouse  heavy chain
antibodies (Sigma) for 1 h at r.t. After washing again, phosphatase substrate solution was
added and the plates were incubated in the dark at r.t. until the colorimetric reaction had
progressed sufficiently. The optical density was measured at 405 nm on a Titertek
Multiscan MCC/340 reader (Labsystems, Helsinki, Finland).
For IFA, multiwell immunofluorescence microscopy slides were pre-treated with
0.01% poly-L-lysine (Sigma) at r.t. for 30 mins and washed five times with RPMI basal
salt medium (Gibco BRL). Erythrocytes from in vitro cultures of P. falciparum strain K1
with a parasitemia of 5-10% were washed twice in RPMI, then resuspended in RPMI and
two volumes of a solution containing 4% formaldehyde and 0.1% Triton X-100. From
this cell suspension, 30 l were added to each well, incubated at r.t. for 30 mins and
washed five times with PBS. Wells were then incubated for 30 mins at r.t. with blocking
solution containing 1% fatty acid-free bovine serum albumin (BSA) in PBS.
Immunostaining was performed by incubating the wells with 25 l of an appropriate
antibody or serum dilution in blocking solution in a humid chamber for 1 h at r.t. After
five washes with blocking solution, 25 l of 5 g/ml cyanine dye (Cy3)-conjugated
affinity-pure F(ab’)2 fragment goat anti-mouse  heavy chain antibodies (Jackson
Immuno Research Laboratories), diluted in blocking solution containing 0.01 mg/ml
Hoechst dye no. 33256 (Sigma) were added to the wells and incubated for 1 h at r.t.
Finally, wells were washed five times, mounted with mounting solution (90% v/v
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glycerol containing 0.1 M Tris-Cl, pH 8.0 and 2 mg/ml o-phenylenediamine), and
covered with a coverslip. Antibody binding and DNA staining were assessed by
fluorescence microscopy on a Leitz Dialux 20 fluorescence microscope. For analysis of
the parasite binding inhibitory activity of mimetic 13, blood stage parasites were
incubated for 30mins with serum diluted 1:1000 in the presence or absence of peptides
42, 43 or 44 at a final concentration of 50 g/ml.
3.2.15 Synthesis of alanine-scanning library
Sequences:
15: NISQHQCVAKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
16: NISQHQCVKAQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
22: NISQHQCVKKQCPQNSGCARHLDEREECKCLLNYKQEGDKCVENPNPT
23: NISQHQCVKKQCPQNSGCFAHLDEREECKCLLNYKQEGDKCVENPNPT
24: NISQHQCVKKQCPQNSGCFRALDEREECKCLLNYKQEGDKCVENPNPT
28: NISQHQCVKKQCPQNSGCFRHLDEAEECKCLLNYKQEGDKCVENPNPT
31: NISQHQCVKKQCPQNSGCFRHLDEREECACLLNYKQEGDKCVENPNPT
35: NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNAKQEGDKCVENPNPT
36: NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYAQEGDKCVENPNPT
40: NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDACVENPNPT
41: NISQAQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
3.2.15.1 Common sequence
Preloading of 2-chlorotrityl chloride resin with Fmoc-Thr(tBu)-OH was carried
out on a 10 g scale. Fmoc-Thr(tBu)-OH (1.073 g, 2.7 mmol) was dissolved in DMF (12
ml) with DIEA (1.78 ml, 10.8 mmol). This solution was added to the pre-swelled resin
which was agitated for 2 h. The resin was then washed five times with
DCM/MeOH/DIEA 17:2:1, three times with DCM and three times with DMF. The level
of loading was estimated using the procedure described by Chan and White [190] and
found to be 0.25 mmol/g. After drying in vacuo, preloaded resin (4 g, 1 mmol) was taken
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for the synthesis of the sequence Cys-Val-Glu-Asn-Pro-Asn-Pro-Thr. The synthesis was
carried out using standard 1 mmol FastMoc chemistry. 3 mmol Fmoc amino acid, 3
mmol HBTU, 3 mmol HOBt and 6 mmol DIEA were used for each coupling reaction. A
standard coupling time of 20 mins was used for each cycle. Ac2O capping was used to
block unreacted sites after each coupling cycle. After completion of the peptide
assembly, the resin was split into three portions of (A) 25%, (B) 37.5% and (C) 37.5%.
These resin portions were then treated as follows:
3.2.15.2 Synthesis of peptides 15, 16 and 41
For the synthesis of peptides 15, 16, and 41, the sequence Gln-Cys-Pro-Gln-Asn-
Ser-Gly-Cys-Phe-Arg-His-Leu-Asp-Glu-Arg-Glu-Glu-Cys-Lys-Cys-Leu-Leu-Asn-Tyr-
Lys-Gln-Glu-Gly-Asp-Lys was appended onto the sequence described in 3.2.15.1 (A)
above. The sequence was assembled using standard 0.25 mmol FastMoc chemistry with
a single coupling of 20 mins. For certain residues, an extended coupling time of 55 mins
was used: His(11), Lys(19), Cys(20), Asn(23), Lys(25), Gln(26), Lys(30). For some
other residues, a longer extended coupling time of 85 mins was used: Gln(1), Cys(2),
Pro(3), Gln(4), Asn(5), Cys(8), Arg(10), Arg(15), Cys (18). Ac2O capping was carried
out after each coupling cycle to block the unreacted sites. After peptide chain assembly,
the resin was split into three equal portions for the preparation of peptides 15, 16 and 41.
For peptide 41, taking 1/3 of the resin from above, the sequence Asn-Ile-Ser-Gln-
Ala-Gln-Cys-Val-Lys-Lys was appended using standard 0.1 mmol FastMoc chemistry,
which uses 1mmol Fmoc-amino acid, 1 mmol HBTU, 1 mmol HOBt and 2 mmol DIEA
per coupling cycle. An extended coupling time of 55 mins was used as standard. For
certain residues, a longer extended coupling of 85 mins was used: Asn(1), Gln(4),
Ala(5), Gln(6), Cys(7). Ac2O capping was used after each coupling cycle to block
unreacted sites.
For peptide 15, taking 1/3 of the resin from above, the sequence Asn-Ile-Ser-Gln-
His-Gln-Cys-Val-Ala-Lys was appended using standard 0.1 mmol FastMoc chemistry,
which uses 1 mmol Fmoc-amino acid, 1 mmol HBTU, 1 mmol HOBt and 2 mmol DIEA
per coupling cycle. An extended coupling time of 55 mins was used as standard. For
certain residues, a longer extended coupling of 85 mins was used: Asn(1), Gln(4),
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His(5), Gln(6), Cys(7). Ac2O capping was used after each coupling cycle to block
unreacted sites.
For peptide 16, taking 1/3 of the resin from above, the sequence Asn-Ile-Ser-Gln-
His-Gln-Cys-Val-Lys-Ala was appended using standard 0.1 mmol FastMoc chemistry,
which uses 1 mmol Fmoc-amino acid, 1 mmol HBTU, 1 mmol HOBt and 2 mmol DIEA
per coupling cycle. An extended coupling time of 55 mins was used as standard. For
certain residues, a longer extended coupling of 85 mins was used: Asn(1), Gln(4),
His(5), Gln(6), Cys(7). Ac2O capping was used after each coupling cycle to block
unreacted sites.
3.2.15.3 Synthesis of peptides 22, 23, 24 and 28
For the synthesis of peptides 22, 23, 24 and 28, the sequence Glu-Glu-Cys-Lys-
Cys-Leu-Leu-Asn-Tyr-Lys-Gln-Glu-Gly-Asp-Lys was appended onto the sequence
described in 3.2.15.1 (B) above. The sequence was assembled using standard 0.25 mmol
FastMoc chemistry with a single coupling of 20 mins. For certain residues, an extended
coupling time of 55 mins was used: Lys(4), Cys(5), Asn(8), Lys(10), Gln(11), Lys(15).
A longer extended coupling time of 85 mins was used for Cys (3). Ac2O capping was
carried out after each coupling cycle to block the unreacted sites. After peptide chain
assembly, the resin was split into four equal portions for the preparation of peptides 22,
23, 24 and 28.
For the synthesis of peptide 28, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Phe-Arg-His-
Leu-Asp-Glu-Ala was appended. The sequence was assembled using standard 0.1 mmol
FastMoc chemistry with a standard single coupling of 20 mins. For certain residues, an
extended coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21).
A longer extended coupling of 85 mins was used for : Asn(1), Gln(4), His(5), Gln(6),
Cys(7), Gln(11), Cys(12), Pro(13), Gln(14), Asn(15), Cys(18), Arg(20), Ala(25).
For the synthesis of peptide 24, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Phe-Arg-Ala-
Leu-Asp-Glu-Arg was appended. The sequence was assembled using standard 0.1 mmol
FastMoc chemistry with a standard single coupling of 20 mins. For certain residues, an
extended coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), Ala(21).
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A longer extended coupling of 85 mins was used for : Asn(1), Gln(4), His(5), Gln(6),
Cys(7), Gln(11), Cys(12), Pro(13), Gln(14), Asn(15), Cys(18), Arg(20), Arg(25).
For the synthesis of peptide 23, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Phe-Ala-His-
Leu-Asp-Glu-Arg was appended. The sequence was assembled using standard 0.1 mmol
FastMoc chemistry with a standard single coupling of 20 mins. For certain residues, an
extended coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21).
A longer extended coupling of 85 mins was used for : Asn(1), Gln(4), His(5), Gln(6),
Cys(7), Gln(11), Cys(12), Pro(13), Gln(14), Asn(15), Cys(18), Ala(20), Arg(25).
For the synthesis of peptide 22, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Ala-Arg-His-
Leu-Asp-Glu-Arg was appended. The sequence was assembled using standard 0.1 mmol
FastMoc chemistry with a standard single coupling of 20 mins. For certain residues, an
extended coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21).
A longer extended coupling of 85 mins was used for : Asn(1), Gln(4), His(5), Gln(6),
Cys(7), Gln(11), Cys(12), Pro(13), Gln(14), Asn(15), Cys(18), Arg(20), Arg(25).
3.2.15.4 Synthesis of peptides 31, 35, 36 and 40
For the synthesis of peptide 40, on ¼ of the resin from 3.2.15.1 (C) above, the
sequence Asn-Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-
Cys-Ala-Arg-His-Leu-Asp-Glu-Arg-Glu-Glu-Cys-Lys-Cys-Leu-Leu-Asn-Tyr-Lys-Gln-
Glu-Gly-Asp-Ala was appended. The sequence was assembled using standard 0.1 mmol
FastMoc chemistry with a standard single coupling of 20 mins. For certain residues, an
extended coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21),
Lys(29), Cys(30), Asn(33), Lys(35), Gln(36), Ala(40). A longer extended coupling of 85
mins was used for : Asn(1), Gln(4), His(5), Gln(6), Cys(7), Gln(11), Cys(12), Pro(13),
Gln(14), Asn(15), Cys(18), Arg(20), Arg(25), Cys (28).
For the synthesis of peptide 36, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Ala-Arg-His-
Leu-Asp-Glu-Arg-Glu-Glu-Cys-Lys-Cys-Leu-Leu-Asn-Tyr-Ala-Gln-Glu-Gly-Asp-Lys
was appended. The sequence was assembled using standard 0.1 mmol FastMoc
chemistry with a standard single coupling of 20 mins. For certain residues, an extended
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coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21), Lys(29),
Cys(30), Asn(33), Ala(35), Gln(36), Lys(40). A longer extended coupling of 85 mins
was used for : Asn(1), Gln(4), His(5), Gln(6), Cys(7), Gln(11), Cys(12), Pro(13),
Gln(14), Asn(15), Cys(18), Arg(20), Arg(25), Cys (28).
For the synthesis of peptide 35, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Phe-Arg-His-
Leu-Asp-Glu-Arg-Glu-Glu-Cys-Lys-Cys-Leu-Leu-Asn-Ala-Lys-Gln-Glu-Gly-Asp-Lys
was appended. The sequence was assembled using standard 0.1 mmol FastMoc
chemistry with a standard single coupling of 20 mins. For certain residues, an extended
coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21), Lys(29),
Cys(30), Asn(33), Lys(35), Gln(36), Lys(40). A longer extended coupling of 85 mins
was used for : Asn(1), Gln(4), His(5), Gln(6), Cys(7), Gln(11), Cys(12), Pro(13),
Gln(14), Asn(15), Cys(18), Arg(20), Arg(25), Cys (28).
For the synthesis of peptide 31, on ¼ of the resin from above, the sequence Asn-
Ile-Ser-Gln-His-Gln-Cys-Val-Lys-Lys-Gln-Cys-Pro-Gln-Asn-Ser-Gly-Cys-Phe-Arg-His-
Leu-Asp-Glu-Arg-Glu-Glu-Cys-Ala-Cys-Leu-Leu-Asn-Tyr-Lys-Gln-Glu-Gly-Asp-Lys
was appended. The sequence was assembled using standard 0.1 mmol FastMoc
chemistry with a standard single coupling of 20 mins. For certain residues, an extended
coupling of 55 mins was used: Ile(2), Ser(3), Val(8), Lys(9), Lys(10), His(21), Ala(29),
Cys(30), Asn(33), Lys(35), Gln(36), Lys(40). A longer extended coupling of 85 mins
was used for : Asn(1), Gln(4), His(5), Gln(6), Cys(7), Gln(11), Cys(12), Pro(13),
Gln(14), Asn(15), Cys(18), Arg(20), Arg(25), Cys (28).
3.2.15.5 Synthesis of oxidized mimetics 45-55
These peptides are the oxidized forms of the peptides described above.
Linear peptide 15 – oxidized peptide 45
Linear peptide 16 – oxidized peptide 46
Linear peptide 22 – oxidized peptide 47
Linear peptide 23 – oxidized peptide 48
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Linear peptide 24 – oxidized peptide 49
Linear peptide 28 – oxidized peptide 50
Linear peptide 31 – oxidized peptide 51
Linear peptide 35 – oxidized peptide 52
Linear peptide 36 – oxidized peptide 53
Linear peptide 40 – oxidized peptide 54
Linear peptide 41 – oxidized peptide 55
All of the mimetics were oxidized by dissolving at a concentration of 5 mg/ml in
0.1 M Tris buffer (pH 8.4) containing cysteine (3 mM), cystine (0.3 mM) and EDTA (5
mM) and stirring for 24 h. Oxidative folding was monitored by RP-HPLC using a Vydac
C18 218TP54 column with a gradient of 5 to 50% acetonitrile over 30 mins. Purification
was carried out by preparative RP-HPLC using a Zorbax eclipse XDB-C18 (7 m, 21.2 x
250 mm) column (flow rate 15 ml/min, gradient 5 to 27.5% acetonitrile over 18 minutes).
All of the purified oxidatively folded peptides, along with the oxidatively folded native
sequence, the unfolded native sequence, and the unfolded native sequence with alkylated
thiol groups, were analysed by RP-HPLC (Vydac C18 218TP54 column with a gradient
of 5 to 50% acetonitrile over 30 mins), ESI-MS, NMR (1H, TOCSY (80ms) and NOESY
(60ms)) and by circular dichroism. Retention times, extinction coefficients and measured
and calculated masses of the mimetics are summarized in Table 16. NMR spectra are
presented in Appendix 2, CD spectra are presented in chapter 1.2.
3.2.15.6 CD measurements
Amino acid analysis of each mimetic was carried out. From these, the extinction
coefficients given in Table 16 could be calculated. This allowed an accurate calculation
of peptide concentrations in stock solutions. Subsequently, samples of peptide
(approximately 0.3 mg/ml, 0.05 mM) in phosphate buffer (25 mM pH 6.2), were
prepared. These samples were used for CD measurements in a 0.1 mm quartz
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thermostatable cuvette at 25oC, using a JASCO J-715 spectropolarimeter. A scan speed
of 50 nm/min, a 1 second response time and a 1 nm spectral bandwidth were used. CD
spectra are presented after subtraction of a blank containing only buffer and the optical
activity is reported in units of mean residue ellipticity (deg cm2 dmol-1). Spectra are
presented as an average of four scans and results are given for the range 185-260 nm.
peptide Calculated mass
(g/mol)
Measured m/z
(MALDI-MS)
Retention
time*
Extinction
coefficient
43 5587.3 5585.9 14.5 2056
44 5935.7 5935.425 13.9 2338
45 5530.2 5529.838 13.8 1969
46 5530.2 5531.001 14.0 3340
47 5511.2 n.d. n.d. n.d.
48 5502.2 5502.351 13.3 2617
49 5521.2 5520.637 13.3 2443
50 5502.2 5502.052 13.9 2184
51 5530.2 5530.885 14.1 2605
52 5495.2 5496.490 13.6 390
53 5530.2 5530.525 15.4 2162
54 5530.2 5530.607 15.0 2157
55 5521.2 5520.631 13.9 2606
*For HPLC conditions, see 3.2.15.5.
Table 16: Analytical data for alanine scanning mimetics
3.2.16 Synthesis of linear mimetic 42
Mimetic 42:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
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The peptide was assembled as described for peptide 1 above, but on the threonine-
preloaded chlorotrityl chloride resin described in 3.2.15.1 above. One half of the cleaved
crude linear product was taken for oxidation to produce mimetic 43. The remainder was
purified by semi-preparative RP-HPLC using a Zorbax eclipse XDB-C18 column (9.4 x
250 mm, 5 m), 4 ml/min flow rate and a gradient of 5 to 33% acetonitrile over 15
minutes. 78 mg of purified peptide were obtained (yield 11%). Calculated MW: 5593.3
g/mol. Measured m/z (MALDI-Tof-MS) 5593.31 (±0.1%).
3.2.17 Synthesis of oxidised mimetic 43
Mimetic 43:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
The peptide was prepared from crude peptide 42, as described for peptide 2, by
oxidation at a concentration of 5 mg/ml in 0.1M Tris buffer (pH 8.4) containing 3mmol
cysteine, 0.3 mmol cystine and 10 mmol EDTA. The oxidised peptide was purified by
semi-preparative RP-HPLC using a Zorbax eclipse XDB-C18 column (9.4 x 250 mm, 5
m), 4 ml/min flow rate and a gradient of 5 to 33% acetonitrile over 15 minutes. The
mass spectrometry results and HPLC retention time are given in Table 16. 45 mg of
purified oxidized peptide were obtained (yield 6%).
3.2.18 Synthesis of alkylated mimetic 44
Mimetic 44:
NISQHQCVKKQCPQNSGCFRHLDEREECKCLLNYKQEGDKCVENPNPT
H2N H2N H2N
O O
NH2 NH2
O
O O
NH2
O
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The mimetic was prepared from purified mimetic 42 (30 mg), which was
dissolved in phosphate buffer (10 ml, 0.1 M, pH 7.5), with iodoacetamide (119 mg, 644
mol, 20 eq. per thiol group). After 30 mins stirring at room temperature, only masses
corresponding to the desired product could be seen in LC-MS (989.1 (M+6H)/6, 1187.0
(M+5H)/5, 1483.75 (M+4H)/4). The reaction mixture was then immediately purified by
semi-preparative RP-HPLC using a Zorbax eclipse XDB-C18 column (9.4 x 250 mm, 5
m), 4 ml/min flow rate and a gradient of 5 to 37% acetonitrile over 15 minutes. Mass
spectrometry results and HPLC retention time are given in Table 16. 18 mg of purified
product were obtained (yield 56 %).
3.3 MSP-4 peptides
3.3.1 Synthesis of peptide 56
Peptide 56:
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS-NH2
The linear peptide was assembled on Rink Amide resin (390 mg, loading 0.64
mmol/g) on a 0.25 mmol scale. For the first coupling reaction, Fmoc-Ser(tBu)-OH (0.27
mmol, 103.5 mg) were used. The standard coupling time for amino acids was 55 mins.
For the following amino acids, a coupling time of 20 mins was used: Leu(49) Ala(50).
For some amino acids, a long extended coupling was used: Leu(1), Glu(2), Ser(51).
Double couplings were used where needed: Leu(6), Lys(8), His(9), Asn(11), Asp(13),
Cys(13), Leu(19)-Val(23), Arg(26), Arg(27), Lys(29)-Glu(34), Tyr(36)-Glu(39),
Cys(43)-Glu(45). Fmoc-Leu-Ser(Me,Mepro)-OH was used for Leu(47) and Ser(48).
Each coupling cycle was followed by Ac2O capping to block unreacted sites. Following
completion of peptide chain assembly, the resin was dried under vacuum over KOH for 5
h. The peptide was cleaved from the resin and side-chain deprotected by treatment with a
mixture of TFA/TIS/H2O/EDT 94:1:2.5:2.5 (30 ml) for 3 h. The resin was then filtered
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off and washed twice with TFA (1 ml). The solution was concentrated under reduced
pressure until a precipitate began to form. The suspension was then transferred into 2
centrifuge tubes and the product was fully precipitated by the addition of cold diethyl
ether. The tubes were centrifuged at 2500 rpm for 7 mins, then the liquid was decanted
off. The peptide was washed twice with diethyl ether and centrifuged in the same way,
then allowed to air-dry for 1 h, to give approx. 600 mg of crude product. Purification was
carried out by semi-preparative RP-HPLC using a Vydac C18 218TP1010 column (10
m, 125 A, 10 x 100 mm, flow rate 5 ml/min), and a gradient of 10 to 50% acetonitrile
over 20 mins. Purification yielded 30-40 mg of linear peptide. (6% yield). Analytical
HPLC: Vydac C18 218TP54, flow rate 1 ml/min, 5 to 50% acetonitrile over 29 mins,
retention time 20.9 mins. Calculated MW: 5735.42 g/mol, measured ESI-Tof-MS:
5735.1±0.01% (m/z)
3.3.2 Synthesis of oxidised peptide 58
Peptide 58:
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS NH2
Peptide 56 was dissolved at a concentration of 5 mg/ml in an oxidation buffer
made up of Tris buffer (0.1 M, pH 8.4) containing EDTA (10 mM), cysteine (3 mM) and
cystine (0.3 mM). The mixture was stirred for 48 hours and then the product was purified
by semi-preparative RP-HPLC using a Vydac C18 218TP1010 column and a gradient of
5 to 50% acetonitrile over 25 mins. Analytical HPLC: Vydac C18 218TP54, flow rate 1
ml/min, gradient 5 to 50% acetonitrile over 29 mins, retention time: 18.4 mins.
Calculated MW: 5729.53g/mol, measured m/z (ESI-Tof MS): 5729.2 (±0.01%).
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3.3.3 Synthesis of mimetic 60
Mimetic 60:
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS NH2
H
N
H2N
O
The peptide sequence was assembled as described above. Hydrazinoglycine (7)
was coupled to the peptidyl resin as described for peptide 8. Peptide was cleaved from
the solid support and side-chain deprotected using TFA containing 1% TIS, 2.5% EDT
and 2.5% water for 3 h. After this time, the solution was concentrated in vacuo until a
precipitate began to form. The solution was then transferred into two centrifuge tubes
and the peptide product was fully precipitated by the addition of cold diethyl ether. The
tubes were centrifuged at 2500 rpm for 7 mins, then the liquid was decanted off. The
peptide was washed twice with diethyl ether and centrifuged in the same way, then
allowed to air-dry for 1 h, to give approx. 600 mg of crude product. This crude product
was oxidised directly at a concentration of 5 mg/ml in an oxidation buffer made up of
Tris buffer (0.1 M, pH 8.4) containing EDTA (10 mM), cysteine (3 mM) and cystine (0.3
mM). The mixture was stirred for 48 h and then the product was purified by semi-
preparative RP-HPLC using a Vydac C18 218TP1010 column and a gradient of 5 to 50%
acetonitrile over 25 mins. Typical yields of oxidised product were around 40 mg (7 %
yield). Analytical HPLC: Vydac C18 218TP54, flow rate 1 ml/min, gradient 5 to 50%
acetonitrile over 29 mins, retention time: 18.9 mins.Calculated MW 5801.60 g/mol,
measured ESI-Tof-MS (m/z): 5801.4±0.01%.
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3.3.4 Synthesis of lipopeptide 61
Lipopeptide 61:
LEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS NH2
H
N
HN
O
HN
O
O P
O
O-
O
O
O
C15H31
C15H31
O
O
O
Peptide 60 (3 mg) was dissolved in water (500 l) and the pH adjusted to 5.0-5.4
using NaOH (0.1 M). A solution of 60 (1.5 eq) in tert-butanol (500 l) was added to this
solution. The mixture was stirred at room temperature and samples were removed at
frequent intervals for LC-MS analysis. Several peaks appeared in the chromatogram and
that at highest retention time showed the expected mass of the desired product. Measured
m/z: 1316 (M+5H)/5, 1097 (M+6H)/6. After 1-4 h, the peak of desired mass no longer
increased in size and the solution was purified by RP-HPLC using an analytical Vydac
C4 214TP104 column and a gradient of 10 to 100% acetonitrile over 45 mins. The
fractions containing the product peak were collected, frozen and lyophilised. Calculated
MW: 6574.45 g/mol, Measured m/z (ESI-Tof-MS): 6575.1 (± 0.01%).
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3.3.5 Synthesis of oxidised peptide 63
Peptide 63:
KKKKLEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS
H
N
H2N
NH2
O
The peptide sequence was assembled as described for peptide 56 above. The
additional lysine residues were coupled using a 55 min extended single coupling cycle.
Peptide was cleaved from the resin and side-chain deprotected as described above. The
crude linear peptide was oxidised directly as described above. After 48 h of oxidation,
the product was purified directly by semi-preparative RP-HPLC using a Vydac C18
218TP1010 column and a gradient of 5 to 50% acetonitrile over 25 mins. Around 25 mg
of purified peptide were obtained (yield 1.6%). Calculated MW: 6314.30 g/mol,
Measured m/z (MALDI-Tof-MS): 6314.021.
3.3.6 Synthesis of lipopeptide 64
Lipopeptide 64:
KKKKLEDEDLCKHNNGDCGDDKLCEYVGNRRVKCKCKEGYKLEGIECVELLSLAS
H
N
HN
O
HN
O
O P
O
O-
O
O
O
C15H31
C15H31
O
O
NH2
O
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Peptide 63 (3 mg) was dissolved in water (500 l) and the pH adjusted to 5.0-5.4
using NaOH (0.1 M). A solution of 60 (1.5 eq) in tert-butanol (500 l) were added to
this solution. The mixture was stirred at room temperature and samples were removed at
frequent intervals for LC-MS analysis. Several peaks appeared in the chromatogram and
the largest showed the expected mass of the desired product: Calculated MW: 7087.33
g/mol, Measured m/z (ESI-MS): 1418.2 (M+5H/5), 1182.0 (M+6H/6), 1012.5
(M+7H)/7). This product could be purified by RP-HPLC using an analytical Vydac C4
214TP104 column and a gradient of 10 to 100% acetonitrile over 45 mins. Measured m/z
(MALDI-Tof-MS): 7088.022.
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3.4 GLURP peptides
Structures of GLURP mimetics:
G G C I N E E D S E P F P R Q K H K K V D N H N E C G
NH2
O
NH2
O
NH2X
G G C I N E E D S
E P F P
R
Q
KHKKVDNHNEC
G
NH2
X
G G K D T I S T E P F P N Q K H K D L Q Q D L N
NH2
X
G G N Q K H K D L Q Q D L N D E P L E P F P T Q
NH2
X
G G N D E P L E P F P T Q I H K D Y K E K N L I N E E
NH2
X
G G N E E D S E P F P R Q K H K K V D N H N E E K NH2
X
G G D T I S T E P F P N Q K H
K D L Q Q
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L
N
DEPLEPF
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IHKDYK
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NH2
X
G G
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N
L
INEEDSEPFPRQKHKKVDN
X
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Peptides 65, 73
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For peptides 73-78, X= -COCH3, For peptides 65-72, X=
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3.4.1 Synthesis of 65, 66, 67, 68, 71 and 72
Each of the six GLURP lipopeptide mimetics for immunization studies was
prepared in the same way, using Rink Amide resin on the ABI 433A on a 0.25 mmol
scale and a standard single coupling of 20 minutes, with Ac2O capping after each cycle.
After automated peptide synthesis, the half of the resin for PE-Succ coupling was treated
with a solution of PE-Succ (11) as follows: 11 (592 mg , 0.75 mmol) was dissolved in a
minimal amount of DMF with HATU (286 mg, 0.75 mmol) and HOAt (116 mg, 0.75
mmol). DIEA (352 l) was added and this solution was then added to the peptidyl-resin.
The resin suspension was agitated overnight, then filtered and washed five times with
DMF and five times with DCM. The resin now gave a negative result in the Kaiser test,
suggesting that the PE had been fully coupled. The resin was washed five times with
DMF then five times with DCM and then treated for 3 h with TFA containing 2.5% TIS
and 2.5% water, and precipitated using cold diethyl ether as described previously. The
peptides were then purified by preparative RP-HPLC using an Interchrom
UP10WC4/25M column and a gradient of 40 to 100% acetonitrile over 35 mins.
Analytical data:
(65) ESI-MS (m/z): 1742.5 (M+2H)/2, 1162.3 (M+3H)/3, 871.8 (M+4H)/4. RP-
HPLC. Vydac C4 214TP104 column, gradient 30 to 100% acetonitrile over 33 mins.
Retention time: 21.4 mins.
(66) ESI-MS (m/z): 1762.0 (M+2H)/2, 1174.6 (M+3H)/3, 881.3 (M+4H)/4. RP-
HPLC. Vydac C4 214TP104 column, gradient 30 to 100% acetonitrile over 33 mins.
Retention time: 21.9 mins.
(67) ESI-MS (m/z): 1964.9 (M+2H)/2, 1310.5 (M+3H)/3, 982.8 (M+4H)/4,
786.5 (M+5H)/5. RP-HPLC. Vydac C4 214TP104 column, gradient 30 to 100%
acetonitrile over 30 mins. Retention time: 22.1 mins.
(68) ESI-MS (m/z): 1241.7 (M+3H)/3, 931.4 (M+4H)/4, 745.2 (M+5H)/5, 621.2
(M+6H)/6 . RP-HPLC. Vydac C4 214TP104 column, gradient 30 to 100% acetonitrile
over 33 mins. Retention time: 19.8 mins.
Chapter 3: Experimental part 167
(71) ESI-MS (m/z): 1417.8 (M+4H)/4, 1134.1 (M+5H)/5, 945.3 (M+6H)/6, 810.6
(M+7H)/7. RP-HPLC. Vydac C4 214TP104 column, gradient 30 to 100% acetonitrile
over 33 mins. Retention time: 20.34 mins.
(72) ESI-MS (m/z): 1434.6 (M+4H)/4, 1147.8 (M+5H)/5, 956.9 (M+6H)/6, 820.4
(M+7H)/7. RP-HPLC. Vydac C4 214TP104 column, gradient 30 to 100% acetonitrile
over 30 mins. Retention time: 20.0 mins.
3.4.2 Synthesis of 73-76
The resin prepared as described in section 3.4.1 was treated, in each case, twice
with a solution of Ac2O/DIEA/HOBt/NMP (475 l/225 l/20 mg/9.3 ml), each time for
10 mins. The reaction was monitored using the Kaiser test. The resin was washed five
times with NMP and five times with DCM and then cleaved and side-chain deprotected
as described previously. The peptides were then purified by preparative RP-HPLC using
a Vydac C18 218TP1022 column and a gradient of 5 to 45% acetonitrile over 30mins.
Analytical data:
(73) ESI-MS (m/z): 1376.8 (M+2H)/2, 918.0 (M+3H)/3, 688.7 (M+4H)/4, 551.3
(M+5H)/5. RP-HPLC. Vydac C18 218TP104 column, gradient 5 to 55% acetonitrile
over 29 mins. Retention time: 13.4 mins.
(74) ESI-MS (m/z): 1395.8 (M+2H)/2, 930.8 (M+3H)/3, 698.6 (M+4H)/4. RP-
HPLC. Vydac C18 218TP104 column, gradient 5 to 55% acetonitrile over 29 mins.
Retention time: 15.1 mins.
(75) ESI-MS (m/z): 1066.2 (M+3H)/3, 800.0 (M+4H)/4. RP-HPLC. Vydac C18
218TP104 column, gradient 5 to 55% acetonitrile over 29 mins. Retention time 15.3
mins.
(76) ESI-MS (m/z): 997.6 (M+3H)/3, 748.5 (M+4H)/4, 599.0 (M+5H)/5. RP-
HPLC. Vydac C18 218TP104 column, gradient 5 to 55% acetonitrile over 29 mins.
Retention time: 9.4 mins.
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3.4.3 Synthesis of peptides 69 and 77
The linear peptide was prepared on Rink amide resin (379 mg, loading 0.66
mmol/g) and synthesised on a 0.25 mmol scale on an ABI 433A using single coupling of
20 mins with capping for each cycle. After completion of the peptide chain assembly,
with final Fmoc deprotection, a small portion of the resin was removed and found to give
a positive result in the Kaiser test.
69: PE-Succ (11) was prepared as described above and coupled to the N-terminus
of the resin-bound peptide as follows: 11 (592 mg, 0.75 mmol) was dissolved in a
minimal amount of DMF with HATU (286 mg, 0.75 mmol) and HOAt (116 mg, 0.75
mmol). DIEA (352 l) was added and this solution was then added to the peptidyl-resin.
The resin suspension was agitated for 16 h, then filtered and washed five times with DMF
and five times with DCM. The resin now gave a negative result in the Kaiser test,
suggesting that the PE had been fully coupled.
The peptide was cleaved from the resin and deprotected using TFA containing 1%
TIS, 2.5% EDT and 2.5% water, and precipitated with cold diethyl ether as described
previously. The product showed two peaks in LC-MS and RP-HPLC, the second peak
had the expected mass of the desired product: (m/z) 1281.7 (M+3H)/3, 961.4 (M+4H)/4,
769.7 (M+5H)/5 and was purified by preparative RP-HPLC using an Interchrom
UP10WC4/25M column.
For the capping of the thiol groups, in a typical reaction, peptide 79 (6.8 mg) was
dissolved in phosphate buffer (12 ml, 0.1 M, pH 7.5), along with iodoacetamide (7 mg,
20 eq.). The solution was stirred and the reaction monitored by LC-MS. After 1 h a
single peak was seen in the chromatogram with the expected mass of the desired product
(m/z): 1319 (M+3H)/3. The product was immediately purified by semi-preparative RP-
HPLC using a Vydac C4 214TP1010 column and a gradient of 40 to 100% acetonitrile
over 30mins. After purification 4.7 mg of product 69 were obtained (yield 69%).
ESI-MS (m/z): 1978.2 (M+2H)/2, 1319.5 (M+3H)/3.
77: The peptide sequence was assembled as described for peptide 69. The N-
terminal acetylation was carried out manually by treating twice with a solution of
Ac2O/DIEA/HOBt/NMP (475 l/225 l/20 mg/9.3 ml), each time for 10 mins.
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Alkylation of the thiol groups was achieved by the same method as described for 69
above. Calculated MW: 3221.44 g/mol, Measured m/z (ESI-MS) (± 0.01%) 1612.2
(M+2H)/2, 1075.1 (M+3H)/3, 806.7 (M+4H)/4, 645.6 (M+5H)/5.
3.4.4 Synthesis of 70
The synthesis of the linear peptide was carried out in the same way as described
for 69. The formation of the disulfide bond was performed as follows: Peptide 79 (18
mg) was dissolved in ammonium acetate buffer (150 ml, 50 mM, pH 8). TFE (150 ml)
was added and the mixture was stirred in an open atmosphere overnight. The reaction
was monitored by analytical RP-HPLC and after 24 h the starting material had been
completely converted into a product. The product was purified by semi-preparative RP-
HPLC using a Vydac C4 214TP1010 column and a gradient of 40 to 100% acetonitrile
over 30 mins. 4.5 mg of purified product were obtained in total. Analytical HPLC:
Vydac C4 214TP104, flow rate 1 ml/min, gradient 30 to 100% acetonitrile over 29 mins,
retention time 22.6 mins. Calculated MW: 3838.29 g/mol. Measured m/z: (ESI-MS):
1920.2 (M+2H)/2, 1280.4 (M+3H)/3, 960.6 (M+4H)/4.
3.4.5 Immunization studies
The immunogenicity of the lipopeptide mimetics presented on IRIVs was assayed
in mice. Virosomes were prepared and immunizations carried out by Dr Rinaldo
Zurbriggen and co-workers at Pevion Biotech. Analysis of the immunized mouse sera
was performed by Prof. Gerd Pluschke and co-workers at the Swiss Tropical Institute.
BALB/c mice were pre-immunized intramuscularly with the commercial whole-
virus influenza vaccine Inflexal Berna (Berna Biotech). At least three weeks later, they
were immunized with mimetic-loaded IRIVs at intervals of at least two weeks, four
times. Blood was collected before each immunization and after the final injection. Sera
obtained from the immunizations were tested for reactivity with the mimetics by enzyme-
linked immunosorbent assay (ELISA). Sera were also tested for reactivity with blood-
stage parasites in immunofluorescence assays (IFA). Responses in IFA were weak, the
strongest response being from the immunization with 66 and 67.
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3.5 Peptoid-peptide hybrids
3.5.1 Syntheis of bromoacetic acid allyl ester (90)
Bromoacetic acid (18.1 g, 0.13 mol) was dissolved in benzene (60 ml) containing
conc. H2SO4. (0.12 ml). Allyl alcohol (20 ml, 0.15 mol) was added and the mixture was
heated to reflux and refluxed for 6 h. A Dean-Stark trap was used to collect the water
formed. The organic phase was washed three times with NaHCO3 (20 ml, 1 M), then the
aqueous phase was extracted three times with benzene. The organic phases were
collected, dried over MgSO4 and concentrated in vacuo. The product was purified by
distillation under reduced pressure (31 mbar, 85-87oC). Yield 16.1 g (69.3%). 1H NMR:
4.00 ppm (s), 2H (BrCH2), 4.80 ppm (d), 2H (CH2CH=CH2), 5.45 ppm (m), 2H
(CH2CH=CH2), 6.05 ppm (m), 1H (CH2CH=CH2).
3.5.2 Synthesis of (4-amino-butyl)-carbamic acid tert-butyl ester (93)
To 1,4-diaminobutane (100 mmol, 8.8 g) in DCM (500 ml), was added (Boc)2O
(20 mmol, 4.36 g) in DCM (250 ml) dropwise at 0oC over 3-4 h. The reaction mixture
was stirred at room temperature overnight. The solution was filtered and the solvent was
removed by rotary evaporation. The oily residue was diluted with AcOEt (150 ml) and
washed twice with 150 ml brine. The aqueous layer was then extracted three times with
AcOEt (180 ml). The organic layers were dried over Na2SO4 and the solvent evaporated
to leave a waxy white solid product in 70-80% yield. 1H NMR: 1.45 ppm (s), 9H(-
C(CH3)3), 1.55-1.7 ppm (m), 4H(-CH2CH2CH2CH2-), 2.65 ppm (t) 2H(-CH2NH2), 3.15
ppm (m) 2H(-CONHCH2). Calculated MW: 188.27 g/mol. Measured m/z (ESI-MS):
189.1 (M+H).
3.5.3 Synthesis of (4-tert-butoxycarbonylamino-butylamino)-acetic acid
allyl ester (94)
To 93 (5 g, 26.6 mmol) was dissolved in dry THF (30 ml), triethylamine (7.4 ml,
53 mmol) was added. A solution of of 90 (4.76 g, 26.6 mmol) in dry THF (30 ml) was
added dropwise over 4 h. The solution was then stirred at room temperature for 16 h.
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Solvent was removed in vacuo and the product suspended in diethyl ether. The Et3NHBr
that precipitated was removed by filtration. The product was purified by flash
chromatography (eluant: ethyl acetate). TLC: Rf value (eluant: ethyl acetate) 0.29
(revealed using ninhydrin). Yield: 25%. 1H NMR: 1.65 ppm (s), 9H (Boc), 1.75-1.95
ppm (m), 4H (NHCH2CH2CH2CH2NH), 2.85 ppm (q), 2H (NHCH2CH2CH2CH2NH),
3.35 ppm (q), 2H (NHCH2CH2CH2CH2NH), 3.70 ppm (s), 2H (NHCH2CO), 4.85 ppm
(d), 2H (OCH2CH=CH2), 5.4-5.6 ppm (m), 2H (OCH2CH=CH2), 6.1-6.2 ppm (m), 1H
(OCH2CH=CH2). Calculated MW: 286.37 g/mol. Measured m/z (ESI-MS): 287.2
(M+H).
3.5.4 Synthesis of [(4-tert-butoxycarbonylamino-butyl)-(9H-fluoren-9-
ylmethoxycarbonyl)-amino]-acetic acid allyl ester (95)
To a solution of 94 (1.5 g, 5.24 mmol) in dry DCM (50 ml) at 0oC was added
DIEA (1.8 ml, 10.5 mmol), followed by Fmoc-Cl (1.56 g, 6 mmol). The reaction was
monitored by TLC (eluant: ethyl acetate). After 2 h the solvent was removed in vacuo.
The product was used for the next step without further purification.
3.5.5 Synthesis of [(4-amino-butyl)-(9H-fluoren-9-ylmethoxycarbonyl)-
amino]-acetic acid allyl ester (96)
Crude product 95 (11 g) was dissolved in TFA/DCM 3/7 (40ml) at 0oC and stirred
for 20 minutes. The solution was concentrated in vacuo, then dissolved in cold diethyl
ether. The organic phase was extracted five times with HCl (50 ml, 1M). The aqueous
phases were collected and lyophilised and found to contain a small amount of the desired
product. LC-MS revealed that much of the desired product was present in the organic
phase which was therefore re-extracted with cold water and the product lyophilised.
Trituration with cold diethyl ether/cyclohexane (9:1) yielded 3 g (yield 35%) of a yellow
oil showing a single peak in LC-MS. 1H NMR: 1.0-1.5 ppm (m), 4H
(NHCH2CH2CH2CH2NH), 2.85 ppm (m), 2H (NHCH2CH2CH2CH2NH), 3.20 ppm (m),
4H (NHCH2CH2CH2CH2NH), 3.85 ppm (d) 2H (NCH2CO), 4.20 ppm (m), 1H (Fmoc
CH-CH2O), 4.40 ppm (m), 4H (OCH2CH=CH2) and (Fmoc-CHCH2O), 5.20 ppm (m),
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2H, (OCH2CH=CH2), 5.80 ppm (m), 1H (OCH2CH=CH2), 7.15-7.80 ppm (m), 8H
(Fmoc). ESI-MS: 409.2 (M+H) (calculated mass: 408.5).
3.5.6 Synthesis of Fmoc-Lys(Boc)-Lys(Boc) dimer (98)
Dimer 96:
OHLysLys
BocBoc
Fmoc
Chlorotrityl chloride resin (2.5 g, loading 1-1.2 mmol/g) was swelled in DCM (25
ml) for 60 mins. A solution containing Fmoc-Lys(Boc)-OH (1.687 g, 3.6 mmol) and
DIEA (2 ml, 12 mmol) in DCM (15 ml) was then added to the resin, and the resin
suspension agitated for 2 h, after which the resin was washed five times with
DCM/MeOH/DIEA 17:2:1, three times with DCM, then three times with DMF. The
resin was treated twice with a solution of piperidine (15 ml, 20 % in DMF) for 15 mins,
then washed five times with DMF. A positive Kaiser test result showed that the Fmoc
deprotection had been successful. For the coupling of the second lysine residue, a
solution of Fmoc-Lys(Boc)-OH (5.622 g, 12 mmol), HBTU (4.552 g, 12 mmol) and
HOBt (1.837 g, 12 mmol) in DMF (20 ml) with DIEA (6 ml) was added to the resin. The
resin suspension was agitated for 1.5 h, after which time it was washed five times with
DMF. A negative Kaiser test result showed that coupling was complete. The resin was
washed five times with DCM, then treated five times for one minute with a solution of
TFA (1% in DCM). The resin was washed five times with DCM and the organic phases
were collected. Solvent was removed in vacuo, and the product was triturated with cold
water to provide 1.2 g of a white solid (yield 68%).
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3.5.7 Peptide-peptoid hybrid mimetic 88
Mimetic 88:
H2N
N
Lys
Lys
Leu
Arg
Leu
Pro
p
ro
Val
Arg
Tyr
Lys
Trp
Arg
O
(A) Via on-resin cyclisation:
2-chlorotrityl chloride resin (1 g, loading 1-1.2 mmol/g) was swelled in DCM for
1 h. The oily product 96 (2.99 g, 7.3 mmol) from 3.5.5 above was dissolved in dry DCM
(50 ml). This solution (10.5 ml, 0.63 g of product, 1.53 mmol) were added to the resin
with DIEA (0.6 ml, 3.6 mmol). The resin suspension was agitated for 40 mins, then
washed five times with DCM, once with MeOH for 15 minutes, and again with DCM.
Level of loading was estimated according to Chan and White [190] and found to be 1
mmol/g.
The pre-loaded resin (250 mg) was swelled in DCM for 30 mins, then the resin
washed five times with DMF. The resin was treated twice with a solution of piperidine
(20% in DMF, 5 ml), then the resin was washed five times with DMF.
The Fmoc-Lys(Boc)-Lys(Boc) dimer 98 (697 mg, 1 mmol) from 3.5.6 above,
HOBt (153 mg, 1 mmol) and HBTU (379 mg, 1 mmol) in DMF (5 ml) with DIEA (650
l, 3.7 mmol) were added to the resin, then the resin suspension was agitated for 1.5 h.
The resin was washed five times with DMF and three times with DCM. A negative
Kaiser test result showed that the coupling was complete. The assembly of the peptide
sequence was then continued manually, using protected amino acid (1 mmol), HBTU (1
mmol), HOBt (1 mmol) and DIEA (3 mmol) in DMF for each coupling step, and two 15
minute Fmoc deprotection cycles with piperidine (20 % in DMF, 5 ml) each time. Each
coupling step lasted 1.5 hs and was monitored using the Kaiser test.
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For the deprotection of the allyl group, the peptidyl resin was swelled for 30
minutes in dry DCM. Under argon, Pd(PPh3)4 (289 mg, 0.25 mmol) was dissolved in dry
DCM (4 ml). To this solution, acetic acid (0.25 ml) and NMM (0.125 ml) were added.
This solution was added to the resin, and the peptidyl resin was agitated for 1.5 h with
exclusion of light. The resin was then washed three times with DCM, three times with
DMF, three times with DCM, once with 0.5% DIEA in DMF, three times with 0.5%
diethyldithiocarbamate in DMF, three times with DMF and finally three times with
DCM.
For the cyclisation, peptidyl resin (80 mg) was swelled overnight in DMF. HOBt
(184 mg, 1.2 mmol), HBTU (455 mg, 1.2 mmol) and DIEA (356 l, 2 mmol) were
dissolved in DMF (2.5 ml) and added to the resin. The resin suspension was agitated for
5 h. The resin was then washed three times with DMF, twice with DCM, three times
with DMF, twice with MeOH, twice with DMF and twice with diethyl ether. The peptide
was then cleaved from the resin and side-chain deprotected using TFA/TIS/H2O
(95:2.5:2.5) for 3 h. The resin was washed twice with TFA and the washings collected.
TFA was then removed in vacuo, and the oily product obtained was washed five times
with cold diethyl ether. It was then dissolved in water and lyophilised to provide a white
powder. The product was purified by RP-HPLC using a Vydac C18 218TP1022 column
(10 m, 125 Å, 22 x 100 mm, flow rate 10 ml/min) and a gradient of 24 to 34%
acetonitriles over 11 minutes. The purified product was analysed by RP-HPLC (Vydac
C18 218TP54 (5 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), gradient 5 to 40%
acetonitrile over 33 minutes, retention time 28.4 mins) HPLC-MS and ESI-MS, which
showed it to have the expected mass for the desired product. Calculated MW: 1850.35
g/mol, Measured m/z (ESI-MS): 926.5 (M+2H)/2.
(B) Via solution cyclisation:
2-chlorotrityl chloride resin (1 g, loading 1-1.2 mmol/g) was swelled for 20 mins
in DCM. The resin was then washed twice with DCM. Bromoacetic acid (4.8 mmol,
0.67 g, 4 eq) was dissolved in a minimal amount of DCM and DIEA (9.6 mmol, 1.64 ml,
8 eq) was added with stirring. The resin suspension was agitated gently for 1 h and the
resin was then washed 6 times with DCM. (4-amino-butyl)-Carbamic acid tert-butyl
ester (12 mmol, 2.6 g, 10 eq) dissolved in a minimal amount of DMF was added to the
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resin and the resin suspension gently agitated overnight. After this time the resin was
washed 5 times with DMF and 5 times with DCM. The peptoid-resin was then
transferred to the synthesis vessel of an Applied Biosystems ABI 433A synthesiser and
the remainder of the peptide chain was built up using FastMoc® chemistry, with single
coupling cycles of 20 minutes. An extended coupling of 55 mins was used for Lys, Pro
and DPro residues. A long extended coupling of 85 mins was used for Arg residues.
To cleave the mimetic from the solid phase, resin was washed twice with DCM
and then treated three times with a solution of 1% TFA in DCM (10 ml) for 1 minute,
then 7 times for two minutes. Finally, the resin was washed twice with DCM and twice
with MeOH. The solutions were collected in a flask containing pyridine (0.5 ml)
Solvents were removed by rotary evaporation until around 4 ml of solution remained.
Cold water (100 ml) was added to this solution in order to precipitate the linear protected
peptide. The slightly off-white product was filtered off using a Buchner funnel and
washed three times with water, twice with aqueous NaHCO3 (5%), three times with
water, twice with aqueous NaHSO4 (0.05 M) and finally five times with water. The
product was then dried in vacuo over KOH for 3 hours. 420 mg of dry product were
obtained.
Cyclisation: The linear protected peptide (200 mg) was dissolved in DMF (80
ml). An RP-HPLC (C4) chromatogram of this solution was recorded. HOAt (16 mg, 1.5
eq), HATU (38 mg, 1.5 eq). and DIEA (12 l, 3.5 eq) were added to the solution, which
was then stirred overnight. RP-HPLC using the same column and gradient showed that
after this time the linear product had been consumed and a new peak had appeared. This
observation was consistent with the formation of a cyclic product. The DMF was then
removed under reduced pressure to leave a sticky pale yellow product.
For side-chain deprotection, a mixture of TFA/TIS/H2O (95:2.5:2.5) (20 ml) was
added to the cyclic product and the solution was stirred under nitrogen for 3 h. During
this time the solution changed from pale yellow to a deep red. The stirring was then
stopped and TFA was removed from the solution by rotary evaporation until around 3ml
remained. This solution was split into two centrifuge tubes. Cold diethyl ether was then
added to the tubes to precipitate the side-chain deprotected cyclic product. The tubes
were centrifuged for 8 mins at 2200 rpm. The solution was decanted off and the white
product was washed and centrifuged twice with diethyl ether in the same way. Finally
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the product was allowed to air-dry for 1 h and was then weighed. Mass of crude cyclic
product obtained:100 mg.
The product was dissolved in water (10 mg/ml) and purified by RP-HPLC using a
Vydac C18 218TP1022 column (10 m, 125 Å, 22 x 100 mm, flow rate 10 ml/min) and a
gradient of 24 to 34 % acetonitrile over 11 minutes. One main peak was seen in the
chromatogram and when this peak was collected and concentrated, HPLC-MS and ESI-
MS showed it to have the expected mass for the desired product. M/z (M+H): 1850,
(M+2H)/2: 925, (M+3H)/3: 617, (M+4H)/4: 463. The purified product was analysed by
RP-HPLC (Vydac C18 218TP54 (5 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min),
gradient 22 to 34% acetonitrile in 19 minutes, Retention time 16.9 mins). The
cyclization, deprotection and purification steps were repeated for the remaining material.
Total purified product obtained: 14 mg.
3.5.8 Peptoid-peptide hybrid mimetic 89
Mimetic 98:
N
H2N
Lys
N
O
LeuH2N
Arg
Leu
Pro p
ro
Val
Arg
Tyr
Lys
Trp
Arg
O
The loading of the resin with bromoacetic acid and displacement of the bromo
group were carried out in the same way as described for mimetic 88, but on a 2 g rather
than a 1 g scale.
Fmoc-Lys(Boc)-OH, (3.75 g, 4 eq), HOBt (1.22 g 4 eq) and HBTU (3.03 g, 4 eq)
were dissolved in a minimal amount of DMF. DIEA (4.1 ml, 12 eq) were added with
stirring, then this solution was added to the resin. The resin suspension was agitated
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overnight. After this time the resin was filtered and washed 5 times with DMF and 5
times with DCM. The resin was then treated twice with a solution of piperidine (15 ml,
20% in DMF) for 15 mins. The resin was washed 5 times with DMF and 5 times with
DCM. A positive Kaiser test showed that the deprotection had occurred.
To bromoacetic acid (2.78 g, 10 eq) dissolved in a minimal amount of DMF was
added DIC (3.1 ml, 10 eq) dropwise. The solution was stirred for 5 mins then added to
the resin. The resin suspension was agitated for 2 h, then washed 5 times with DMF and
5 times with DCM. A negative Kaiser test showed that coupling was complete.
(4-amino-butyl)-Carbamic acid tert-butyl ester (3.77 g, 10 eq) were then dissolved
in a minimal amount of DMF and added to the resin. The resin suspension was agitated
overnight. After this time the resin was washed 5 times with DMF and 5 times with
DCM.
For the leucine coupling, to a solution of Fmoc-Leu-OH (7 g, 10 eq) and HOAt
(3.1 g, 10 eq) dissolved in a minimal amount of DMF was added DIC (3.1 ml, 10 eq)
dropwise and the solution was stirred for 20 mins. The solution was then added to the
resin and the resin suspension agitated for 4 hours. The resin was finally washed 5 times
with DMF and 5 times with DCM.
The resin was then transferred to the synthesis vessel of an ABI 433A and the
peptide chain was built up using FastMoc® chemistry. Single couplings of 20 mins
without capping were used. An extended coupling of 55 mins was used for Lys, Pro and
DPro residues. A long extended coupling of 85 mins was used for Arg residues.
Cleavage, cyclisation, deprotection. These three steps were carried out in the
same way as for mimetic 88. The purified product was analysed by RP-HPLC (Vydac
C18 218TP54 (5 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), gradient 5 to 40%
acetonitrile over 33 minutes, retention time 27.5 minutes). Mass of linear protected
product obtained: 470 mg. Mass of crude deprotected cyclic product: 303 mg. Mass of
purified product: 15 mg. Measured m/z (ESI-MS): (M+H): 1851, (M+2H)/2: 926,
(M+3H)/3: 618.
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3.5.9 NMR Studies on peptides 88 and 89
1D and 2D 1H NMR spectra were recorded at 600 MHz at a peptide concentration
of 20 mg/ml in H2O/D2O 9:1 and in D2O at pH 5 and 298 K. Water suppression was
performed by presaturation [203]. The sequential resonance assignments were based on
DQF-COSY [204] and TOCSY [205] measurements. Distance restraints were obtained from
ROESY [212] [213] spectra with mixing times of 40, 80, 120 and 250 ms. Spectra were
collected with 1024 x 256 complex data points zero-filled prior to Fourier transformation
to 2048 x 1024, and transformed with a cosine-bell weighting function. Data processing
was carried out with XWINNMR (Bruker) and XEASY [207].
The structure calculations were performed by restrained molecular dynamics in
torsion angle space by applying the simulated annealing protocol implemented in the
program DYANA [96].
3.5.10 Antimicrobial activity assays
Lyophilized peptides were weighed and dissolved in 0.01% acetic acid. The
antimicrobial activities of the peptides were determined by the standard NCCLS broth
microdilution method[191] in sterile 96-well plates (Nunclon polystyrene microtiter
plates). Innocula of the bacteria were diluted into Mueller-Hinton (MH) broth to give
approximately 106 colony forming units (CFU) per ml. Aliquots (50 l) of the innocula
were added to MH broth (50 l) containing the peptide in serial two-fold dilutions.
Antimicrobial activities are expressed as the minimal inhibitory concentration in g/ml,
the minimal concentration at which 100% inhibition of growth was observed after 18-20
h incubation at 37oC. Determinations were performed in triplicate. Microorganisms
tested were Escherichia coli (ATCC 25922), Pseudomonas aeruginosa (ATCC 27853)
and Staphylococcus aureus (ATCC 29213 and ATCC 25923).
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3.5.11 Haemolytic activity measurements
Fresh human red blood cells were washed three times with phosphate-buffered
saline (PBS), and then incubated with peptide at a concentration of 100 g/ml for 1 h at
37oC. The final erythrocyte concentration was approximately 0.9 x 109 per ml. The
values at 0% and 100% lysis were determined by incubation of cells with PBS or 0.1%
Triton X-100 in water, respectively. The samples were centrifuged, the supernatant
diluted twentyfold in PBS, and the optical density was measured at 540 nm.
3.5.12 N-{2-[2-(2-amino-ethylamino)-ethylamino]-ethyl}-2,2,2-
trifluoroacetamide (102)
To triethylene tetramine (7.3 g, 50 mmol) was dissolved in MeOH (700 ml) and
cooled to ~ 83oC was added ethyl trifluoroacetate (5.96 ml, 50 mmol) dropwise over 1 h.
The solution was then stirred for a further 30 mins under nitrogen.
3.5.13 {2-[tert -butoxycarbonyl-(2-{tert -butoxycarbonyl-[2-(2,2,2-
trifluoro-acetylamino)-ethyl]-amino}-ethyl)-amino]-ethyl}-
carbamic acid tert -butyl ester (103)
The flask containing the product from 3.5.12 was transferred to an ice bath.
(Boc)2O (42.3 g, 200 mmol) was dissolved in MeOH 100 ml. This solution was added
dropwise to the flask over 20 mins. The ice bath was then removed and the mixture
stirred at r.t. overnight.
3.5.14 {2-[(2-amino-ethyl)-tert -butoxycarbonyl-amino]-ethyl}-(2-tert -
butoxy carbonylamino-ethyl)-carbamic acid tert -butyl (104)
The solution from 3.5.13 was treated with aqueous ammonia until it reached
pH>11. The solution was then stirred at room temperature overnight. The solvents were
removed by rotary evaporation to yield 12.8 g of a sticky pale orange solid. This product
was purified by flash chromatography in 3 batches of 4-5 g using a 7 cm diameter column
with DCM/MeOH/NH4OH (95:5:1) as eluant. The fractions containing the desired
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product (from comparison by TLC to a known sample) together gave 6.3 g of an oily
yellow product.
1H NMR (in MeOD): 1.25-1.45ppm (m), 29H; 3.1-3.3ppm (m), 12H.
Measured m/z (ESI-MS): (M+H): 447.3, (M+Na): 469.2
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3.5.15 Peptide-peptoid hybrid mimetic 99
Mimetic 99:
N
Lys
Lys
Leu
Arg
Leu
Pro p
ro
Val
Arg
Tyr
Lys
Trp
Arg
OHN
N
H
H2N
2-chlorotrityl resin (500 mg) was swelled in DCM for 30 mins, then the resin was
washed 3 times with DCM. A solution of bromoacetic acid (500 mg, 5 eq) and DIEA (3
ml, 12 eq) in DCM (5 ml) was added to the resin and the resin suspension was agitated
for 1 h. The resin was then washed 5 times with DCM.
The tri-Boc protected tetramine 104 (1.5 g, 5 eq) was dissolved in DCM (4 ml)
and added to the resin and the suspension was agitated overnight. The resin was then
washed 5 times with DCM.
To check that the correct product was present on the resin, a small portion (~40
mg) of the resin was transferred to a Pasteur pipette plugged with cotton wool. The resin
was treated with 1% TFA in DCM 8 times to cleave the protected peptoid unit from the
resin. The solvents were evaporated off to leave a film of product on the inside of the r.b.
flask. This film was washed with ether. The washing was repeated twice, then the
product was dissolved in MeOH (0.5 ml). A main peak with the expected mass of the
desired product m/z: [(M+H): 505] was observed in ESI-MS..
To a solution of Fmoc-Lys(Boc)-OH (1.64 g, 5 eq) and HOAt (0.54 g, 5 eq)
dissolved in a minimal amount of DMF, DIC (0.54 g, 5 eq) was added dropwise. The
resin suspension was agitated for 20 mins. A little more DMF was added to dissolve the
ppt which had formed, then the solution was added to the resin and the resin suspension
agitated for 4 h. The solution was drained off from the resin and the resin washed 5 times
with DMF.
The resin was then transferred to the synthesis vessel of the ABI 433A and the
remainder of the peptide chain was built up using FastMoc ® chemistry. Single coupling
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cycles of 20 mins were used. An extended coupling of 55 mins was used for Lys, Pro
and DPro residues. A long extended coupling of 85 mins was used for Arg residues.
Cleavage of the fully protected linear peptide from the resin was carried out in the
same way as for mimetic 88. 700 mg of dry product obtained.
For the cyclisation, the product (350 mg) was dissolved in DMF (140 ml). This
solution was analysed by RP-HPLC. HATU (57 mg, 1.5 eq), HOAt (23mg, 1.5eq) and
DIEA (60 l, 3.5 eq) were added to this solution and the mixture was stirred overnight.
RP-HPLC analysis showed that the starting material had disappeared after this time and
that a new product had been formed with a longer retention time. The DMF was removed
under reduced pressure.
The sticky colourless product was dissolved in TFA/TIS/H2O 95:2.5:2.5 (30 ml)
and stirred under nitrogen for 3 h. Approx. 4/5 of the TFA was removed by rotary
evaporation and the remaining solution was split between two centrifuge tubes. The
product was precipitated and washed as previously described. 160 mg of crude product
obtained.
Purification was carried out by preparative RP-HPLC using a C18 Xterra column.
25 mg of pure product were obtained.
Analytical RP-HPLC: The purified product was analysed by RP-HPLC (Vydac
C18 218TP54 (5 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), gradient 5 to 55%
acetonitrile over 33 minutes, retention time 23.5 mins)
Measured m/z ESI-MS: (M+H): 1908, (M+2H)/2: 955.2, (M+3H)/3: 637.1,
(M+4H)/4: 478, (M+5H)/5: 382.5
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Appendix 1: Abbreviations
Acm
aq.
Boc
(Boc)2O
CS
DCC
DCM
DNA
DIC
DIEA
DMF
DQF-COSY
EDT
EGF
ELISA
eq.
ESI-MS
Fmoc
GLURP
HATU
HBTU
HOAt
HOBt
HPLC
IFA
IRIV
MALDI
MSP
…………………………………………………….Acetamidomethyl
…………..…………………………………………………..Aqueous
…………..……………………………………Tert-butyloxycarbonyl
……………………………………………..di- tert-butyl dicarbonate
…………………………………………………….Circumsporozoite
…………………………………………...Dicyclohexylcarbodiimide
…………………….……………………………….Dichloromethane
………………….……………………………Deoxyribonucleic acid
………………..…………………………….Diisoproplcarbodiimide
…………...…………………………………..Diisopropylethylamine
…………...……………………………………..Dimethylformamide
……………………Double quantum filtered correlated spectroscopy
…………………………………………………………Ethanedithiol
………..……………………………………Epidermal growth factor
……………………………….Enzyme-linked immunosorbant assay
……..……………….……………………………………Equivalents
………………………….Electrospray ionisation mass spectrometry
……..…………………………(9H-fluoren-9-yl)methyloxycarbonyl
……………………………………………….Glutamate-rich protein
……...…O-(7-azabenzotriazol-1-yl)-N,N,N’,N’, tetramethyluronium
…….……………………………………………hexafluorophoshate
…….……….O-(benzotriazol-1-yl)-N,N,N’,N’, tetramethyluronium
…….……………………………………………hexafluorophoshate
…….………………………………….1-hydroxy-7-azabenzotriazol
………………………………………………1-hydroxybenzotriazol
………….……..High pressure/performance liquid chromatography
………………………………………….Immunofluorescence assay
……………..Immunopotentiating reconstituted influenza virosome
…………………………Matrix desorption laser-assisted ionisation
……………………………………………Merozoite surface protein
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NHS
NMP
NMR
NOESY
Pbf
PBS
PE
r.b.
ROESY
RP-HPLC
Rpm
r.t.
TFA
TFE
TIS
TLC
TMS
TOCSY
Trt
TSP
………………………………………………N-hydroxysuccinimide
………………………………………….……...N-methylpyrrolidine
……….……..………………………….Nuclear magnetic resonance
………….…………………Nuclear Overhauser effect spectroscopy
………….………………Pentamethyldihydrobenzofuran-5-sulfonyl
…….……………………………………..Phosphate-buffered saline
……….………………….1,3-dipalmitoylphosphatidylethanolamine
.…………………………………………………….Round-bottomed
….…..…..…Rotating frame nuclear Overhauser effect spectroscopy
.…….……….……………………………….Reversed-phase HPLC
….……………………………………….….Revolutions per minute
……..…………………………………………….Room temperature
….………………………………………………Trifluoroacetic acid
….….……………………………………………….Trifluoroethanol
….………………………………………………...Triisopropylsilane
…….…………………………………….Thin layer chromatography
……………………………………………………Tetramethylsilane
……………………………….……..Totally correlated spectroscopy
………………………………………………………………….Trityl
……………………….3-trimethylsilylpropionic acid-d4 soldium salt
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Figure 97: Top: 1H-NMR spectrum (600MHz) of peptide 1 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 98: Top: 1H-NMR spectrum (600MHz) of peptide 2 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 99: Top: 1H-NMR spectrum (600MHz) of peptide 45 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 100: Top: 1H-NMR spectrum (600MHz) of peptide 46 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 101: Top: 1H-NMR spectrum (600MHz) of peptide 48 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 102: Top: 1H-NMR spectrum (700MHz) of peptide 49 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 103: Top: 1H-NMR spectrum (700MHz) of peptide 50 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 104: Top: 1H-NMR spectrum (600MHz) of peptide 51 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 105: Top: 1H-NMR spectrum (700MHz) of peptide 52 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 106: Top: 1H-NMR spectrum (600MHz) of peptide 53 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 107: Top: 1H-NMR spectrum (700MHz) of peptide 54 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 108: Top: 1H-NMR spectrum (600MHz) of peptide 55 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 109: Top: 1H-NMR spectrum (600MHz) of peptide 58 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 110: Top: 1H-NMR spectrum (600MHz) of peptide 73 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 111: Top: 1H-NMR spectrum (600MHz) of peptide 74 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 112: Top: 1H-NMR spectrum (600MHz) of peptide 75 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 113: Top: 1H-NMR spectrum (600MHz) of peptide 76 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 114: Top: 1H-NMR spectrum (600MHz) of peptide 97 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Figure 115: Top: 1H-NMR spectrum (600MHz) of peptide 98 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
Figure 116: Top: 1H-NMR spectrum (600MHz) of peptide 104 in H2O/D2O (9:1), pH 5, 300K. Bottom:
expansion of the amide NH region.
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Residue NH CH CH Others
Asn1 4.388 2.962, 2.962 NH2
Ile2 8.615 4.265 1.876 CH3 0.922
Ser3 8.461 4.435 3.815, 3.898 -
Gln4 8.468 4.215 1.848, 1.941 CH2 2.234, 2.234; NH2
His5 8.363 4.854 2.999, 2.999 CH 7.306; CH 8.522
Gln6 7.975 4.419 2.004, 2.067 CH2 2.385, 2.385; NH2
Cys7 8.907 4.271 3.126, 3.317 -
Val8 10.307 4.274 2.153 CH30.879, 0.879
Lys9 9.332 4.463 1.819, 1.819 CH2 1.397, 1.437; CH2 1.680, 1.680;
CH2
Lys10 8.554 4.125 1.822, 1.822 CH2 1.295, 1.295; CH2 1.598, 1.680;
CH2
Gln11 8.396 4.469 1.908, 2.059 CH2 2.301, 2.301; NH2
Cys12 8.561 5.150 2.374, 3.462 -
Pro13 4.564 2.033, 2.408 CH2 1.790, 2.068; CH2
Gln14 8.467 4.020 1.939, 1.989 CH2 2.417, 2.417; NH2
Asn15 8.886 3.889 1.493, 2.646 NH2
Ser16 7.629 4.967 3.515, 3.754 -
Gly17 8.778 3.697, 4.524 -
Cys18 8.569 5.255 2.965, 3.032 -
Phe19 9.471 - 2.907, 2.907 CH 6.913, 6.913; CH
Arg20 8.221 4.903 1.283, 1.469 CH2 1.482, 1.585; CH2;
NH
His21 9.127 - 3.506, 3.506 CH 7.078; CH 8.483
Leu22 8.889 4.141 1.679, 1.825 CH 1.743; CH3
Asp23 7.950 4.551 2.592, 3.060 -
Glu24 8.017 3.829 2.181, 2.494 CH2
Table 17: Chemical shifts (600MHz) for 2 at 298K in H2O/D2O (9:1), pH 5
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Arg25 7.994 4.248 1.744, 1.848 CH2 1.514, 1.600; CH2;
NH
Glu26 8.615 5.107 1.908, 1.908 CH2
Glu27 8.920 4.720 1.994, 2.142 CH2
Cys28 8.976 5.396 2.813, 3.042 -
Lys29 8.858 - 1.680, 1.773 CH2, 1.393; CH2, 1.499;
CH2
Cys30 9.078 - 2.661, 3.047 -
Leu31 8.091 4.257 1.492, 1.671 CH CH3
Leu32 7.945 4.112 1.597, 1.652 CH CH3
Asn33 8.699 4.386 2.862, 3.074 NH2
Tyr34 8.386 4.867 2.556, 3.207 CH 6.774, 6.774; CH
Lys35 9.489 - 1.770, 1.770 CH2, 1,327; CH2, 1.654;
CH2
Gln36 8.771 4.725 2.077, 2.077 CH2 2.328, 2.388; NH2
Glu37 8.921 4.579 1.802, 1.994 CH2
Gly38 9.133 3.712, 4.060 -
Asp39 8.792 4.694 2.779, 2.779 -
Lys40 7.869 4.696 1.844, 1.885 CH2, 1.504; CH2, 1.693;
CH2
Cys41 8.825 5.336 2.649, 2.881 -
Val42 9.462 4.722 2.213 CH3
Glu43 9.033 3.548 1.804, 1.804 CH2
Asn44 8.285 4.865 2.351, 2.706 NH2
Pro45 4.364 1.906, 2.223 CH2 1.963, 1.963; CH2
Asn46 8.329 4.970 2.663, 2.798 NH2
Pro47 4.438 1.997, 2.276 CH2 2.017, 2.017; CH2
Thr-NH248 8.123 4.306 4.272 CH3
Table 17 (continued): Chemical shifts (600MHz) for 2 at 298K in H2O/D2O (9:1), pH 5
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Residue NH CH CH Others
Leu1 7.86 4.39 1.47, 1.84 CH 1.60; CH3 0.87, 0.96
Arg2 8.43 4.70 1.72, 1.72 CH2 1.47, 1.61; CH2 3.14, 3.14;
NH 7.13
Leu3 8.50 4.63 0.90, 1.34 CH 1.34; CH2 0.82, 0.85
Lys4 8.32 5.12 1.64, 1.82 CH2 1.31, 1.31; CH2 1.64, 1.64;
CH2 2.95, 2.95
Lys5 8.99 5.05 1.91, 2.02 CH2 1.42, 1.51; CH2 1.64, 1.64;
CH2 2.84, 2.84
Nlys6 - 3.75, 4.35 - CH2N 3.58, 3.70; CH2N 1.75,
1.78; CH2N 3.09, 3.09
Arg7 8.41 4.20 1.44, 1.60 CH2 1.03, 1.23; CH2 2.97, 2.97;
NH 6.95
Trp8 8.08 4.85 3.28, 3.39 H1 7.30; H3 7.75; H3 7.08, H2
7.19; H2 7.47; NH1 10.10
Lys9 8.30 5.04 1.63, 1.73 CH21.30, 1.43; CH2 1.63, 1.63;
CH2 2.93, 2.93
Tyr10 8.69 4.78 2.82, 2.82 H6.84, 6.84; H 6.59, 6.59
Arg11 8.53 5.12 1.72, 1.85 CH2 1.50, 1.64; CH2 3.16, 3.16;
NH 7.13
Val12 8.35 4.51 2.00 CH3 0.95 0.95
DPro13 - 1.93, 2.32 CH2 2.05, 2.16; CH2 3.53, 3.91;
Pro14 - 4.50 CH21.94, 2.09; CH2 3.75, 4.01
Table 18: Chemical shifts for peptide 97 at 300K in H2O/D2O (9:1), pH 5.
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Peptide 2:
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 7 7.9 12.30
Glu 10 8.3 16.69
Ser 2 1.7 15.33
His 2 1.6
Gly 2 2.1 5.33
Thr 1 1.1 7.44
Ala 0 0.1
Arg 2 1.9 6.69
Tyr 1 1.2
Val 2 2.0 1.90
Met 0 0.1
Phe 1 0.9 7.60
Ile 1 0.8 16.60
Leu 3 3.1 2.09
Lys 5 4.9 2.33
Pro 3 3.9
Peptide 42:
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 7 7.8 11.55
Glu 10 10.5 5.2
Ser 2 1.6 19.9
His 2 1.7
Gly 2 2.2
Thr 1 1.0 3.22
Ala 0
Arg 2 1.8 8.08
Tyr 1 1.2
Val 2 1.9 5.32
Met 0 0.2
Phe 1 0.9 8.97
Ile 1 1.1 6.06
Leu 3 3.2 5.03
Lys 5 4.7 5.87
Pro 3 3.2 5.99
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Peptide 73
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 5 5.5 10.82
Glu 4 4.4 10.90
Ser 1 0.9 12.08
His 1 0.9 6.58
Gly 2 2.0 0.04
Thr 2 1.8 10.61
Ala 0 0.0
Arg 0
Tyr 0
Val 0 0.0
Met 0 0.1
Phe 1 1.0 0.66
Ile 1 1.0 1.95
Leu 2 2.0 1.62
Lys 3 2.8 5.08
Pro 2 2.1 3.13
Peptide 74
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 5 5.3 6.21
Glu 6 6.6 9.88
Ser 0 0.0
His 1 0.8 16.50
Gly 2 1.9 4.13
Thr 1 0.9 10.36
Ala 0 0.0
Arg 0
Tyr 0
Val 0 0.0
Met 0 0.1
Phe 1 1.0 0.73
Ile 0 0.0
Leu 3 3.0 0.42
Lys 2 1.8 8.71
Pro 3 3.1 4.13
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Peptide 75
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 5 5.6 11.60
Glu 6 6.6 10.65
Ser 0 0.1
His 1 0.7
Gly 2 2.1 3.53
Thr 1 0.9 9.51
Ala 0 0.1
Arg 0
Tyr 1 0.9 14.89
Val 0 0.0
Met 0 0.2
Phe 1 1.0 1.65
Ile 2 1.9 3.13
Leu 2 2.1 3.93
Lys 3 2.9 4.05
Pro 3 3.1 3.75
Peptide 76
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 5 6.6 32.50
Glu 6 6.3 4.51
Ser 1 0.9 8.58
His 2 1.9
Gly 2 2.0 0.63
Thr 0
Ala 0 0.0
Arg 1 0.9 9.01
Tyr 0
Val 1 1.0 3.93
Met 0 0.1
Phe 1 1.1 6.94
Ile 0 0.0
Leu 0 0.0
Lys 4 4.0 0.27
Pro 2 2.2 9.79
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Peptide 77
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 5 6.3 26.93
Glu 5 5.1 2.24
Ser 1 0.8 16.83
His 2 1.9 6.72
Gly 3 2.8 5.12
Thr 0
Ala 0 0.0
Arg 1 0.9 12.63
Tyr 0 0.0
Val 1 1.1 5.16
Met 0
Phe 1 0.9 5.19
Ile 1 1.0 3.47
Leu 0 0.0
Lys 3 3.3 11.19
Pro 2 2.3 14.54
Peptide 97
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 0 0.0
Glu 0 0.1
Ser 0 0.0
His 0
Gly 0 0.1
Thr 0
Ala 0 0.0
Arg 3 2.8 6.97
Tyr 1 1.0 2.72
Val 1 0.9 5.57
Met 0 0.0
Phe 0 0.0
Ile 0 0.0
Leu 2 2.1 5.23
Lys 3 3.0 0.09
Pro 2 2.2 10.12
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Peptide 98
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 0 0.0
Glu 0 0.1
Ser 0 0.0
His 0
Gly 0 0.1
Thr 0
Ala 0 0.0
Arg 3 2.8 5.74
Tyr 1 1.0 3.39
Val 1 1.0 3.83
Met 0 0.1
Phe 0
Ile 0 0.0
Leu 2 2.2 8.96
Lys 2 1.8 9.25
Pro 2 2.3 13.25
Peptide 104
Amino acid Residues
(theoretical)
Residues
(measured)
Error (%)
Asp 0 0.4
Glu 0 0.4
Ser 0 0.2
His 0
Gly 0 0.5
Thr 0
Ala 0 0.2
Arg 3 2.8 7.20
Tyr 1 1.1 5.40
Val 1 1.0 2.16
Met 0 0.3
Phe 0
Ile 0
Leu 2 2.2 8.38
Lys 3 2.9 4.41
Pro 2 2.9
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Figure 16 (A): Vydac C18 218TP54, flow rate 1 ml/min, 5 to 100% acetonitrile over 29
mins. (B): Vydac C18 218TP54, 5 to 17% acetonitrile over 4 mins, then 17 to 33% over
29 mins.
Figure 18: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 19: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 20: Vydac C18 218TP54, flow rate 1 ml/min, 5 to 17% acetonitrile over 4 mins,
then 17 to 33% over 26 mins.
Figure 22: Vydac 218TP54 column, flow rate 1 ml/min, 5 to 23% acetonitrile over 34
mins.
Figure 23: Zorbax eclipse analytical C18, (4.6 x 250 mm, 5 m, flow rate 1 ml/min), 3
to 30% acetonitrile over 34 mins.
Figure 27: Vydac C4 214TP104 (10 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), 40-
100% acetonitrile over 29 mins.
Figure 31: Vydac C18 218TP54, flow rate 1 ml/min, 5 to 17% acetonitrile over 4 mins,
then 17 to 33% over 26 mins.
Figure 32: Vydac C18 218TP54, flow rate 1 ml/min, 5 to 17% acetonitrile over 4 mins,
then 17 to 33% over 26 mins.
Figure 33: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 35: Vydac C4 214TP104 (10 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), 10-
100% acetonitrile over 16.5 mins.
Figure 37: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 100% acetonitrile over 34
mins.
Figure 38: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
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Figure 39: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 40 (A): Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins. (B): Zorbax eclipse XDB-C18 (7 m, 21.2 x 250 mm), flow rate 15 ml/min, 5 to
27.5% acetonitrile over 18 minutes. (C): Vydac C18 218TP54 , flow rate 1 ml/min, 5 to
50% acetonitrile over 29 mins.
Figure 48: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 49: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 50: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 51: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 55: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 50% acetonitrile over 29
mins.
Figure 56: Vydac C4 214TP104 (10 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), 10-
100% acetonitrile over 16.5 mins.
Figure 59: Vydac C18 218TP54 , flow rate 1 ml/min, 5 to 60% acetonitrile over 39
mins.
Figure 61: Vydac C4 214TP104 (10 m, 125 Å, 4 x 100 mm, flow rate 1 ml/min), 10-
100% acetonitrile over 16.5 mins.
Figures 66-69 (A): Vydac C4 214TP104, 30 to 100% acetonitrile over 33 mins. (B):
Vydac C18 218TP104 column, gradient 5 to 55% acetonitrile over 29 mins.
Figure 71: Vydac C4 214TP104, 30 to 100% acetonitrile over 33 mins.
Figure 73: Vydac C18 218TP104 column, gradient 5 to 40% acetonitrile over 21 mins.
Figure 74 (A), (B), (C): Vydac C4 214TP104, 50 to 100% acetonitrile over 29 mins.
(D): Vydac C4 214TP104, 30 to 100% acetonitrile over 33 mins.
Figures 75 and 76: Vydac C4 214TP104, 30 to 100% acetonitrile over 33 mins.
Figure 86: Vydac C18 218TP54 column, gradient 5 to 40% acetonitrile over 39 mins.
Figure 87: Vydac C18 218TP54 column, gradient 5 to 40% acetonitrile over 33 mins.
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Figures 88 and 89: Vydac C4 214TP104, 5 to 100% acetonitrile over 41 mins.
Figure 90: Vydac C18 218TP54 column, gradient 5 to 37% acetonitrile over 39 mins.
Figure 91: Vydac C18 218TP54 column, gradient 5 to 27% acetonitrile over 1 minute,
then 27 to 33% over 19 mins.
Figure 92: Vydac C4 214TP104, 5 to 100% acetonitrile over 41 mins.
Figure 93: Vydac C18 218TP54 column, gradient 5 to 50% acetonitrile over 33 mins.
Figure 98: Vydac C18 218TP54 column, gradient 5 to 55% acetonitrile over 33 mins.
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Summary
This work deals with the development of new synthetic peptide-based molecules
designed either to play a role in preventing disease as components of a malaria vaccine,
or to treat infections as antimicrobial peptidomimetics.
As parasites develop resistance to traditional antimalarial drugs and mosquitoes
develop resistance to known insecticides, the need for an effective vaccine to control
malaria becomes greater than ever. In this project, mimetics of malaria vaccine candidate
proteins MSP-1, MSP-4 and GLURP were synthesised and tested in animal models,
exploiting the virosome technology for the presentation of the mimetics to the immune
system. Multiple copies of the mimetics were inserted into the lipid bilayer of
immunostimulating reconstituted influenza virosomes by virtue of a phospholipid tail
coupled to the N-terminus of the mimetic.
Merozoite surface protein 1 (MSP-1) is the major surface protein on the
erythrocyte-invasive form of Plasmodium parasites. The protein undergoes proteolytic
processing after merozoite release into the plasma, leading to a 42-kDa membrane-bound
fragment (MSP-142), which is further processed around the time of erythrocyte invasion
to leave a 19 kDa C-terminal fragment (MSP-119) which is carried into the invaded
erythrocyte. Antibodies that bind to MSP-119 can inhibit both the second processing step
and erythrocyte invasion. MSP-119 consists of two epidermal growth factor (EGF)-like
domains.
In this project, a synthetic peptide mimetic of the first EGF-like domain of MSP-1
was synthesised and suitable conditions were found for oxidative folding of the linear
peptide to give one major, fully oxidised product. NMR studies proved that the structure
of the synthetic peptide was closely related to that of the corresponding domain in the
two-domain protein MSP-119. Enzymatic digestion studies revealed that the disulfide
bonding pattern of the synthetic peptide corresponded to the known pattern for the two-
domain protein. Thus, the mimetic should represent a good mimetic of the first EGF-like
domain of MSP-1.
A modified peptide mimetic containing an N-terminal hydrazinoglycine could be
oxidatively folded in the same way and was chemoselectively coupled to a phospholipid
moiety to provide a suitable mimetic for insertion into virosomes. Immunizations with
virosomes loaded with this mimetic induced sera which were able to recognise blood-
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stage parasites. These promising results suggest that this mimetic could form a
component of a multi-antigen synthetic peptide malaria vaccine.
Merozoite surface protein 4 (MSP-4) is another membrane-bound merozoite
surface protein containing an EGF-like domain. Based on the successful synthesis of the
MSP-1 mimetic, a peptide mimetic of the EGF-like domain of MSP-4 was prepared and
oxidised under analogous conditions. Initial synthetic problems in the peptide chain
assembly were overcome by the introduction of a pseudoproline residue, intended to
disrupt interchain aggregation, which is believed to be the main cause of low coupling
yields. On reaction of the hydrazinoglycine-coupled folded peptide with phospholipid, a
sticky product was formed that was difficult to handle. Immunological studies with this
product failed to produce sera that were cross-reactive with the parasite, probably due to
the physical properties of the mimetic. Therefore, a related phospholipid-bound folded
peptide product with improved physical characteristics was prepared by the inclusion of a
series of extra lysine residues at the N-terminal of the peptide sequence. Immunological
testing of this product has not yet been carried out. Despite the problems encountered,
the work proved the possibility of the synthesis of another EGF-like domain of interest
here. There are also several other EGF-like domains present in Plasmodium falciparum
proteins that could be investigated by similar methods in the future.
The third Plasmodium protein to be investigated was the glutamate rich protein
(GLURP). This protein is expressed at all stages of the parasite life cycle, and can be
found on the surface of erythrocytes. A series of peptide mimetics directly coupled to
phospholipid tails were prepared in this project, based on epitopes identified by other
groups, found in the well-conserved non-repeat region of the protein. NMR spectra of
non-phospholipid-coupled analogues of these mimetics were also measured.
Unfortunately the spectra suggested that the peptides were not well-structured, and the
mimetics failed to induce immune responses that cross-reacted with the parasites.
Therefore, these mimetics in their current form do not represent good candidates for a
malaria vaccine.
In the second part of this work, the synthesis of some macrocyclic peptoid-peptide
hybrid mimetics is presented. One or two peptoid units were included in the sequence of
a backbone cyclic peptide with known antimicrobial activity. Studies showed that the
inclusion of a peptoid unit did not have a detrimental effect of antimicrobial activity, and
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in one case seemed to reduce the haemolytic activity of the peptide. The inclusion of
peptoid units could help to improve the stability of antimicrobial peptidomimetics
towards proteolysis. A different peptoid monomer unit was introduced into the same
sequence to lead to a peptide which could bind to Re(CO)3. Rhenium is believed to
behave chemically in a similar way to 99Technetium. Therefore, this work suggests it
would be possible to build a 99Technetium-labelled antimicrobial peptidomimetic, which
could be useful for imaging studies of the uptake, processing, and excretion of
antimicrobial peptidomimetics in humans.
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Zusammenfassung
Diese Arbeit befasst sich mit der Entwicklung neuer synthetischer, peptidbasierter
Moleküle, die entworfen wurden um entweder eine Rolle bei der Krankheitsprävention
als Bestandteile eines Malaria-Impfstoffes oder zur Behandlung von
Infektionskrankheiten in der Form antimkrobieller Peptidmimetika zu spielen.
Da einerseits Parasiten Resistenz gegen traditionelle Antimalariawirkstoffe, sowie
andererseits die Anophelesmücke Resistenz gegen gebräuchliche Insektizide entwickeln,
wird der Bedarf für einen effektiven Malariaimpfstoff grösser denn je. Bei diesem
Projekt wurden Mimetika der Malariaimpfstoffanwärter-Proteine MSP-1, MSP-4 und
GLURP synthetisiert und in Tiermodellen unter Verwendung der Virosom Technologie,
welche der Präsentation der Mimetika für das Immunsystem dient, getestet. Unter
Zuhilfenahme eines Phospholipidschwanzes, welcher über die N-Termina der Mimetikas
gekoppelt ist, wurden vielfache Kopien derselben in die Lipid-Doppelschicht der
immunostimulierenden rekonstituierten Influenza Virosome insertiert.
Merozoiten Oberflächenprotein 1 (MSP-1) ist das hauptsächlich vorkommende
Oberflächenprotein der Erythrozyten-invasiven Form des Plasmodium Parasiten. Dieses
Protein unterliegt nach seiner Freisetzung ins Plasma einer proteolytischer Veränderung,
welche zu einem 42 kDa membrangebunden Fragment (MSP-142) führt. Dieses Fragment
wird zum Zeitpunkt des Erythrozytenbefalls weiter zu einem 19 kDa (MSP-119) Fragment
prozessiert, welches in den befallenen Erythrozyten übertragen wird. Antikörper die an
MSP-119 binden, können sowohl den zweiten Prozessierungsschritt als auch den Befall
des Erythrozyten verhindern. MSP-119 besteht aus zwei epidermalen Wachstumsfaktor-
ähnlichen (EGF-ähnlichen) Domänen.
In diesem Projekt wurden ein synthetisches Peptidmimetikum der ersten EGF-
ähnlichen Domäne des MSP-1 synthetisiert und passende Bedingungen für die oxidative
Faltung des linearen Peptides, die zu einem vollständig oxidierten Hauptprodukt führten,
gefunden. NMR Untersuchungen zeigten, dass die Struktur des synthetischen Peptids
eng mit der Struktur der entsprechenden Domäne des aus zwei Domänen bestehenden
MSP-119 Proteins verwandt ist. Enzymatische Verdauexperimente ergaben, dass das
Dissulfidbrücken-Bindungsmuster des synthetischen Peptids dem bekannten Muster des
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die beiden Domänen umfassenden Proteins entsprach. Folglich sollte diese Verbindung
ein gutes Mimetikum der ersten EGF-ähnlichen Domäne des MSP-1 darstellen.
Ein modifiziertes Mimetikum welches ein N-terminales Hydrazinoglycin enthält,
konnte auf die gleiche Weise oxidativ gefaltet werden und wurde chemoselektiv an eine
Phospholipideinheit gekuppelt, um ein geeignetes Mimetikum für die Einführung in
Virosomen zu erhalten. Immunisierungen mit Virosomen welche mit diesem Mimetikum
beladen waren, induzierten Sera die in der Lage waren Parasiten in der Blut-Phase zu
erkennen. Diese vielversprechenden Ergebnisse deuten darauf hin, dass dieses
Mimetikum Bestandteil eines synthetischen Multi-Antigen Peptid Malaria Impfstoffes
bilden könnte.
Merozoitenoberflächenprotein 4 (MSP-4) ist ein weiteres membran-gebundenes
Merozoitenoberflächenprotein, welches eine EGF-ähnliche Domäne enthält. Basierend
auf der erfolgreichen Synthese des MSP-1 Mimetikums wurde ein Peptidmimetikum der
EGF-ähnlichen Domäne von MSP-4 hergestellt und unter analogen Bedingungen
oxidiert. Anfängliche Probleme beim Aufbau des Peptidgerüstes wurden durch
Einführung eines Pseudoprolinrestes, welcher eine Aggregation der Peptidketten während
der Festphasensynthese verhindern sollte - was mutmasslich die Hauptursache niedriger
Kopplungsausbeuten war - überwunden. Bei der Reaktion des an Hydrazinoglycin
gekuppelten, gefalteten Peptides mit dem Phospholipid wurde ein hochviskoses, schwer
handhabbares Produkt gebildet. Immunologische Studien mit diesem Produkt ergaben
keine Sera die Kreuzreaktivität mit dem Parasiten aufwiesen, was wahrscheinlich durch
die physikalischen Eigenschaften des Peptides bedingt war. Aus diesem Grund wurde
durch Einbau einer Reihe von zusätzlichen Lysin Resten am N-Terminus der
Peptidsequenz, ein verwandtes phospholipidgebundenes gefaltetes Peptidprodukt mit
verbesserten physikalischen Eigenschaften hergestellt. Immunologische Unter-
suchungen mit diesem Produkt wurden noch nicht durchgeführt. Trotz der aufgetretenen
Schwierigkeiten bestätigte diese Arbeit die Möglichkeit der Synthese einer anderen EGF-
ähnlichen Domänen von Interesse. Darüberhinaus existieren mehrere weitere EGF-
ähnliche Domänen in Proteinen aus Plasmodium falciparum die mit vergleichbarer
Methodik in Zukunft untersucht werden könnten.
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Das dritte Plasmodium Protein welches untersucht werden sollte war das
glutamatreiche Protein (GLURP). Die Expression dieses Proteins, welches an der
Oberfläche von Erythrozyten gefunden werden kann, findet während allen Phasen des
parasitären Lebenszyklusses statt. Bei diesem Projekt wurden eine Reihe von direkt an
Phospholipidschwänze gebundenen Peptidmimetika hergestellt, die auf von anderen
Arbeitsgruppen in der hochkonservierten nicht repetetiven Region des Proteins
identifizierten Epitopen basieren. Die NMR Spektren der nicht an Phospholipid
gekuppelten Analoga dieser Mimetika wurden ebenfalls aufgenommen.
Unglücklicherweise deuteten diese Spektren darauf hin, dass die Peptide in Lösung nicht
wohlstrukturiert sind; ebenfalls misslang die Induktion einer Immunantwort welche
Kreuzreaktivität mit den Parasiten aufweist. Aus diesem Grund stellen diese Mimetika in
ihrer jetzigen Form keine guten Kandidaten für einen Malariaimpfstoff dar.
Im zweiten Teil dieser Arbeit wird die Synthese einiger makrozyklischer Peptoid-
Peptid Hybridmimetika beschrieben. Eine, beziehungsweise zwei Peptoideinheiten
wurden hierbei in die Sequenz eines Rückgrat-zyklisierten Peptids mit bekannter
antimikrobieller Aktivität eingefügt. Untersuchungen zeigten, dass die Einführung der
Peptoideinheiten keinen nachteiligen Einfluss auf die antimikrobielle Aktivität hatten,
und in einem Fall sogar die hämolytische Aktivität des Peptides reduzierten. Der Einbau
von Peptoideinheiten könnte somit helfen die proteolytische Stabilität antimikrobieller
Peptidmimetika zu verbessern. Eine unterschiedliche Peptoideinheit wurde in dieselbe
Sequenz eingefuehrt und ergab ein Peptid, an welches Re(CO)3 gebunden werden konnte.
Da davon ausgegangen wird, dass sich Rhenium chemisch ähnlich zu 99Technetium
verhält, deutetet diese Arbeit darauf hin, dass es möglich sein sollte 99Technetium
markierte antimikrobielle Peptidmimetika aufzubauen, welche von Nutzen bei der
Untersuchung der Aufnahme, der Prozessierung, und der Ausscheidung von
antimikrobiellen Peptiden beim Menschen, sein könnten.
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